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Nanoparticles (NPs) can be used in clinical applications (e.g. for drug delivery or 
bioimaging) in order to better treat and diagnose disease. Many nanomedicines are made 
from polymers, and improvements in polymer NP synthesis methods have made it easier 
to design and synthesise complex and diverse polymer NPs (PNPs) for clinical use. 
However, investigation into PNP safety has lagged behind their development, resulting 
in uncertainties regarding the safety of these PNPs. In vitro studies conducted to date have 
focused on assessment of cytotoxicity and cytokine production to screen the toxicity of 
nanomedicines. 
 
Micelles are one of the most attractive PNPs for medical use as they have a hydrophobic 
core that can carry cargo and a hydrophilic shell that interacts with the exterior 
environment. A panel of micellar PNPs of varying complexity were selected for 
investigation in this study. In the first instance, a novel polymer was used to generate poly 
(decamethylene succinate-co-pheylsuccinate) (PDP) NPs to investigate the influence of 
an adsorbed pluronic acid (PF68) coating on the toxicity of NPs. Next, the impact of poly-
lactic-co-glycolic acid (PLGA) chain length (4K, 15K and 55K) on PNP toxicity was 
investigated. Finally, the toxicity of redox-reactive (RR)-NPs, composed from PLGA, 
was compared to NPs which lacked this element (nRR-NP). All NPs tested had a 
polyethylene glycol (PEG) element in the shell.  
 
PNP safety was investigated via assessment of cytotoxicity, cytokine production, cellular 
uptake, genotoxicity, reactive oxygen species (ROS) production, urea and albumin 
production and intracellular calcium concentration ([Ca2+]i). The toxicity of the PNP 
panel to the C3A hepatocyte cell line was assessed in vitro as it is established that NPs 
administered via various routes (e.g. inhalation, ingestion, intravenous injection) 
accumulate in the liver.  
 
There was little to no cytotoxicity observed for all PNPs. Uptake of the PDP NPs by C3A 
cells was greatest, but low for 4K, 15K, 55K, RR and nRR NPs. PDP-PF68 PNPs and 
nRR-NPs induced genotoxicity via an oxidative mechanism, whereas the other NPs did 
not. Production of the anti-inflammatory cytokine interleukin (IL)-1ra, was elevated. No 





(TNF)α, IL-1β) was observed. ROS production was elevated by all PNPs investigated. 
Liver-specific markers of toxicity (urea and albumin production) were decreased for all 
PNPs investigated, with the greatest effect observed for nRR-NPs. A slight increase in 
[Ca2+]i was observed for cells exposed to RR-NPs.  
 
The findings obtained allowed the physicochemical properties of the PNPs which 
conferred toxicity to be identified; this can inform the design of PNPs in the future. More 
specifically, the addition of a PF-68 shell or a redox-responsive linker increased the safety 
of the PNPs. However, increasing chain length enhanced PNP toxicity. This study could 
also aid in developing evidence-based in vitro approaches to screen PNP safety, and 
therefore contribute to the development of a tiered testing strategy to facilitate assessing 
the toxicity of future generations of PNPs. By using a battery of tests to screen the toxicity 
of the PNP panel in this study a comprehensive assessment of PNP safety was performed, 
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1.1 Nanoparticles and nanomedicines  
 
Engineered nanoparticles (NPs) are defined as a population of particles where 50% or 
more have one or more dimension in the nanoscale (1-100 nm) (Potočnik 2011). NPs are 
currently being used in many different industries including electronics, cosmetics, food 
and pharmaceuticals (Lin et al. 2006; Erickson 2009; Kong et al. 2011; Athinarayanan et 
al. 2014). With growing use and exposure to NPs, a comprehensive understanding of their 
impacts on human health and the environment is required (Donaldson et al. 2004; 
Maynard et al. 2006; Oberdörster et al. 2007; Maynard & Aitken 2016). The properties 
of NPs can be strikingly altered compared to those observed for the bulk material they 
are composed from, allowing NPs to have new and useful properties which as exploited 
by industry (Edwards-Jones 2009; Zhang et al. 2016). 
 
The low solubility, instability and untargeted nature of many pharmaceuticals such as 
chemotherapies can make it challenging to administer them without adverse (side) effects 
(Guo et al. 2011; Li et al. 2014). Therefore, there is a call for new and improved drug 
delivery systems that can contain these challenging cargos as well as target their delivery 
to specific diseased cells. Nanomedicine is an exciting, relatively new field that uses NPs 
for medical applications and has the potential to address unmet clinical needs in 
diagnosing and treating a wide range of diseases (Fangueiro et al. 2015). Indeed, it is 
hoped that NPs can provide improved efficacy and targeting of pharmaceuticals, while 
decreasing adverse effects (Chen et al. 2001; Constantin et al. 2017). 
 
However, investigations into NP safety have lagged behind NP production. As a result, 
many uncertainties linger regarding the potential adverse health effects of these materials. 
Nanotoxicology investigates the potential detrimental impacts of NPs on human health 
and the environment (Donaldson et al. 2004; Maynard et al. 2006; Oberdörster et al. 2007; 
Maynard & Aitken 2016). The uncertainty regarding NP toxicity can result in industries 





1.2 Designing nanomedicines 
 
When designing a NP for medical use, physiochemical characteristics can be selected that 
could aid in achieving the desired clinical outcome. However, the physicochemical 
properties of NPs (e.g. composition, shape, size, charge and surface properties) also 
influence their toxicity (Hoshino et al. 2012). It is therefore important to understand which 
physicochemical properties influence the toxicity of nanomedicines. Accordingly, the 
physicochemical properties of NPs are commonly characterised in parallel to NP hazard 
assessments.  
 
A decrease in NP size can result in a larger surface-to-volume ratio, as the rate of reactions 
can depend on surface area, an increase in area could increase the probability of chemical 
interactions, therefore potentially increasing surface reactivity; this can give NPs 
desirable qualities such as increased interaction with target cells and therefore improved 
cellular targeting and internalisation (Win & Feng 2005). However, the same 
characteristics that make NPs appealing for medical applications can contribute to their 
toxicity. For example, silver (Ag) NPs have been used successfully to inhibit bacterial 
growth and have great potential for use in wound dressings (Rennukka et al. 2014). 
However, previous in vitro research has observed that a decrease in the size of Ag NPs 
(4.7 to 42 nm) can result in an increase in cell death in hepatoma and leukaemia cells 
(Avalos et al. 2014).  
 
Also, a NP’s surface charge can help overcome the challenge of cellular internalisation 
of low solubility, unstable medical treatments. Previously a positively charged tri bock 
polymeric NP (PNP), meaning it is composed of 3 blocks (lengths) of connection 
polymers, poly(ethylene glycol)-block-poly(e-cap-rolactone)-block-poly(2-aminoethyl 
ethylene phosphate) has been shown to have increased cellular uptake compared with 
neutral or negatively charged PNPs and therefore, has the potential to be utilised in the 
delivery of negatively charged genetic material such as small interfering RNA for the 
treatment of cancer (Mao et al. 2011). However positively charged NPs had been 
observed to elicit higher levels of toxicity than neutral or negative NPs. For example, 
positively charged NPs were more toxic to human brain cells (1321N1) in vitro which 






NPs can differ in shape, such as spheres, nanotubes or rods (Boyles et al. 2015; Sato et 
al. 2017). Previously, spherical gold (Au) NPs have been observed to be internalised by 
cervical cancer cells (HeLa) more readily than rod-shaped Au NPs of a similar size 
(Chithrani et al. 2006). This pattern of preferential NP uptake has led to many NPs for 
medical use being spherical (Zhang & Eisenberg 1995; Li et al. 2011).  
 
Nanomedicines are a diverse population of materials, with NPs composed of lipids, 
polymers, metals and metal oxides (Haldemann et al. 1995; Seyednejad et al. 2011; Hutter 
& Maysinger 2013; Bozzuto & Molinari 2015; Liu et al. 2016). The composition of NPs 
can influence their toxic potency. For example, previous research using human 
neutrophils cells (HL60) comparing the toxicity of a panel of NPs including titanium 
dioxide (TiO2) NPs and zinc oxide (ZnO) NPs of similar size range and shape showed 
that composition was capable of influencing toxicity, with TiO2 eliciting lower toxicity, 
as observed in previous studies using different endpoints (Joshi-Barve et al. 2007; 
Kermanizadeh et al. 2013; Johnston et al. 2015) 
 
Liposomes are spherical NPs composed of a phospholipid bilayer similar to that of the 
cell's membrane (Bozzuto & Molinari 2015). Doxil, a liposomal NP, was one of the first 
nanomedicines to gain approval over 2 decades ago from the Food and Drug 
Administration (FDA) of the United States of America. This liposome NP encapsulates 
the chemotherapeutic doxorubicin. Doxil has successfully been used in the treatment of 
ovarian cancer and has shown increased site-specific delivery as well as decreased 
toxicity when compared to doxorubicin in a non-nano form (James et al. 1994).  
 
1.3 Polymer nanomedicines  
 
Thanks to improvements in controlled polymer synthesis techniques, it has become easier 
to design a range of polymers such as polyesters, polyethers or polyamides for clinical 
use. Polymers are made up of repeating monomers that can either all be the same to form 
homopolymers such as polyethene glycol (PEG) or Poly(lactide) PLA, or a combination 
of these units can be generated to produce heteropolymers such as poly-lactic-co-glycolic 





and freedom in the design process of PNPs makes them an attractive candidate to generate 
simple and complex NPs for drug delivery and diagnostics for diseases such as arthritis 
and cancer (Wuelfing et al. 1998; Peracchia et al. 1999; Kanaras et al. 2002; Koole et al. 
2008; Muthu et al. 2014; Niemirowicz et al. 2016). 
 
Increasing interest in PNPs is also attributed to PNPs having several factors that are useful 
for medical applications including biocompatibility; biodegradability; increased 
circulation time and an ability to protect sensitive or challenging to formulate cargo 
(Conde et al. 2014). Additionally, PNPs are relatively quick and inexpensive to produce, 
leading to the rapid development of a diverse array of PNPs.  
 
In nanomedicine, when using polymer-based NPs, micellar PNPs are predominantly 
utilised. Micelles are formed when copolymers, composed of two or more different 
polymers, are added to an aqueous solution. These NPs self-assemble into spherical NPs 
with a core-shell structure, where the hydrophobic portion of the polymer is driven inside 
the micelle to form the core and the hydrophilic portion faces the outside to form the shell. 
When hydrophobic therapeutics such as low solubility drugs are present in the aqueous 
solution, these will become trapped at the core of these PNPs ( Figure 1.1) (Kataoka et al. 
2001; Kim et al. 2010; Pamujula et al. 2012). The preparation of micellar NPs can be 
relatively quick, cost-effective and straightforward (Mura & Couvreur 2012; Hare et al. 
2017). A potential advantage of loading drugs within the core of a micellar PNP, is that 
the toxicity of the administrable drug may be decreased, for example, formulations of 
paclitaxel as a free drug usually requires excipients. However, the excipient Cremophor 
used to formulate free drug paclitaxel into Taxol™ can elicit toxicity, while the paclitaxel-
containing PNPs do not require Cremophor and has been shown to elicit lower adverse 
effects in vivo (Kim et al. 2007).  
 
The first and currently only micelle PNP to be approved by the FDA, Estrasorb (over 15 
years ago), is a micellar NP used to encapsulate the pharmaceutical, Estrodiol, a 
menopause hormone therapy (Simon et al. 2006). However, the translation of 
nanomedicines from preclinical development to medical use has been slow (Maynard & 
Aitken 2016). Over 2210 patents have been applied for, and 320 nanoforms are in clinical 





focused trials, also known as phase I trials (epo.org, clinicaltrials.gov). Additionally, it 
can be challenging to upscale the production of PNPs for use in the pharmaceutical 
industry due to multiple chemical reactions and purification steps required, making 
upscaling PNP production time and resource consuming (Lammers et al. 2012). Also, 
PNP production can have a large number of variables that affect size or stability such as 
the specific polymer used; preparation method or storage conditions, therefore possibly 
leading to batch to batch variation (Sharma et al. 2015). These factors may make it 
difficult to produce the uniform PNPs that are required for consistent medical outcomes 
and to conform to appropriate regulations (EMA 2013a; EMA 2013b; Hatton et al. 2014). 
 
Nanomedicine toxicity studies commonly compare the free cargo to the cargo within the 
NPs, but often fail to investigate the toxicity associated with the NP delivery system alone 
or with a non-medical cargo such as a dye (Yoo & Park 2001; Khalil et al. 2013; 
Arunkumar et al. 2015; Vasconcelos et al. 2015; Jin et al. 2017; Radwan et al. 2017). 
Therefore, it is essential to fill this knowledge gap. This is especially relevant for in vivo 
studies where there has been limited investigation of the toxicity of PNPs such as PLGA-












Figure 1.1 Micelle NP. 
Representation of polymer micellar NP used in nanomedicine made up of polymer 
consisting of hydrophilic head (blue) and hydrophobic tail (orange) containing 







1.4 Passive and active targeted nanomedicines  
 
Although NPs have the potential to treat many diseases, cancer treatment has been the 
focus of many nanomedicines, to date. This focus on cancer may be in part attributed to 
the enhanced permeability and retention (EPR) effect, where the leaky vasculature of 
tumours allows NPs under 200 nm to passively target cancer cells (Matsumura & Maeda 
1986; Yokoyama et al. 1990; O’Neal et al. 2004). Indeed, the EPR effect has been 
exploited with clinically approved PNPs, such as intravenously administered Genexol, a 
copolymer of PEG and PLA to deliver the broad-spectrum chemotherapy Paclitaxel 
(Werner et al. 2013).  
 
Active targeting can be achieved via functionalisation of the NP surface, for example with 
peptides or antibodies. The epidermal growth factor receptor (EGFR) is overexpressed 
on tumour cells making it a promising target for nanomedicines (Laskin & Sandler 2004). 
In previous studies to promote targeted delivery of the chemotherapeutic, doxorubicin 
PLGA–PEG NPs were conjugated to a peptide that targets the EGFR. When ovarian 
adenocarcinoma cells (SKOV) were exposed to these PNPs; cellular uptake increased 
300% compared to PLGA-PEG NPs lacking the peptide (Hou et al. 2011). Furthermore, 
in 2013, the federal agency in the United States of America that is responsible for health 
and human services, the food and drug administration (FDA) approved Kadcyla, a PNP 
with a monoclonal antibody for EGFR-2 on its surface. These antibodies target metastatic 
breast cancer cells over-expressing EGFR-2 to deliver therapy directly to the diseased 
cell, reducing widespread damage to healthy cells (Chung et al. 2014; Weissig et al. 
2014). 
 
1.5 Controlled targeting of nanomedicines  
 
PNPs can be generated that release their cargo in response to one or several intracellular 
or extracellular stimuli such as temperature, pH or redox potential (Han et al. 2015; 
Constantin et al. 2017; Yeh et al. 2018). Previously PEGylated liposomal PNPs sensitive 
to both pH and temperature were used for vaginal administration of potential anticancer 
drug Arctigenin. The pH sensitivity was conveyed by an acid cleavable linker between 





the PNPs to transform from a solid to gel allowing for prolonged drug contact (Chen et 
al. 2012). 
 
Previous research has shown that a high redox environment of thiols such as glutathione 
(GSH) levels within cancer cell intracellular compartments as well as in the tumour cells 
microenvironment are present (Russo et al. 1986; Raghavendra et al. 2008; Sun & Davis 
2010; Brülisauer et al. 2014). The ability to include redox sensitive elements, such as 
disulphide bonds in NPs which respond to differences in redox potential are promising as 
they could enable effective targeting of cancer cells (Tobı́o et al. 2000; Wang et al. 2010). 
To date, redox reactive NPs have been used for the delivery of cancer drugs and gene 
therapy in vitro using human cervical cells (HeLa) using polymer and liposomal-based 
NPs (Petros et al. 2008; Takae et al. 2008).  
 
Furthermore, disulphide linkers have been utilised in the development of FDA approved 
PNPs such as Gemtuzumab ozogamicin, used in the treatment of myeloid lymphoma 
(Lehner et al. 2012). Additionally, the presence of disulphide linker has previously been 
seen to increase NP stability within biological media (Sun & Davis 2010). This increased 
stability could influence the safety profile of these NPs as they may circulate in the body 
for longer, possibly leading to differential NP-cell interactions. 
 
1.6 Coatings of nanomedicines  
 
When nanomedicines are administered intravenously, orally, dermally or via inhalation 
an exposure route specific layer of proteins adhere to the outer surface of the NP, known 
as the protein corona (Kreyling et al. 2002; Kreyling et al. 2014). There is evidence that 
the protein corona can affect NP size and can influence NP interactions with cells and 
thus affect the safety of the NPs (Fischer & Chan 2007; Lazarovits et al. 2014). When 
administering NPs in vivo one of the biggest challenges to be overcome is clearance by 
the reticuloendothelial system (RES). The RES is found in macrophage rich organs such 
as the liver and spleen, and the internalisation of NPs by these macrophages reduces their 
circulation time, to reduce their interaction with target cells/tissues (Singh et al. 2006; 






NP coatings can help reduce the interaction of NPs with the RES. One of the most 
common coatings for nanomedicines is PEG, which is FDA approved and is generally 
regarded as safe for medical use (Gref et al. 2000; Cruz et al. 2011; Svenson 2015). 
Previous research with PEGylated poly (n-butyl cyanoacrylate) PNPs showed a reduction 
of surface protein-binding to the NP, that altered the NP fate by providing a “stealth” like 
property as it prevented RES recognition and reduced clearance by macrophages in vivo, 
therefore increasing circulation time (Chaudhari et al. 2012; Bertrand et al. 2017). The 
increase in circulation time with PEG coating of PNPs may be attributed to PEG’s 
hydrophilic nature resulting in less protein opsonisation; meaning that when the NP is 
administered in vivo, fewer proteins bind to the NP surface (Alexis et al. 2008; Sheng et 
al. 2009; Li et al. 2011). This increased circulation time, could potentially reducing drug 
administration frequency, which may reduce adverse effects and enhance patient 
adherence to treatment (Li & Huang 2011). PEG also reduces NP 
aggregation/agglomeration (Murali et al. 2015). It is desirable to inhibit NP 
aggregation/agglomeration as it will reduce their usefulness in a clinical setting due to 
aggregation/agglomeration making it challenging to maintain the even dispersion 
necessary for administration and treatment (Cao et al. 2016). 
 
Furthermore, PEG has already been used for protein-PEG conjugated drugs that are FDA 
and the European Medicine Agency (EMA) approved such as Adagen, a PEGylated 
adenosine deaminase used to treat immunodeficiency disease (Hershfield et al. 1987). 
PEG, is often used to coat NPs composed of other materials such as metals, for example, 
superparamagnetic iron oxide nanoparticles used for bioimaging (Yu et al. 2012). 
Additionally, there are PEGylated lipid NPs FDA/EMA approved and in clinical use such 
as the doxorubicin containing, Doxil, used in the treatment of breast cancer (Barenholz 
2012).  
 
Studies investigating the impacts of PNP coating on safety have been performed 
predominantly with PLGA NPs. The addition of PEG to PLGA NPs can improve the NPs 
usefulness as a nanomedicine as PEG increases drug loading capability, solubility and 
stability (Danhier et al. 2009). Interestingly PEGylation of PLGA NPs can change the 





NPs were observed to specifically target tumour cells unlike PLGA NPs lacking PEG 
(Senthilkumar et al. 2008; Danhier et al. 2009).  
 
Another way of decreasing opsonisation and reducing NP aggregation/agglomeration and 
increasing NP stability is to absorb surfactants to the surface of NPs such as block 
copolymer Poloxamine 188, also known as Pluronic F68 (PF68) (Morales et al. 2005; 
Santander-Ortega et al. 2006; Gref et al. 2012). Previous research suggests that PF68-
coated NPs degrade more rapidly within the cell than uncoated NPs, to enhance the 
release of cargo and potentially impacting on PNP safety (Astete & Sabliov 2006; 
Anderson & Shive 2012; Narayanan et al. 2013).  
  
1.7 Nanomedicine accumulation in the liver 
 
Currently, the use of in vitro models is promoted for safety testing of NPs by the EMA 
(EMA 2013a) for ethical, financial and time reasons (EMA 2013b). Furthermore, there 
have been concerns about rodent (mouse and rat) use in toxicology testing due to species 
differences between rodents and humans and poor reproducibility (Bale et al. 2014; 
Johnston et al. 2018). Previous studies have shown that polymer and metal-based NPs 
accumulate within the liver after intravenous injection, oral administration, and 
inhalation, suggesting that circulating NPs could enter the liver independently of the route 
of exposure (Figure 1.2) (Ogawara et al. 1999; Park et al. 2010; Schleh et al. 2012; Hirn 
et al. 2011; Sharma et al. 2012).  
 
Hepatocytes are the main cell population in the liver, making up over 65% of the volume 
(Racanelli & Rehermann 2006). In addition, hepatocytes are responsible for many of the 
liver’s functions such as albumin production, one of the most abundant serum proteins. 
Albumin is responsible for essential functions in hepatocytes including maintaining the 
osmotic pressure of the cell, scavenging of reactive oxygen species (ROS) and transport 
of different ligands as well as drugs (Lepedda et al. 2014; Larsen et al. 2016). Therefore, 
investigation of impacts of NPs on hepatocytes in vitro is an appropriate model to assess 






Previously in vitro 2-D hepatocyte cell lines have been used to assesse a range of 
engineered nanomaterials such as TiO2, Ag, ZnO and multi-walled carbon nanotubes. 
Observations have primarily been via single exposure, at 24-72 hours post exposure for 
the potential effects on viability, cytokine production, ROS production, uptake, 
genotoxicity, intracellular calcium concentration as well as urea and albumin production 
(Kermanizadeh et al. 2012; Kermanizadeh et al. 2012; Gaiser et al. 2013; Kermanizadeh 
et al. 2013; Nguyen et al. 2015). However, few studies have investigated the toxicity of 
PNPs to hepatocytes in vitro. 
 
Previous cytotoxicity studies have been performed to assess the toxicity of (clinically 
relevant) NPs to hepatocytes in vitro. For example, highly fluorescent Au nanoclusters 
stabilized with dihydrolipoic acid (DHLA) are intended for biomedical imaging, and drug 
delivery stimulated a decrease in cell viability and an increase reactive oxygen species 
production in human hepatocyte cells (HepG2) (Shang et al. 2011; Yang et al. 2014). 
However, when superparamagnetic Fe3O4 NPs, proposed to improve magnetic resonance 
imaging were exposed to hepatocyte cells (HepG2) using the MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
assay low cytotoxicity was observed at concentrations up to 10 mg/mL (Solar et al. 2015). 
Additionally, PLGA NPs containing a near-infrared dyes intended as a contrast agents for 
molecular imaging were observed to have no effect on the viability or mitochondrial 
activity of hepatocyte cells (HepG2) (Kohl et al. 2011). Furthermore, although PNPs 
poly(6-O-methacryloyl-D-galactopyranose)-b-poly(L-lactide)-b-poly(6-O-
methacryloyl-D-galactopyranose), were observed to accumulate in hepatocyte cells 
(HepG2) these PNPs were observed to not affect cell viability up to 10 µg/ml using the 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Wang et al. 
2016).  
 
Quantification of urea and albumin production can be used as a specific indicator of liver 
function (Watts et al. 1995). Urea is formed when ammonia is detoxified predominantly 
in the liver (Gong et al. 2015). A decrease in urea or albumin production by the liver 
suggests a loss of hepatic function. Therefore, quantification of urea and albumin 
production can be used as indicators of liver or hepatocyte function (Watts et al. 1995). 





exposure of primary hepatocytes to TiO2 NPs in vitro (Natarajan et al. 2015). These 
results reflected earlier in vivo findings where a decrease in blood urea nitrogen (BUN), 
the in vivo equivalent of urea concentration, and a decrease in liver function was observed 
in mice following oral administration of TiO2 NPs (Xu et al. 2013). Additionally, 
hepatocytes (C3A) exposed to ZnO NPs showed decreased albumin production in vitro 
that did not affect urea production (Kermanizadeh et al. 2012). To date, this endpoint has 












Figure 1.2 Exposure routes: Nanomedicines. 
Poly nanomedicines in this study have been designed to be administered orally, via 
inhalation or via injection. The black arrows indicate possible fate of nanomedicines with 
in the body following exposure. The red arrows indicate how nanomedicine may enter 






1.8 Safety profiling  
 
Employing a tiered testing strategy to assess nanomedicine toxicity could speed up 
nanomedicine progression to clinical application, and save time and resources (Figure 
1.3) (Johnston et al. 2018). More specifically, using this type of approach testing 
progresses from consideration of toxicity within the design of  NPs, to characterisation of 
physicochemical properties to predict toxicity before performing in vitro testing to screen 
toxicity and then finally progressing to in vivo investigations and human studies. Using 
this type of approach, it is intended that in vivo testing is minimised, making testing more 
ethical.  
 
Another way to reduce in vivo investigations in the future could be to utilise read-across, 
which enables a prediction of the safety of novel NPs by using existing data from similar 
NPs (Arts et al. 2015). Additionally the use of in silico (computational) tools such as 
Lazar, a free web-based platform that uses read-across to predict potential NP toxicity 
based on descriptors for the NP core (current database: Ag or Au cores) and the NP 
coating (current database: 30+ coatings e.g. citrate to polyvinyl alcohol) (Helma et al. 
2017; nano-lazar.in-silico.ch/predict). Applying these principles would be in line with the 
3Rs (replace, refine, reduce) which advocates the replacement of in vivo methods with 
alternatives where possible, refinement of current in vivo methods and reduction of animal 
numbers (Burden et al. 2017; Johnston et al. 2018). 
 
Ideally, the safety testing of PNPs would be performed using standardised methods, were 
possible rely on alternative models. However, due to the complexity of PNPs under 
development and use, the testing strategy used to assess toxicity may need to be tailored 
to specific PNPs, until the level of understanding of nanotoxicity and the impact of 







Figure 1.3 Tiered testing strategy for assessment of nanomedicine safety. 
A tiered testing approach for screening PNP toxicity from NP design progressing to 
assessment of physiochemical characteristic, then in vitro analysis, then only 
progressing with suitable NPs to in vivo analysis before progressing to clinical trials. 
Information gained from each step in the tiered testing strategy can feed back into the 
safer design of NPs in the future. This approach has the potential to reduce the resources 





1.9 Cytotoxicity  
 
Endpoints used to investigate the toxicity of PNPs can be selected based on the large body 
of evidence for engineered NPs (metal, metal oxides and carbon NPs) (Brown et al. 2004; 
Huang et al. 2010; Kermanizadeh et al. 2012; Arai et al. 2015). The first step of assessing 
NP toxicity in vitro is commonly the investigation of cytotoxicity. It is crucial to establish 
the cytotoxicity of these PNPs in vitro initially, so that further testing can then be 
performed at non-lethal concentrations and more can be learned about the mechanism of 
nanotoxicity. When assessing the toxicity of nanomedicines it is also important to 
consider relatively realistic concentrations when assessing safety (Section 2.2.4). 
 
Several studies assessing PNP cytotoxicity use a single assay, primarily the MTT assay 
in a range of cells such as alveolar epithelial cells (A549), human breast adenocarcinoma 
(MCF-7 and MDA-MB-23), mouse fibroblasts (L929) and red blood cells (Fischer et al. 
2003; Esfandyari-manesh et al. 2016). The MTT assay evaluates cell viability via the 
assessment of mitochondrial function. However, a variety of alternative assays such as 
Alamar Blue (AB), AM (5-Carboxyfluorescein Diacetate, Acetoxymethyl Ester) (CFDA-
AM) and Neutral Red (NR) assays can be used to gather data on metabolic activity, 
membrane integrity and lysosomal function respectively to assess cytotoxicity/cell 
viability simultaneously (Figure 1.4) (Yuan 2014; Connolly et al. 2015). The AB assay 
measures cell metabolic activity based on the reduction of non-fluorescent Resazurin to 
fluorescent Resorufin by metabolically active cells. The CFDA-AM assay assesses 
plasma membrane integrity based on the conversion of non-fluorescent CFDA-AM to 
fluorescent 5-carboxyfluorescein by esterases within living cells. Thus, dye retention 
occurs only in cells with an intact plasma membrane. The NR assay can determine 
lysosomal function based on the uptake and retention of fluorescent 3-amino-7 
dimethylamino-2-methyl phenazine hydrochloride in functional undamaged lysosomes 
(Cenni et al. 2008). Of benefit is that these cytotoxicity assays are amenable to high 














Figure 1.4 Cytotoxicity assays.  
The AB assay measure cell metabolic activity when non-fluorescent Resazurin (blue) 
is converted to fluorescent Resorufin (purple). The CFDA-AM assay measures plasma 
membrane integrity when non-fluorescent CFDA-AM (green) is converted to 
fluorescent 5-carboxyfluorescein (orange) by esterases. The NR assay measures 










Assessing PNP uptake when investigating the toxicity of PNPs is crucial, as it can 
influence the efficacy and toxicity of PNPs (Nie et al. 2011; Zhao et al. 2011). The uptake 
of PNPs by target and non-target cells can be investigated in vitro or in vivo. Lower 
internalisation by non-target cells can be beneficial for nanomedicines, in order to reduce 
side effects. Within studies conducted to date, visualisation and quantification of the 
uptake of fluorescent PNPs by cells is the most common means of assessment. Uptake 
has been quantified for fluorescent polystyrene and PLGA NPs in macrophage, kidney, 
epithelial, fibroblast, and endothelial cell lines using predominately microscopy and flow 
cytometry (Davda & Labhasetwar 2002; Firdessa et al. 2014). Additionally, electron 
microscopy such as transmission electron microscopy (TEM) possesses a high enough 
resolution to image individual NPs; and can be a useful tool to investigate NP uptake and 
intracellular fate (Zhang et al. 2014; Niemirowicz et al. 2016).  
 
Quantification of NP uptake by cells can be challenging but essential to help understand 
the mechanism of nanotoxicity. There can be vast differences in the level of NP uptake 
between cell types. For example, Firdessa et al. showed that macrophages internalised 
100% of 200 nm polystyrene NPs using flow cytometry, whereas kidney epithelial cells 
internalised approx. 5-10% (Firdessa et al. 2014; Oh & Park 2014).  
 
Particles can enter cells via different routes, that are either active (energy dependent) or 
passive (energy independent). NPs can enter the cell passively through the cell membrane. 
However, this is not often observed and is dependent on the physiochemical properties of 
the NP (e.g. lipophilicity) (Underhill & Ozinsky 2002). To investigate the uptake of NPs 
via passive transport red blood cells are a useful model as they cannot perform energy 
dependent uptake (Underhill & Ozinsky 2002). Previous studies have observed that red 
blood cells passively internalise D-penicillamine-coated quantum dots (QD) (8 nm) with 
no damage to the cell's membrane observed (Wang et al. 2012).  
 
Energy-dependent uptake of NPs by cells occurs predominantly via phagocytosis or 
pinocytosis (Figure 1.4). Phagocytosis is mostly performed by specialised cells 





phagosomes (Conner & Schmid 2003). Macrophages internalise cell debris, particles and 
bacteria ranging from 100 nm to 6 µm, via phagocytosis, (Shu et al. 2005; Tsai & Discher 
2008; Rodriguez 2013). Macrophages are found in a range of tissues such as the liver and 
lungs and are known to accumulate NPs in vivo (Ruge et al. 2012; Jemnit et al. 2017). 
Furthermore, macrophage cells (J774) in vitro have been observed to readily internalise 
polystyrene PNPs of 20-200 nm diameter (Clift et al. 2008). Once internalised, the 
phagosome fuses with lysosomes containing hydrolytic enzymes which at a low pH digest 
the contents of the phagolysosome (Conner & Schmid 2003; Qiu et al. 2013).  
 
Knowledge of the uptake mechanism can be essential for assessing downstream toxicity, 
as uptake can determine intracellular localisation. Pinocytosis is performed by most cells 
and occurs mostly via invagination of the cell membrane to form a membrane-bound 
vesicle (endosome), that can then be transported to a range of organelles within the cells 
such as lysosomes, mitochondria or even the nucleus (Conner & Schmid 2003; Sahay et 
al. 2010). Pinocytosis can be further divided into clathrin-dependent and independent 
endocytosis for NPs ~100-200 nm and under 100 nm respectively. Clathrin-independent 
endocytosis can also include caveolae-dependent (<80 nm) and clathrin/caveolae 
independent endocytosis known as macropinocytosis (Conner & Schmid 2003; Sahay et 
al. 2010; Kasper et al. 2013). 
 
The mechanism of PNP uptake into cells can be investigated using specific inhibitors of 
endocytic processes such as Wortmannin, which prevents phagocytosis and 
macropinocytosis, or chlorpromazine hydrochloride, which inhibits clathrin-mediated 
endocytosis (Firdessa et al. 2014). PNPs such as poly(methacrylic acid-co-cholesteryl 
methacrylate) containing the chemotherapy doxorubicin have been observed to be 
internalised by hepatocyte cells (HepG2) via caveolae-dependent and clathrin-mediated 
endocytosis using pharmacological inhibitors (Sevimli et al. 2015). Moreover, hepatocyte 
cells (HepG2) have been observed in vitro to endocytose cholesterol-modified pullulan 
(a natural polymer) PNPs via both macropinocytosis and clathrin-mediated endocytosis 
(Jiang et al. 2013). These results highlight that hepatocytes internalise PNPs via several 
mechanisms of uptake. However as the inhibitors used to determine the uptake 
mechanisms can themselves cause alterations to the cells, it can be challenging to make 





Fluorescent probes (to identify specific organelles) and TEM have also been used to 
















Figure 1.5 Schematic of the NP-cell interaction. 
NPs can enter the cells through a range of mechanisms passive, clathrin-dependent 
endocytosis, caveolae-dependent endocytosis, micropinocytosis and phagocytosis. Once 
inside the cell NPs (green) are transported either directly to the lysosome for degradation 
or indirectly via the early and late endosome. NPs can also be transported to the nucleus, 





1.9.2 Cytokine production 
 
Activation of an inflammatory response by NPs is commonly observed in vivo, with 
inflammatory responses typically monitored via assessment of immune cell accumulation 
or cytokine production (e.g. (Park et al. 2010; Yukawa et al. 2014), reviewed by (Johnston 
et al. 2018)). For example, exposure of mice to cobalt NPs (50 μg/ animal) via 
intratracheal installation resulted in an increase in the infiltration of neutrophils and 
macrophages in the alveolar space indicating acute lung inflammation (Wan et al. 2017). 
Additionally, when mice were exposed via the murine air pouch model to 
polyamidoamine (PAMAM) dendrimer PNPs, an increase in the infiltration of 
leukocytes, the majority of which were neutrophils, was observed indicating these PNPs 
had proinflammatory activities (Durocher & Girard 2016) 
 
Investigation of cytokine production is also commonly used as an indicator of NP toxicity 
in vivo and in vitro (Stone et al. 2009). Interleukin-8 (IL-8) is a chemokine that can initiate 
a pro-inflammatory response via activation and migration of immune cells, and in 
particular neutrophils (Larsen et al. 1989). Cationic polyethyleneimine (PEI) NPs caused 
an increase in keratinocyte chemoattractant (KC) levels (the mouse homolog of IL-8), 
following intraperitoneal injection of mice bearing tumours (Cubillos-Ruiz et al. 2009). 
In vitro, several studies have indicated that NPs of diverse physicochemical properties 
stimulate an increase in IL-8 production by hepatocytes (Cho et al. 2012; Dobrovolskaia 
& McNeil 2013; Elsabahy et al. 2013). Interestingly, low-toxicity NPs such as TiO2, as 
well as high-toxicity NPs including Ag NPs, can stimulate IL-8 production by 
hepatocytes (e.g. C3A cells and primary human hepatocytes) (Joshi-Barve et al. 2007; 
Kermanizadeh et al. 2013). Tumour necrosis factor alpha (TNF-α) is a cytokine that plays 
a role in acute phase response as well as tissue repair and upon upregulation can promote 
systemic inflammation (Natanson et al. 1989; Marino et al. 1997; Goeddel 1999). TNF-α 
has previously been seen to be produced by hepatocytes following inflammation in vivo 
in mice (Spencer et al. 2013).  
 
IL-6 is a proinflammatory cytokine that plays a role in the acute phase response as well 
as liver regeneration following injury (Ferguson-Smith et al. 1988 ; Cressman et al. 1996). 





observed to induce IL-6 expression and production when challenged by 
lipopolysaccharide (LPS), a bacterial hepatotoxin (Norris et al. 2014). Additionally, 
respiratory epithelial cells (A549) had elevated IL-6 production when exposed to PNPs 
such as PEI NPs and PLGA/ polyvinyl alcohol NPs. However these NPs failed to increase 
production of IL-8 (Robbens et al. 2010; Grabowski et al. 2013). Furthermore, PNPs 
made up of N-isopropylacrylamide, vinylpyrrolidone and acrylic acid have been seen to 
elicit a cytokine response in hepatocyte cell lines (HSC-T6), with an increase in the 
production of both IL-6, and TNF-α observed (Bisht et al. 2011). 
 
IL-1β is a proinflammatory cytokine that is expressed by many cell lines such as 
macrophages and hepatocytes (Saklatvala & Dingle 1980 ; Negrin et al. 2014; Chen & 
Xu 2018). Mice instilled intratracheally with TiO2 NPs had increased IL-1β mRNA 
expression observed in the kidneys (Huang et al. 2015), while in vitro macrophage cell 
lines have been seen to increase production of IL-1β when exposed to Ag or silicon 
dioxide (SiO2) NPs (Carlson et al. 2008; Park & Park 2009). The IL-1 inhibitor, IL-1 
receptor antagonist (IL-1ra), is an anti-inflammatory cytokine that has previously been 
suggested to have a protective role during liver inflammation (Gabay et al. 2010). 
Additionally, previous studies suggest in vivo in mice that hepatocytes can produce high 
levels of IL-1ra in response to LPS (Lamacchia et al. 2012). There are limited studies 
assessing IL-1ra production by PNP exposure in vitro and in vivo. Although for NPs 
composed of other materials IL-1ra production in response to NPs has been studied, in 
vitro. For example, a significant increase in IL-1ra production was observed from THP-
1 cells (human monocyte) exposed to TiO2 NPs (Kim et al. 2007). While, in vivo when 
osteoporosis patients were treated with 100 mg/day of sodium alginate NPs (approx. 200 
nm), this also induced an increase in circulating levels of IL-1ra (Qu et al. 2017).  
 
TiO2 NPs in relation to nanotoxicity are much like PNPs as they are assumed to have 
relatively low toxicity due to relatively low reactivity, however proinflammatory 
cytokines (TNF-α, IL-1β and IL-6) have been elevated in cells  (e.g. hepatocytes) 
following exposure to TiO2 NPs (Cui et al. 2011; Kermanizadeh et al. 2012) as well as 
IL-1ra (Bale et al. 2014). However, several studies suggest that PNPs do not elicit a potent 
cytokine response. For example, monocytes and polymorphonuclear cells were exposed 





TNF-α or IL-8 cytokine production (Segat et al. 2011). While, alveolar epithelial cells 
(A549) exposed to cationic polystyrene NPs (57 nm), observed a slight reduction in IL-8 
production (Thach & Finkelstein 2013). Investigation of the capacity of PNPs to stimulate 
an inflammatory response is essential to screen during nanomedicine safety profiling as 
prolonged inflammation could result in adverse effects in the clinic. 
 
1.9.3 Oxidative stress 
 
ROS such as hydrogen peroxide, superoxide and hydroxyl radical are normal by-products 
of metabolism and can have essential physiological functions. However, they can also 
compromise cell function by damaging lipids, protein and DNA. When ROS levels are 
raised within cells, this can lead to oxidative stress, a potential detrimental state for the 
cell which is characterised by an increase in ROS production and depletion in protective 
antioxidants (Sims et al. 2017). In the liver (as well as other cell types), an increase in 
intracellular ROS could result in an imbalance of ROS and antioxidants, which favours 
ROS, leading to indirect downstream effects such as DNA damage and metabolism 
changes to the hepatocytes (Filippi et al. 2014; Evans et al. 2017). ROS generation can 
also decrease mitochondrial membrane potential resulting in unhealthy mitochondria and 
potentially cells (George et al. 2009). 
 
ROS production has been studied for engineered NPs (e.g. copper oxide (CuO), Ag) in 
hepatocytes in vitro as well as macrophages (e.g. Liu et al. 2016; Ahmad et al. 2016). 
Additionally, an increase in ROS production was observed following cadmium 
selenide/zinc sulfide QD exposure in rat pheochromocytoma cells (PC12), primary 
human umbilical vein endothelial cells (HUVEC) and murine neural progenitor cells 
(C17.2) (Soenen et al. 2014). Interestingly, the addition of a polymer coating to a metal 
or metal oxide NPs has previously been seen to reduce NP induced ROS production, for 
example, mice orally administered poly-vinyl-pyrrolidone coated Au NPs had a lower 
level of ROS production in the liver in comparison to the uncoated Au NPs (Iswarya et 
al. 2016). Similarly, when superparamagnetic iron oxide NPs were coated with PEG and 
administered in vitro to porcine aortic endothelial cells less ROS production was observed 






Previous research shows low levels of ROS production elicited by PNPs, such as cervical 
cancer cells (HeLa) exposed to natural chitosan PNPs (< 30 nm) or macrophages 
(RAW264.7) and human lung cells (BEAS-2B) exposed to PLGA NPs < 200 nm (Benito-
Miguel et al. 2015; Zheng et al. 2015). However, studies using hepatic cells (HuH7), as 
spheroid cultures, have indicated that PEGylated and non-PEGylated PAMAM dendrimer 
NPs could produce a ROS response (Chen et al. 2016). Also, PLGA NPs coated with PEI 
have been observed to increase ROS production in hepatocytes in vitro (HepG2) (Yu et 
al. 2014). Interestingly this response was not seen to change with increasing concentration 
(25-250 µg/mL) indicating that ROS production can occur at relatively low 
concentrations without affecting cell viability (Yu et al. 2014).  
 
1.9.4 Genotoxicity  
 
DNA damage (genotoxicity) can lead to mutations, which may promote disease 
development such as cancer. Therefore testing of NP genotoxicity is an integral part of 
nanomedicine safety profiling, as the adverse effects of genetic damage may out weight 
the therapeutic benefits (Vidal et al.2001). Previous studies have shown that NPs of 
different physicochemical properties may be able to stimulate genotoxic effects directly 
via NP-DNA interactions (An et al. 2010; Tang et al. 2012), indirectly via NP-induced 
ROS production (Sharma et al. 2012) or via interactions with proteins relevant to cell 
division or DNA repair (Huang et al. 2009). Direct NP-DNA interactions may correlate 
with uptake and be size-dependent, with smaller NPs potentially entering the nucleus via 
nuclear pores and directly interacting with the DNA (Barillet et al. 2010; Jin et al. 2012). 
For example, silicon carbide NPs of approx. 10 nm have been shown to enter the nucleus 
of alveolar epithelial cells (A549) (Barillet et al. 2010). Also, NPs could potentially 
interact directly with DNA or nuclear proteins during mitosis (Frohlich 2012). 
 
NPs generated ROS may potentially induce oxidative damage leading to DNA strand 
breaks or base lesions (Cooke et al. 2003). In a previous study, ZnO NPs were observed 
to cause DNA damage mediated via oxidative stress in hepatocyte cells (HepG2) 
(Kermanizadeh et al. 2014). This study used the alkaline comet assay that allows for the 





stress with the addition of formamidopyrimidine DNA glycosylase (Fpg), repair enzyme 
that recognises oxidised bases in damaged DNA (Collins 2004; Sharma et al. 2012).  
 
As highlight by the EMA, genotoxicity is a crucial safety assent endpoint when assessing 
PNP nanomedicines (EMA 2012). When genotoxicity is observed for PNP 
nanomedicines, this can hinder progression of these PNPs to the clinic as genotoxicity 
can be related to the deployment of cancers. However to date, there are relatively limited 
publications on ROS-mediated genotoxicity for PNPs, compared to publications based on 
genetic damage mediated by metal and metal oxide NPs (Deng et al. 2017). However, in 
a prior comparative study, PLGA- poly (ethyl oxide) (PEO) NPs, at therapeutically 
relevant concentrations, were seen to be genotoxic to hepatocytes as well as Kupffer cells 
4 hours and 24 hours post exposure in vitro in rat hepatocytes (Cowie et al. 2015). 
Interestingly, using eight different cell lines, hepatocytes were the most sensitive cell line 
to DNA strand breaks when exposed to iron (II, III) oxide (Fe3O4), TiO2 and SiO2 NPs at 
concentrations up to 80 µg/cm2, highlighting the sensitivity of hepatocytes to NP toxicity 
(Cowie et al. 2015).  
 
Several in vitro studies investigating genotoxicity of polymer-based nanomedicines at 
more realistic non-cytotoxic concentrations showed limited genotoxicity. Studies 
investigating the cytotoxicity and genotoxic capability of thermo-responsive dendritic 
polymer nanogels (polyglycerol-poly(glycidyl methyl ether-co-ethyl glycidyl ether) 
designed as novel drug delivery systems for dermal application indicated that in primary 
normal human keratinocytes (NHK), adult human skin (HaCaT) and dendritic (XS52) 
cell lines, neither cytotoxic and genotoxic effects were observed (Edlich et al. 2017; 
Gerecke et al. 2017). Additionally, using human isolated peripheral blood mononuclear 
cell the cytotoxicity and genotoxicity of PLGA-PEO NPs were investigated. While,  there 
were indications of cytotoxicity above 75 mg/cm2, assessment of genotoxicity at non-
cytotoxic concentrations revealed that there was no genotoxic observed by DNA strand 
breaks, oxidised bases or chromosomal aberrations (Tulinska et al. 2015). 
 
Although, there have been studies that point towards PNPs having the capabilities to 
induce genetic damage using different endpoints. Previously investigating DNA stand 





human T lymphocyte cells (Jurkat) (Acosta- et al. 2012). Genotoxicity was also explored 
in fibroblast cells (L929) using poly(methyl- methacrylate) NPs, although there was 
limited internalisation of these NPs, genotoxicity was as chromosol damage (Graça et al. 
2017). These studies show the importance of using multiple endpoints to investigate 
genotoxicity. 
 
Also, the physicochemical characteristic of the PNPs along with the sensitivity of 
different cell lines has been investigated. The effects of NP surface charge on in vitro 
genotoxicity were investigated using both using PLGA NPs with three different cell lines 
(mouse lymphoma (L5178Y), human B-lymphoblastoid (TK6) and human bronchial 
epithelial (16HBE14o-)). Interestingly no genotoxicity was observed for negatively or 
neutral PNPs however, PLGA NPs with a positive charge on their surface were cytotoxic 
and capable of inducing chromosomal damage in 16HBE14o- cells but not induce DNA 
strand breaks (Platel et al. 2016). 
 
Importantly in vitro and in vivo models are being used to assess genotoxicity of PNPs. 
Both in vitro and in vivo investigations were performed for the biodegradable copolymer 
(ethyl vinyl ether and maleic anhydride) intended for oral drug delivery (Iglesias, Cerain, 
et al. 2017)(Iglesias, Dusinska, et al. 2017)(Iglesias, Irache, et al. 2017). In vitro studies 
showed that these copolymer NPs did not induced genotoxicity in Caco-2 cells up to 2 
mg/mL or mouse lymphoma cells up to 600 µg/mL (Iglesias, Cerain, et al. 2017)(Iglesias, 
Dusinska, et al. 2017). However, in vivo studies in mice, using these copolymer NPs 
indicated, these NPs were capable of induction DNA strand breaks and oxidised bases in 
the duodenum at a dose of 2000 mg/kg (Iglesias, Irache, et al. 2017). Although 2000 
mg/kg is a relatively high does, these results do highlight the importance of though 
genotoxicity assessment of PNPs for medical use.  
 
1.9.5 Intracellular calcium  
 
Intracellular calcium concentration ([Ca2+]i) is strictly regulated and has essential roles in 
cell metabolism and gene expression. An increase in [Ca2+]i can lead to membrane 
damage, apoptosis, cytokine production as well as DNA damage (Florea et al. 2005; 





injury and has potential as a marker for nanomedicine induced hepatotoxicity (Trump et 
al. 1984; Tolosa et al. 2012; Jemnitz et al. 2017). Previous studies have seen an increase 
in [Ca2+]i in a variety of cell types following NP exposure, including Ag NPs (Johnston 
et al. 2015), TiO2 NPs, (Simon et al. 2011), ZnO NPs (Huang et al. 2010), polymer NPs 
(Jemnitz et al. 2017) and ultrafine carbon black (UFCB) (Stone et al. 2000; Möller et al. 
2005). In vitro studies have demonstrated that increased [Ca2+]i following NP exposure 
can be associated with decreased cell viability in neuroblasts (Meindl et al. 2015) and 
membrane repair in cervical cancer cells (HeLa) (Shareia et al. 2009). Additionally, an 
increase in [Ca2+]i in rat pulmonary artery smooth muscle cells was linked to an increase 
in cell proliferation which can be an indicator of a damaged cell, following acute SiO2 
NP exposure (Dubes et al. 2017). 
 
Limited studies have assessed the impact of PNPs on [Ca2+]i. However, there is evidence 
that polystyrene NPs of <100 nm are capable of inducing an increase in [Ca2+]i in 
macrophages and neuroblasts (Brown et al. 2001; Meindl et al. 2015). Furthermore, 
PLGA NPs <100 nm increased intracellular calcium influx in both macrophage cells 
(RAW264.7) and human lung cells (BEAS-2B) (Zheng et al. 2015). Interestingly, 
hepatocytes derived from rats have shown an increase [Ca2+]i when exposed to polymer 
PAMAM dendrimers NPs. However this increase in [Ca2+]i did not occur when cells were 
exposed to PEGylated PAMAM dendrimers NPs (Jemnitz et al. 2017). These results 
indicate that polymer NPs can elicit an increase in [Ca2+]i in a range of cell lines and that 
NP physicochemical properties such as shell/coatings may impact upon the magnitude of 
the response observed. 
 
It is uncommon to assess [Ca2+]i, however, the addition of this endpoint could provide 
valuable insight into the effects of shorter NP-cell interaction times that are not examined 
in routine assays that are predominantly performed at 24 hours such as following 
intravenous administration. This shorter NP-cell interaction times may have clinical 
relevance for nanomedicines that are administered intravenously. 
 






The overall aim of this project is to guild the development of evidence-based in vitro 
approaches to screening the toxicity of PNPs of various physiochemical properties. This 
information could be used in a tiered testing approach which enables a screening of PNP 
toxicity using a battery of in vitro tests before progressing with in vivo testing. This 
approach has the potential to reduce the resources required for testing these PNPs such as 
time, financial investment and animal number, therefore becoming more in line with the 
principles of the 3Rs (Burden et al. 2017).  
 
Therefore, this study aims to investigate the toxicity of a panel of PNPs to the liver in 
vitro via investigation of: 
 
1. The role of a polymer coating (PF68) on the toxicity of PNPs to hepatocyte and 
macrophage cells in vitro. 
 
2. The role of polymer composition (PLGA and PEG chain length) on the toxicity of PNPs 
to hepatocyte cells in vitro. 
 
3. The role of controlled targeting elements (redox sensitive PLGA PNPs) on the toxicity of 
PNPs to hepatocyte cells in vitro. 
 
Existing knowledge of the mechanism of NP toxicity informed endpoint selection in this 
study. More specifically, a range of tests will be employed to investigate the cellular and 
molecular events underlying the potential toxicity of PNPs to hepatocytes in vitro. The 




II. Cytokine production  
 
 
III. ROS production 
 









VI. Albumin and urea production 
 
VII. Intracellular calcium concentration  
 
It is hypothesised that the physicochemical properties of PNPs (e.g. composition, size, 
surface coating) will influence their uptake by cells and their ability to stimulate 
cytotoxicity, cytokine production, ROS production, genotoxicity, urea and albumin 











Chapter 2. In vitro assessment of the influence of Pluronic coating on polymer NP 






2.1 Introduction  
 
2.1.1 Designing safe novel PDP PNP for nanomedicine 
 
Polymer-based NPs can be relatively quick and inexpensive to produce, leading to the 
rapid development of a diverse array of polymeric NPs. However, investigations into 
polymer NP safety have lagged-behind their production. As a result, many uncertainties 
linger regarding the potential adverse health effects of these materials and how the 
polymer characteristics vary, highlighting an urgent need to assess polymer NP safety. 
With the growing use of and exposure to NPs, a comprehensive understanding of NP 
safety is necessary to ensure their safe use.  
 
For this study, a linear polyester with phenyl containing side chains that could form 
micelles was generated by collaborators at the University of Nottingham that could form 
micelles. These NPs were designed as nanomedicines. Previous studies have 
demonstrated that an increase in phenyl content in the side chain of polymers can increase 
the polymers’ biodegradability, a highly desirable trait for nanomedicines (Jin et al. 
2000).  
 
Cancer treatment has been the focus of many nanomedicines. The PNPs in this study 
(section 2.2.1) were designed to be under 200 nm in diameter to take advantage of the 
EPR effect, which allows NPs to accumulate passively within tumours (Matsumura & 
Maeda 1986; Yokoyama et al. 1990; O’Neal et al. 2004). Additionally, the PNPs prepared 
for this study contained the hydrophobic fluorescent dye coumarin-6 to mimic 
hydrophobic drug loading and to allow for NP visualisation using fluorescent microscopy. 
Micellar PNPs were generated using the novel block-copolymer poly (decamethylene 
succinate-co-pheylsuccinate) (PDP) with 70% succinic acid, and 30% phenylsuccinic 
acid as this composition was found to have the highest loading capability (Figure 2.1) 
(Kakde et al. 2016). With safety at the forefront, these PNPs were produced to have a 
negative charge, as earlier studies have shown that positively charged NPs can be more 
toxic, although positively charged NPs have the advantage that they can be taken up more 





In this study, PF68, was adsorbed onto the PNP surface, this surfactant introduces 
“stealth” like properties, decreases polymer NP aggregation/agglomeration and increases 
stability due to steric stabilisation (Moghimi et al. 1994; Reich et al. 1997). PF68 is a 
triblock copolymer, meaning it is composed of 3 blocks (lengths) of connection polymers, 
e.g. PF68 composed of PEO connected to poly (propyl oxide) (PPO) with in turn is 
connected to an additional PEO (PEO-PPO-PE). PF68 containing 80% poly PEO and 
20% PPO (Mei et al. 2009). PEG and PEO are similar as they are composed of the same 
polymer, with differing molecular weights (Moghimi et al. 2004). Adsorbance of the 
surfactant PF68 to the NP’s surface could change the safety profile of the NP by 
decreasing aggregation/agglomeration and increasing NP stability (Morales et al. 2005; 
Santander-Ortega et al. 2006). Using these NPs, it was possible to compared the toxicity 
of coated and non-coated NPs, allowing for the assessment of  how coating (PF68) of 
polymer based nanomedicines could influence overall PNP toxicity. 
 
2.1.2 The effect of PF68 coating on PNP safety 
 
PF68 is a surfactant used as a coating to increase the stability of NP suspensions and has 
previously been shown to decrease PNP uptake in macrophage and hepatocyte cell lines 
(Zhang et al. 1998). Studies investigating the impacts of PF68 coating on PNP safety have 
been performed predominantly with PLGA NPs. For example, Grabowski investigated 
the interaction of PF68-coated PLGA NPs with THP-1 (macrophage) cells and showed 
that exposing cells to concentrations as high as 100 µg/mL of PF68-coated PLGA NPs, 
induced no change in cytotoxicity or cytokine production (IL-8, IL-6, monocyte 
chemoattractant protein 1 (MCP-1) or TNF-α) when compared with uncoated PLGA NPs 
following 24 hours exposure (Grabowski et al. 2013; Grabowski et al. 2015).  
 
However, alveolar epithelial cells (A549) treated with PF68-coated PLGA NPs at 100 
µg/mL, did result in increased production of IL-8, IL-6 and MCP-1 in comparison to cells 
exposed to medium alone. There was also increased PNP internalisation, resulting in 
granulation of the cells when compared with PNPs coated with polyvinyl alcohol and 
chitosan, as well as PF68 alone (Grabowski et al. 2013; Grabowski et al. 2015). 
Interestingly, when a different lung cell model, Calu-3, (lung epithelial) was exposed to 





concentrations (5 mg/mL), with no increase in cytokine production observed (IL-6 and 













Figure 2.1 Scheme of micellar PDP and PDP-PF68 NPs. 
Representation of NPs used in this study made of polymer PDP (orange), coumarin-6 







2.1.3 Study aims and hypothesis  
 
This study aimed to evaluate the impact of a PF68 coating on PDP NP toxicity. Initially, 
after 24-hours exposure, cytotoxicity was assessed in C3A hepatocytes as it is established 
that NPs administered via various routes accumulate in the liver. C3A cells are clonally 
derived from of human hepatocyte cells, HepG2. The C3A cells can be more suitable for 
semi-high throughput assays than HepG2 as C3A cells have stronger contact inhibition 
of growth, promoting a single cell layer, resulting in more reliable assay results (Kelly 
1994).  Next, the uptake of NPs was visualised using fluorescent microscopy and 
quantified using a fluorescence plate reader, followed by measurement of cytokine 
production. The genotoxicity was assessed via the Comet assay and the contribution of 
ROS to DNA damage evaluated. A brief investigation of cytotoxicity and uptake of NPs 
in the macrophage cell line J774 was performed to compare target sites and the usefulness 
of different cell lines as predictive models of PNP toxicity. Due to these batch produced 
NPs having short stability, low volume and low NP concentration, it was not always 
possible to perform all desired endpoints or for a full complement of concentrations to be 
used for applied endpoints. 
 
It was hypothesised that  
1. PDP and PDP-PF68 NPs, at pharmacologically relevant concentrations would 
stimulate minimal cytotoxicity in both C3A hepatocyte cells and J774 
macrophage cells.  
 
2. PF68-coated NPs would be internalised to a lesser extent than uncoated PDP NPs 
and stimulate less cytokine production in both cell lines. 
a. J774 macrophage cells would internalise more NPs that C3A hepatocyte 
cells. 
b. With lower uptake of PDP-PF68 compared to PDP NPs. 
 
3. PDP-PF68 would be less genotoxic than PDP NPs.  





2.2 Materials and methods 
 
2.2.1 NP preparation  
 
NPs were prepared from a novel polyester, by collaborators (Prof Cameron Alexander 
and Dr Kakde) from the University of Nottingham. The polymer, PDP was synthesised 
using succinic acid, phenylsuccinic acid and 1, 10-decandiol (Figure 2.2).  
 
 
Figure 2.2 Polymer synthesis of PDP NPs. 
Chemical structure and synthesis scheme of the block copolymer, PDP, used to 
formulate PF68 coated and uncoated NPs (adapted from Kakde et al. 2016). 
 
 
NPs composed of poly (decamethylene succinate-co-pheylsuccinate) termed PDP, 
containing coumarin-6 dye were prepared using a nanoprecipitation method without and 
with a PF68 coating termed PDP-PF68. In brief, at room temperature (RT) PDP (20 mg) 
and coumarin-6 (1 mg) were dissolved in acetone (5 mL), and then this polymer dye 
solution was added dropwise to high-performance liquid chromatography water (10 mL) 
using a syringe pump, with or without the addition of 0.5% PF68. To help acetone 
evaporation, the suspension was stirred without a lid for four hours and then allowed to 
evaporate overnight without stirring.  
 
Any evaporated water was replaced before the suspensions were filtered through a 
membrane syringe filter (pore size: 220 nm) (Millipore) and passed through PD10 
Desalting Column (GE Healthcare Life Sciences) to separate the free dye from the 





immediately stored at stored at 4○C upon arrival. Stability was determined by monitoring 
changes in hydrodynamic diameter and identified to be one month (Kakde et al. 2016). 
For use in experiments, NPs were freshly diluted in cell culture medium and briefly 
vortexed. 
 
2.2.2 NP characterisation  
 
NPs were characterised by dynamic light scattering (DLS) and TEM. Using DLS, NPs 
were prepared in a phenol-red free Minimum Essential Medium Eagle cell culture 
medium containing 10% heat-inactivated foetal bovine serum (FBS), 2 mM L-glutamine 
(Gibco, Invitrogen), 100 U/mL penicillin/streptomycin (Gibco, Invitrogen), 1 mM 
sodium pyruvate (Sigma-Aldrich) and 1% non-essential amino acids (Sigma-Aldrich) 
termed PRF-Complete Medium at a NP concentration of 125 µg/mL. Hydrodynamic 
diameter, polydispersity index (PDI- an unitless value that reflects size distribution and 
stability of NP suspensions, (section 2.5.2)) and zeta potential were measured using a 
Zetasizer Nano ZS (Malvern) at the time of preparation (T0) and 24 hours post-incubation 
at 37○C and 5 % carbon dioxide (CO2) (T24). Data are expressed as mean ± standard error 
mean (SEM).  
 
TEM was used to verify the shape and size of the NPs, which were prepared at a 
concentration of 125 µg/mL in PRF-Complete Medium, then suspended on 200 mesh 
Formvar/Carbon Copper Grids (TAAB). These grids were air-dried for 30 minutes and 
imaged using a JEM-1400 Plus (JEOL) transmission electron microscope equipped with 
GATAN Oneview Camera and Gatan -GMS3 software operating at 80 kV. Images were 
processed and analysed using ImageJ/Fiji software. 
 
2.2.3 Cell culture and cell treatment with NPs 
 
Human C3A hepatocellular carcinoma cells and mouse J774 macrophage cells were 
obtained from the American Type Culture Collection. C3A cells were cultured in 
Minimum Essential Medium (MEM) supplemented with 10% heat-inactivated FBS, 2 
mM L-glutamine (Gibco, Invitrogen), 100 U/mL penicillin/streptomycin (Gibco, 





(Sigma-Aldrich), termed Complete Medium. J774 cells were cultured in RPMI Medium 
supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin/streptomycin (Gibco, 
Invitrogen), termed Complete J774 Medium.  
 
Both cell lines were maintained at 37○C and 5% CO2 in 75 cm
2 tissue culture flasks 
(Corning). C3A cells were sub-cultured using 0.25% trypsin, in phosphate-buffered saline 
(PBS) (Gibco, Invitrogen). J774 cells were sub-cultured using a cell scraper. For use in 
experiments, cells were counted, and their viability assessed using 0.4% trypan blue 
(Gibco, Invitrogen) and a Bright-Line Haemocytometer (Sigma-Aldrich). Cells were 
seeded into microplates and incubated at 37○C and 5% CO2 for 24 hours before exposure 
to NPs.  
 
2.2.4 Identification of relevant NP concentrations for testing 
 
To determine the appropriate concentrations of NPs for in vitro experiments the dose of 
Genexol ™, a polymeric micellar nanomedicine currently used in the treatment of cancer 
was used as a model nanomedicine (Yang et al. 2011). Genexol is typically administered 
to human patients at dosages of 300 mg/m2 (m2 is area of the human patients), every 3 
weeks for 5 cycles for recurrent breast cancer, resulting in a total dose administration 
(TDA) of 1500 mg/m2 (Kim et al. 2004). To convert mg/m2 to mg/kg for human 
consumption, Km (37 for humans) was used to convert surface area to weight ratio, based 
on guidance from the FDA (FDA 2005). 
Km is a conversation factor, calculated as follows, Km=100/KxW
0.33, were K is a 
dimensionless factor used to adjust for animal body shapes differences that result in 
different surface area to weight ratios and W is body weight in kg (FDA 2005).  
 
A TDA in mg/kg of 40 mg/kg was calculated by dividing the TDA in mg/m2 by the human 
Km. The total dose administered per individual (TDAI) of 2838 mg was calculated by 
dividing the average weight of a human male (70 kg) by the mg/kg calculated 
above. Next, to estimate the possible clinially relevant maxium NP exposure of each 
heptocyte in a liver the following assumptions were made, that 100% of administered NPs 
accumulate in the liver and that the NPs distribute equally amongst all hepatocytes. The 





minimal weight of a healthy human male liver is 986 g, resulting in 1.686x1011 
hepatocytes in the average male liver (Molina & DiMaio 2012). An in vivo dose per 
hepatocyte (DPH) of 1.68×10-5 µg/hepatocyte was calculated by dividing the TDAI by 
the number of hepatocytes in an average male liver. 
 
It was essential to have an in vitro exposure range containing concentrations similar to 
those expected for in vivo dosing to reflect the application of these NPs in the clinic. For 
in vitro experiments, a concentration ranging from 1-300 µg/mL was used. Assuming the 
concentration was distributed equally among all the C3A hepatocytes, a concentration per 
cell in vitro of 6.0×10-4 µg/hepatocyte was calculated by dividing the top concentration 
of NPs (300 µg/mL) by the number of C3A hepatocyte cells (5x105 cells/mL). Therefore, 
300 µg/mL gave µg/hepatocytes one order of magnitude higher than that seen in vivo; it 
was determined that serial dilution from this maximum value would, therefore, generate 
useful data. 
 
2.2.5 Cytotoxicity Assay: AB, CFDA-AM, NR 
 
A 96-well plate fluorescent-based assay which simultaneously assessed the viability of 
C3A cells following exposure to NPs using AB, CFDA-AM and NR assays was applied 
(Connolly et al. 2015).  
 
Cells were seeded at a concentration of 1.56x105 cells/cm2 in 96-well plates and incubated 
for 24 hours at 37○C and 5% CO2. Cells were then exposed to NPs (4.6, 9.3, 18.7, 37.5, 
75.0, 150 and 300 μg/mL) (100 μL/well) or MEM Complete Medium (control), 1% Triton 
X100 (positive control) or sterile water diluted in medium (vehicle control) in triplicate 
for 24 hours at 37○C and 5% CO2.  
 
Following NP treatment, the cell supernatant was collected and frozen at -80˚C, and cells 
were washed twice using PBS. Next, a solution containing 1.25% v/v AB (TREK Lab 
Services) and 4 µM CFDA-AM (Sigma-Aldrich) was prepared in PRF Complete Medium 
and added (100 µL/well), and cells were incubated at 37°C and 5% CO2 for one hour. 
Fluorescence was measured on a SpectraMax M5 Microplate Reader (Molecular Devices) 






Cells were then washed twice using PBS, and NR solution (33 µg/mL) in PRF Complete 
Medium added to each well (100 µL) (Sigma-Aldrich) and incubated at 37○C and 5% 
CO2 for one hour. Following incubation, cells were washed three times with PBS. Then 
50% ethanol and 1% acetic acid was prepared in water (Baxter) and added (100 µL) 
before shaking the plates at RT for 20 minutes. Fluorescence was measured in a 
SpectraMax M5 Microplate Reader at an Ex/Em of 532/645 nm. All experiments were 
repeated three times, with some concentrations changed between each repetition to fill in 
the gaps in the concentration-response curve, according to the benchmark concentration 
approach (De Jong et al. 2013). The benchmark concentration approach here refers to 
building on the previous experiment replicates to form a complete concentration-response 
curve by addressing additional doses between replicates, this can allow for independence 
in concentration choice and concentration spacing as well as allow for comparison 
between different NPs (Wignall et al. 2014). Data are expressed as mean % cell viability 
(i.e. % of untreated control) ± SEM. 
 
To determine the interference potential of the NP with the assay parameters, NPs (4.6, 
9.3, 18.7, 37.5, 75.0, 150 and 300 μg/mL) where prepared in triplicate, in PRF Complete 
Medium alone (100 μL/well) and fluorescence was measured on a SpectraMax M5 
Microplate Reader at excitation/emission (Ex/Em) of 532/590 nm for AB, 485/535 nm 
for CFDA-AM and 532/645 nm for NR immediately following preparation (T0) and 
following 24 hours at 37○C and 5% CO2 (T24). To assess if NPs interfered with the assay 
reagents, NPs (4.6, 9.3, 18.7, 37.5, 75.0, 150 and 300 μg/mL) where prepared in triplicate, 
in PRF Complete Medium containing 1.25% v/v AB, 4 µM CFDA-AM or 33 µg/mL NR 
solution (33 µg/mL) (100 μL/well) and fluorescence was measured on a SpectraMax M5 
Microplate Reader at excitation/emission (Ex/Em) of 532/590 nm for AB, 485/535 nm 
for CFDA-AM or 532/645 nm for NR immediately following preparation (T0) and 
following  1 hour at 37○C and 5% CO2 (T1). To establish if the NPs interference with the 
assays end product that is to be measured fluorescently , NPs (4.6, 9.3, 18.7, 37.5, 75.0, 
150 and 300 μg/mL) where prepared in triplicate, in PRF Complete Medium containing 
the end product of AB, Rescurufin (2uM) or the end product of CFDA-AM, 5-CF(4uM) 
(100 μL/well) and fluorescence was measured on a SpectraMax M5 Microplate Reader 





immediately following preparation (T0) and following 1 hour at 37○C and 5% CO2 (T1). 
Inference results were only reported when positive. 
 
2.2.6 Uptake assay: Confocal microscopy 
 
Cells were seeded onto 12 mm uncoated glass coverslips at a concentration of 6.58x104 
cells/cm2 at 37○C and 5% CO2 in 24-well plates for 24 hours. Next, they were exposed to 
a sub-lethal concentration of NPs (equivalent to 100 µg/mL in 96 well plate set up 
determined during cytotoxicity assays, section 2.2.5) or control (MEM Complete 
Medium) for 10, 60, 240 and 1440 minutes at 37○C and 5% CO2. All steps were performed 
in subdued lighting at RT. Equivalent concentration calculated here and in all following 
experiments by: Mass Dose at 100 µl in 96 well plate = 31.25 µg/cm2 (Concentration x 
Volume)/Surface Area ((100 x 0.1)/0.32). Therefore, concentration needed in 24 well 
plate = 118.75 µg/mL (Mass Dose x Surface Area)/Volume ((33.43 x 1.9)/0.5). 
 
Cells were then washed twice with PBS following exposure and fixed in 3% 
formaldehyde (in PBS) (Sigma-Aldrich) for 30 minutes at 4○C. Subsequently; the cells 
were washed twice with PBS and incubated with 50 mM ammonium chloride (Sigma-
Aldrich) to quench unreacted aldehyde groups, for 10 minutes. Cells were then washed a 
further three times with PBS followed by permeabilisation with 0.1% Triton for 20 
minutes. Cells were further washed twice with PBS, before the addition of the primary 
antibody monoclonal anti α tubulin mouse ascites fluid clone DM1A (Molecular Probes) 
(1:200 in PBS) for one hour. After incubation, cells were washed twice with PBS and 
incubated with the secondary antibody Rhodamine Red goat anti-mouse Immunoglobulin 
G (Molecular Probes) (1:100 in PBS) for one hour. Cells were washed twice and 
incubated for five minutes with 1 µg/mL DAPI (4′,6-diamidino-2-phenylindole) (Sigma-
Aldrich) prepared in PBS.  
 
Finally, cells were washed twice with PBS and coverslips were mounted onto glass slides 
with Vector shield (Vector) and edges sealed with nail varnish. Slides were stored at 4°C 






2.2.7 Uptake Assay: Plate method 
 
A 96-well plate fluorescence-based uptake assay was developed used to determine the 
uptake of fluorescently loaded NPs by C3A cells. Cells were seeded in 96-well plates as 
in section 2.2.5 and were exposed to NPs at sub-lethal concentrations (4.6-300 µg/mL) or 
MEM Complete Medium (control) in duplicate for 10, 60 and 1440 minutes at 37○C and 
5% CO2 or 1440 minutes at 4
○C. All steps were performed in the subdued lighting at RT. 
 
Following NP treatment, cells were washed twice using PBS, then incubated for 10 
minutes in 50 µL of 0.4% volume (of solute) per volume (of solvent) (v/v) Trypan Blue 
to quench extracellular fluorescence. Cells were washed three times using PBS. To lyse 
cells, a working solution of 0.2% Triton X100 was added (100 µL) and the plates were 
shaken for 20 minutes. Fluorescence of the cell lysate was measured in SpectraMax M5 
Microplate Reader at Ex/Em 488/550 nm. Standard curves were prepared in cell lysate at 
concentrations of 4.6-300 µg/mL for each NP and used to calculate µg/mL of NPs 
retained following NP exposure; fluorescence was measured at an Ex/Em of 488/550 nm. 
Data are expressed as µg/mL retained (from appropriate standard curves) ± SEM. 
 
2.2.8 Genotoxicity assessment: Comet assay  
 
A six-well-based assay was used to assess specific oxidative DNA damage and DNA 
strand breaks using the Fpg modified Comet assay. The % DNA tail was measured using 
electrophoresis as cleaved DNA will produce a longer DNA tail than the intact nucleus 
(Bulcão et al. 2014; Annangi et al. 2014). Although guidance documents on genetic 
toxicology testing put forward by the Organisation for Economic Co-operation and 
Development (OECD), advice a minimum of three concentrations be used, due to the 
limited volume and concentration of the NPs for these high-volume genotoxic assays the 
number of concentrations was limited to two, although these results can give insight in to 
the genotoxicity of these NPs, results most be considered preliminary (OECD 2015). 
 
Following 24 hours growth at 37○C and with 5% CO2 in 6-well plates (Costar) (1.56 x10
5 
cells/cm2), C3A cells were washed twice with Hanks Balanced Salt Solution (HBSS) 





hydrogen peroxide (H2O2, positive control) (Sigma-Aldrich) in duplicate for 240 minutes 
at 37°C and 5% CO2. 
 
Cells were washed twice with HBSS and treated with trypsin (section 2.2.3) and then 
resuspended in Complete Medium and centrifuged at 850 g for two minutes. 
Subsequently, the supernatant was discarded, and cells resuspended in HBSS (1 mL). The 
cells were then added (20 L) to low melting point agarose (240 L). The cell-agarose 
suspension (125 L) was then deposited on pre-coated agarose slides in duplicate. Slides 
were incubated on ice for 10 minutes then transferred to a lysis buffer (66.75 mL lysis 
buffer base (Sigma-Aldrich), 7.5 mL dimethyl sulphoxide (Sigma-Aldrich), 750 L 
Triton-X (Sigma-Aldrich)), for 24 hours at 4○C.  
 
After incubation, the slides were washed in a buffer; 400 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), 1 M potassium chloride, 5 mM 
ethylenediaminetetraacetic acid (EDTA) and 2 mg/mL bovine serum albumin at pH8 
(Sigma-Aldrich). Slides were then incubated with Fpg enzyme (Sigma-Aldrich) (1:500 in 
Fpg buffer), or the buffer alone at 37C for 30 minutes. Slides were then transferred to an 
electrophoresis solution (300 mM sodium hydroxide, 200 mM EDTA, 2 L distilled water 
at pH 13) and incubated for 20 minutes at 4○C. Electrophoresis was carried out for 20 
minutes at 24 V and 270 mA. Next, slides were transferred to a neutralisation buffer (48.5 
g Tris base, 900 mL distilled water pH7.5 (Sigma-Aldrich)) for 15 minutes at 4○C. Slides 
were then dried for 15 minutes at RT before being fixed with 100% ethanol and stored at 
4○C. 
 
Samples were stained with GelRed (Biotum) to visualise DNA. They were imaged using 
a fluorescence microscope (Zeiss AX10 with Allied Vision Technologies Stingray 
camera) connected to the image-analysing software (Comet Assay IV, Perceptive 
Instruments, UK). Fifty measurements were taken for each slide per experiment. The % 
DNA in the tail can be used as a proportional measurement of DNA damage. The software 
above used the ratio of the intensity of the comet tail and intensity of the comet head and 







The above experiment, section 2.2.8 was performed by Gavin Millar, School of 
Engineering and Physical Sciences, Nano Safety Research Group, Heriot-Watt University 
as part of his undergraduate research project under supervision by Leagh Powell and Dr 
David Brown of the NanoSafety Research Group. 
 
2.2.9 Measurement of cytokine production 
 
A multiplex sandwich enzyme-linked immunosorbent assay (ELISA) was used to 
measure secretion of IL-8, IL-1ra, growth-regulated α protein (Gro-α) and TNF-α from 
C3A cells exposed to NPs. Supernatants obtained from the cytotoxicity experiments were 
thawed and analysed using a Human Magnetic Luminex Assay kit (R&D Systems) as per 
the manufacturer’s instructions. All steps using cell supernatant were carried out at RT 
and in reduced light. Sublethal NP concentrations (75, 150 and 300 µg/mL as determined 
in section 2.2.5) were assessed as well as Complete Medium (negative control). 
 
Briefly, the microbead cocktail (25 µL) was added to appropriate wells in a 96-well plate, 
followed by samples, negative controls and standards (0-2000 pg/mL prepared in 
Complete Medium) (50 µL) and incubated for two hours shaking at RT. After incubation, 
wells were washed three times with wash buffer (100 µL), before adding biotin antibody 
cocktail (25 µL) and incubation of one hour while shaking at RT. Wells were washed 
three times with wash buffer, followed by the addition of 50 µL of streptavidin-PE, and 
incubated 30 minutes at RT with constant shaking. Before measuring, the wells were 
washed three times with wash buffer, and finally, samples were resuspended in 100 µL 
wash buffer and read using Bio-Plex MAGPIX Multiplex Reader (Bio-Rad). The 
concentration of cytokines present in the samples was calculated from the linear 
regression obtained from the standard curves. Data are expressed as average pg/mL ± 
SEM. 
 
Additionally, NPs’ interference with this assay was established by adding the standard 
curves midpoint (SCM) concentration to 300 µg/mL NPs prepared in the same medium 
as the standard curve. Any interference observed was presented in results, if not presented 







2.2.10 Statistical analysis 
 
Experimental data were analysed using GraphPad Prism software. One-way analysis of 
variance (ANOVA) using Tukey post-test or two-way ANOVA, followed by the 
Bonferroni post-test were used to test significance which was set at p< 0.05. All 






2.3  Results 
 
2.3.1 PDP and PDP-PF68 NPs: Physiochemical characterisation 
 
Measurements of hydrodynamic diameter, zeta potential and the PDI of NPs prepared in 
PRF Complete Medium were performed using DLS immediately after preparation and 
following 24 hours’ incubation at 37°C and with 5% CO2, to reflect assay conditions 
(Figure 2.3). Immediately following preparation, the hydrodynamic diameters of PDP-
PF68 NPs were observed to be significantly (p< 0.05) higher (145.93±1.41 nm) than those 
of the PDP NPs, albeit a small increase in size of ~6 nm (139.50±0.90 nm), no difference 
was seen following 24 hours of incubation (Figure 2.3A).  
 
The zeta potentials of both PDP-PF68 and PDP NPs were slightly negative, ranging from 
-10.7 to -12.7 mV (Figure 2.3C). No significant differences were seen for zeta potential 
between PDP-PF68 and PDP NPs at both time points investigated. The PDI values for 
both PDP-PF68 and PDP NPs were low, 0.13 for PDP NPs and ranging from 0.20-0.22 
for PDP-PF68 NPs. PDI values were significantly higher (p< 0.05) for PDP-PF68 when 
compared to PDP NPs at both time points (Figure 2.3B). The PDI was significantly lower 
(p < 0.05) for PDP-PF68 NPs after 24 hours incubation. 
 
TEM images of PDP-PF68 and PDP NPs suspended in PRF Complete Medium are shown 
in Figure 2.4. TEM images suggest that there are low levels of agglomeration/aggregation 
for both NPs investigated. PDP NPs appeared spherical and monodispersed with evidence 
of a visibly denser core when compared to PDP-PF68 NPs (Figure 2.4A/B). PDP-PF68 
NPs also appear spherical, although there seems to be a small increase in 
aggregation/agglomeration, compared with PDP NPs, reflected in the PDI data (Figure 







Figure 2.3 Characterisation of PDP and PDP-PF68 NPs properties:  DLS. 
NPs (PDP and PDP-PF68) suspended in Complete Medium (125 µg/mL), 
hydrodynamic diameter (A), PDI (B) and zeta potential (C) were assessed at 0 hours 
(T0) and 24 hours (T24) post incubation at 37○C and 5% CO2, using DLS. Significant 
difference indicated by *= p < 0.05 comparing T0 and T24. Significance indicated 
















Figure 2.4 TEM Characterisation of PDP and PDP-PF68 NPs. 
Images of PDP (A) and PDP-PF68 (B) NPs, suspended in PRF Complete Medium at 








2.3.2 PDP and PDP-PF68 NPs: Cytotoxicity in C3A cells 
 
Cells were exposed to NPs using a benchmark concentration approach at concentrations 
ranging from 4.6-300 µg/mL for 24 hours to determine the impact of PDP and PDP-PF68 
NPs on C3A cell viability using three simultaneous fluorescent assays; AB; CFDA-AM 
and NR. Measurement of metabolic activity using the AB assay showed no significant 
reduction in viability for cells exposed to PDP NPs when compared with the control 
(Complete Medium), at the tested concentrations (Figure 2.5A). PDP-PF68 NPs induced 
a significant decrease (p< 0.05) in cell viability at concentrations of 62.5, 250 and 300 
µg/mL, although, cell viability was not reduced to below 80% at the concentrations tested 
and therefore is unlikely to be biologically relevant (Figure 2.5A). 
 
No significant effect on cell viability was observed following exposure of C3A cells to 
PDP NPs at all concentrations tested when the CFDA-AM assay was used (Figure 2.5B). 
At concentrations >150 µg/mL, PDP-PF68 NPs were seen to stimulate a significant 
decrease (p< 0.05) in the viability of C3A cells. Again, cell viability did not fall below 
80% (Figure 2.5B). Using the NR assay, it was observed that PDP NPs had a statistically 
significant effect (p< 0.05) at the two highest concentrations tested (250 and 300 µg/mL), 
with viability falling to 88.4 and 94.6% respectively. The PDP-PF68 NPs had a similar 
effect as PDP NPs at concentrations of 250 and 300 µg/mL with viability seen to be 86.6% 
at 250 µg/mL and 97.1% at 300 µg/mL (Figure 2.5C).  
 
An EC20 value (effective concentration where 20% of cells die), indicating the 
concentration at which NP exposure causes 20% cell death, could not be calculated within 







Figure 2.5 Cytotoxicity of PDP and PDP-PF68 NPs to C3A cells. 
C3A cells were exposed to PDP (black) or PDP-PF68 (red) NPs, 4.6-300 µg/mL for 24 
hours. Percentage viability was measured via AB (A), CFDA-AM (B) and NR (C) 
assays. Data are expressed as mean % cell viability (i.e. % of untreated control) ± SEM 







2.3.3 PDP and PDP-PF68 NPs: Uptake confocal using C3A cells 
 
Cells where exposed to PDP-PF68 and PDP NPs at a sub-lethal concentration (100 
µg/mL) to allow examination of the NPs’ internalisation by C3A cells over time using 
confocal microscopy. Cell structure was visualised by labelling tubulin (red), while DAPI 
was used to stain the nucleus (blue). The PDP and PDP-PF68 NPs were loaded with a 
fluorescent green dye, coumarin-6 (green), to mimic pharmaceutical or bioimaging 
product. A yellow colour was used to indicate points where tubulin and NPs colocalised. 
When DNA and NPs colocalised, a green-blue colour was used.  
 
Both NPs appear to be readily taken up by C3A cells after 10 minutes (Figure 2.6A). 
Internalisation increases progressively from 10 to 1440 minutes for both NPs. 
Confirmation of NP internalisation in the interior of the cell was apparent in xy-yz 
micrographs generated from z-stacks (Figure 2.7). A change in subcellular distribution 
over time was observed. NPs were compartmentalised at 10-240 minutes, potentially 
within the cells’ organelles such as endosomes, lysosomes or mitochondria (Figure 
2.7B/C). Additionally, there was evidence that NPs are localised between cells at 60 and 
240 minutes, which could suggest accumulation in bile canaliculi (Figure 2.6B/C). 
Colocalisation of both NPs with tubulin was evident within the perinuclear region of the 
cells at 60 and 240 minutes (Figure 2.6B/C). 
 
At 240 minutes, both NPs appears to be diffusely accumulated within the nucleus of some 
cells, evident by a green-blue colour (Figure 2.7C). There were vacuoles in the 
perinuclear region which contain PDP NPs at all time points, and for PDP-PF68 NPs this 
was apparent up to 240 minutes. There were changes to the nucleus morphology of cells 
treated with PDP-PF68 NPs. More specifically, at 10, 240 and 1440 minutes there was 
possible nuclear fragmentation or blebbing (Figure 2.6B/C/D indicated by arrow). After 
1440 minutes’ exposure, the pattern of internalised NPs diverged for the PDP-PF68 NPs 
and PDP NPs. The PDP NPs were diffuse throughout the cytoplasm of the cell at 1440 
minutes, with some NP compartmentalisation. For the PDP-PF68 NPs, a diffuse pattern 
was also apparent, but with no NP compartmentalisation. While cells exposed to PDP-
PF68 NPs for 1440 minutes had vacuoles located adjacent to the nucleus that appeared 





observed for cells treated with both NPs (highlighted by white arrows in Figures 2.6D 






Figure 2.6 Uptake of PDP and PDP-PF68 NPs over time by C3A cells. 
Cells were treated with 100 µg/mL PDP NPs or PDP-PF68 (green) for 10 (A), 60 (B), 
240 (C) or 1440 (D) minutes or Complete Medium as a control (E). Tubulin (red), DNA 








Figure 2.7 Uptake of PDP and PDP-PF68 NPs over time by C3A cells: Z stacks. 
Cells were treated with 100 µg/mL PDP NPs or PDP-PF68 NPs (green) for 10 (A), 60 
(B), 240 (C) or 1440 (D) minutes or Complete Medium as a control (E), xy and yz 
micrographs generated from Z-stacks. Tubulin (red), DNA (blue), representative 






2.4.2 PDP and PDP-PF68 NPs: Uptake, plate using C3A cells 
 
The µg/mL retained of the applied NP concentration by the C3A cells following exposure 
was calculated over a range of concentrations (4.6-300 µg/mL). PDP NPs had a 
significant increase (p < 0.001) in uptake at early time points (10 minutes) with a 
concentration-dependent increase (Figure 2.8). At 60 and 1440 minutes significant 
increases (p < 0.001) in uptake were observed at concentrations up to 37.5 and 75 µg/mL 
respectively. While there was less NP internalisation above these concentrations. There 
appears to be no significant internalisation of either NPs at 4○C (Figure 2.9). 
 
More specifically, the µg/mL retained increased with time (Figure 2.8). The PDP NPs 
had the highest level of uptake, 13.8 µg/mL at a NP concentration of 75 µg/mL after 1440 
minutes. Significant uptake (p < 0.001) for PDP-PF68 NPs was only observed at 1440 
minutes, with 2.4 µg/mL retained at a NP concentration of 150 µg/mL. Quantifying 
uptake of PDP-PF68 and PDP NPs using a fluorescence 96-well plate-based method 








Figure 2.8 Uptake of PDP and PDP-PF68 NPs over time in C3A cells:Plate 
method. 
Cells were exposed to PDP (black) or PDP-PF68 (red) NPs for 10 (A), 60 (B) and 1440 
(C) minutes, at 18.75-300 µg/mL. Data are expressed as µg/mL retained (from 
appropriate standard curves) ± SEM (n=3). Significance indicated by ***=p< 0.001 











Figure 2.9 Uptake of PDP and PDP-PF68 NPs in C3A cells, at 4°C: Plate-based 
method. 
Cells were exposed to PDP (black) or PDP-PF68 (red) NPs, at 18.75-300 µg/mL for 







2.3.4 PDP and PDP-PF68 NPs: Genotoxic effect on C3A cells 
 
The genotoxic potential of PDP and PDP-PF68 NPs in C3A cells was assessed using the 
Comet assay in the presence and absence of Fpg to identify the contribution of oxidative 
stress to DNA damage observed. C3A cells were exposed to NPs at concentrations of 75 
and 150 μg/mL for four hours.  
 
Assessment of mean % of DNA in Tail was used to quantify NP-induced genotoxicity. 
PDP NPs did not induce DNA damage at the concentrations used, with or without Fpg 
(Figure 2.10). PDP-PF68 NPs induced a significant increase (p< 0.05-0.001) in DNA 
damage in C3A cells at both concentrations with and without Fpg (Figure 2.10B). Similar 
levels of DNA damage were seen for PDP-PF68 with and without Fpg at 75 μg/mL with 
a significant 2-fold increase in DNA damage (p< 0.05-0.005).  
 
A significant 1.6-fold increase in DNA damage (p< 0.05) at a concentration of 150 μg/mL 
was observed in the absence of Fpg. For PDP-PF68 NPs, DNA damage was increased 
significantly (p< 0.001) in the presence of Fpg at 150 μg/mL, with a four-fold increase in 
DNA damage observed, compared with the untreated control. The PDP-PF68 NPs were 
significantly (p< 0.01-0.001) more genotoxic than the PDP NPs at 75 150 μg/mL with or 
without Fpg while at 150 μg/mL, a significant difference was only seen for with Fpg 
(Figure 2.10A/B). Notably, PF68 (alone) at a concentration representative of PF68 
present in NP suspensions prepared did not induce DNA damage (Figure 2.10 C). The 
positive control H2O2 (60 μM) induced significant DNA damage (p < 0.001) with and 








Figure 2.10 Genotoxicity of PDP and PDP-PF68 NPs in C3A cells: Comet assay. 
Cells were exposed to PDP (A) or PDP-PF68 (B) NPs at 75 and 150 μg/mL, 60 μM 
H2O2 (positive control) or HBSS (untreated control) or 0.5 μg/mL of PF68 (C) for four 
hours ± Fpg. Data are expressed as mean % Tail DNA ± SEM (n = 3). Significance was 
indicated by *** = p< 0.001, ** = p< 0.01 and * = p< 0.05, when compared with 
untreated control. $$$ = p< 0.001 and $$ = p< 0.01 when compared with PDP NPs at 






2.3.5 PDP and PDP-PF68 NPs: Cytokine production in C3A cells 
 
C3A cells were exposed to PDP and PDP-PF68 NPs for 24 hours, and production of IL-
8, TNF-α, IL-ra and Gro-α were measured in the supernatant. There was a minimal yet 
significant decrease (p<0.05-0.001) seen in IL-8 production when C3A cells were 
exposed to PDP-PF68 NPs when compared to untreated cells. However, the low values 
suggest this was not biologically relevant (Figure 2.11A). There was no significant 
change in TNF-α production when cells where exposed to either NP (Figure 2.11B).  
 
When C3A cells were exposed to PDP-PF68 NPs, there was a significant concentration-
dependent increase (p< 0.001) in IL-1ra production from 75-300 µg/mL (Figure 2.12A). 
A similar significant increase (p< 0.001) was seen in Gro-α production for cells exposed 
to 150 and 300 µg/mL of PDP-PF68 NPs (Figure 2.12B). There appeared to no increase 







Figure 2.11 IL-8 and TNF-α production induced by PDP and PDP-PF68 NPs in 
C3A cells. 
Cells were exposed to PDP or PDP-PF68 NPs for 24 hours at 75, 150 and 300 μg/mL, 
IL-8 (A) and TNF-α (B). Data are expressed as mean pg/mL ± SEM (n=3). Significance 









Figure 2.12 IL-1ra and Gro-α production induced by PDP and PDP-PF68 NPs in 
C3A cells. 
Cells exposed to PDP and PDP-PF68 NPs for 24 hours at 75, 150 and 300 μg/mL, IL-
1ra (A), Gro-α (B). Data are expressed as mean pg/mL ± SEM (n=3). Significance 
indicated by ***= p< 0.001, when compared with the untreated control. Significance 
indicated by $$$= p< 0.001 when compared with PDP NPs at the same concentration. 







2.4 Impact of PDP and PDP-PF68 NPs on J774 cells 
 
2.4.1 PDP and PDP-PF68 NPs: Cytotoxicity in J774 cells 
 
J774 cells were exposed to PDP and PDP-PF68 NPs at 4.6-300 µg/mL for 24 hours and 
a benchmark concentration approach was used to assess cell viability (Wignall et al. 
2014). The same three simultaneous fluorescence assays (AB, CFDA-AM, NR) used with 
the C3A cell line were applied. Both the AB and CFDA-AM assays indicated no 
biologically significant adverse effects on cell viability for either NP (Figures 2.13A/B). 
However, the NR assay, a marker of lysosome function, did indicate a significant decrease 
(***= p< 0.001) in viability for J774 cells exposed to PDP-PF68 NPs at 36% viability at 
200 µg/mL and 10% viability at 300 µg/mL (Figure 2.13 C).  
 
The EC20 values for the AB and CFDA-AM assays were above the highest concentrations 
of treatment. Therefore, no accurate EC20 values could be determined. Using the NR 







Figure 2.13 Cytotoxicity of PDP and PDP-PF68 NPs to J774 cells. 
Cells were exposed to PDP (black) or PDP-PF68 (red) NPs (4.6-300 µg/mL) for 24 
hours. Viability was measured via AB (A), CFDA-AM (B) and NR (C) assays. Data 
are expressed as mean % cell viability (i.e. % of untreated control) ± SEM (n=3). 








2.4.2 PDP and PDP-PF68 NPs: Uptake by J774 cells  
 
Differences in the uptake of these NPs in C3A cells was most evident at 1440 minutes. 
Therefore, J774 cells were exposed to PDP-PF68 and PDP NPs at 100 µg/mL for 1440 
minutes. Both NPs were readily taken up into the cytoplasm and compartmentalised in 
the cytoplasm surrounding the nucleus, potentially in organelles such as the lysosomes or 
endosomes. Although, neither NP appeared to enter the nucleus (Figures 2.14A/B).  
 
Visually, there appears to be more uptake of the PDP NPs, and this can also be seen in 
the quantitative uptake analysis of the PDP NPs at 1440 minutes (Figure 2.15C). A 
significant increase (p< 0.05-0.001) in uptake was seen at 150 µg/mL for cells treated 
with PDP NPs for 10 and 60 minutes, while, above this concentration, there was less NP 
internalisation. There appears to be little internalisation of PDP-PF68 NPs at 10 and 60 
minutes (Figures 2.15A/B). A significant increase (p< 0.001) in uptake can be seen, that 
is in a concentration dependent manner, up to 75 µg/mL for cells treated with both NPs 
for 1440 minutes, while there was less NP internalisation above this concentration 
(Figures 2.15C).  
 
Interestingly, when J774 cells were incubated with these NPs at 4○C, there appears to be 
a significant (p< 0.001) internalisation of the PDP NPs up to 150 µg/mL, with less uptake 
at concentrations above this (Figure 2.16). There also appears to be some internalisation 
of PDP-PF68 NPs at 4○C, although, this is not significant. The internalisation of the PDP 









Figure 2.14 Uptake of PDP and PDP-PF68 NPs by J774 cells at 1440 minutes. 
Cells were treated with 100 µg/mL of PDP(A), PDP-PF68 NPs (B) or Complete 
Medium (C) for 1440 minutes. Representative images, tubulin (red), DNA (blue) (n=3), 







Figure 2.15 Uptake of PDP and PDP-PF68 NPs in J774 cells, over time: Plate 
method. 
Cells were exposed to PDP (black) and PDP-PF68 (red) NPs for 10 (A), 60 (B) and 
1440 (C) minutes, at 18.75-300 µg/mL. Data are expressed as mean µg/mL retained 
(from appropriate standard curves) ± SEM (n=3). Significance indicated by *= p< 0.05, 
**= p< 0.01, ***=p< 0.001 compared with untreated control. Significance indicated 
by $$=p< 0.01, $$$=p< 0.001, when PDP NPs compared with PDP-PF68 NPs at same 











Figure 2.16 Uptake of PDP and PDP-PF68 NPs in J774 cells, 4°C: Plate method. 
Cells were exposed to PDP (black) or PDP-PF68 (red) NPs, at 18.75-300 µg/mL for 
1440 minutes. Data are expressed as mean µg/mL retained (from appropriate standard 
curves) ± SEM (n=3). Significance indicated by ***= p< 0.001, *= p< 0.05, compared 
with untreated control. Significance indicated by $= p< 0.05, $$$= p< 0.001 for PDP 









2.5.1 Overview of results 
 
Before NP interaction with hepatocytes was assessed, it was essential to evaluate NP 
physiochemical characteristics that can influence these interactions, such as size and 
surface charge. The PDP-PF68 NPs were larger than the PDP NPs, as would be excepted 
as they had an adsorbed Pluronic coating. Both NPs had a negative surface charge that 
was not significantly different in Complete Medium, suggesting that charge may not 
differentially influence how the PDP-PF68 and PDP NPs interact with the cells. The 
cytotoxicity of the NPs was then assessed (via three assays) to compare the toxic potency 
of the PDP-PF68 and PDP NPs, and to identify sublethal concentrations of NPs to select 
when investigating the cellular response.  
 
Data obtained demonstrated that a lack of biologically significant cytotoxicity was seen 
at the concentrations tested 24 hours post-exposure to C3A cells. Next, the uptake of NPs 
was imaged using confocal microscopy and quantified using a fluorescence plate reader. 
Uptake of the NPs increased in a time and concentration-dependent manner. Initially (10-
240 minutes), NPs were compartmentalised within or between cells, suggesting 
localisation within cells’ organelles (e.g. lysosomes, mitochondria) or structures similar 
to the bile canaliculi, as seen in previous studies (Johnston et al. 2010). However, at 24 
hours post-exposure, PDP-PF68 NPs appeared to have become diffuse throughout the 
cells, while the majority of PDP NPs remained compartmentalised.  
 
The genotoxicity of the NPs was assessed using the Comet assay. It was observed that the 
PDP-PF68 NPs stimulated DNA damage, whereas the PDP NPs were not genotoxic to 
C3A cells. No increased production of IL-8 or TNF-α by C3A cells was observed for 
C£A cells exposed to both NP types. However, there did appear to be an increase in the 
production of IL-1ra and Gro-α, by C3A cells exposed to PDP-PF68 NPs 
 
Although these results suggest possible clinical usefulness for these NPs, there was 





design of safe nanomedicines in the future. Overall, these results indicate a panel of tests 
should be used to build a comprehensive picture of how these NPs affect the cell. 
Accordingly, safety testing should not rely solely on the assessment of the impact on cell 
viability.  
 
2.5.2 Characterisation of PDP and PDP-PF68 NPs 
 
This study focused on assessing size, shape, size distribution and surface charge via TEM 
and DLS. It is established that these parameters can influence the interactions of NPs with 
cells (Brown et al. 2001; Hirn et al. 2011; Schaeublin et al. 2012; Ke et al. 2014). Equally, 
the methods employed have previously been used in numerous studies to characterise NPs 
(e.g. Clift et al. 2011; Kermanizadeh et al. 2013; Brown et al. 2014). Using TEM, both 
NP types appear spherical and relatively monodispersed. The hydrodynamic diameter of 
PDP-PF68 NPs at T0 was significantly higher than for the PDP NPs, likely due to the 
presence of the adsorbed PF68 coating.  
 
Several studies have shown that adding a surface coating can alter the hydrodynamic 
diameter of the NPs (Mulens-Arias et al. 2015; Mahaling & Katti 2016). For example, an 
increase in hydrodynamic diameter was seen when PF68 was adsorbed to Doxorubicin-
loaded Poly(butyl cyanoacrylate) NPs (Petri et al. 2007).  
 
Proteins present in the FBS of the Complete Medium can bind to the surface of NPs 
during incubation, and these proteins may influence NP size (Petri et al. 2007; Voigt et 
al. 2014). There was no significant difference between the hydrodynamic diameter of the 
NPs after 24 hours; this suggests that the sizes of both NPs were stable within the assay 
conditions. Stability can be an issue for nanomedicine production, as batchs produced 
will need to be near identical and be stabile long enough for batch safety testing to be 
performed as well as clinical application.  
 
Zeta potential is a measurement of the electrostatic forces, at a defined distance from the 
NP’s surface, and is used as an indicator of charge for particles in an aqueous dispersion 
(Brown et al. 2014). Zeta potential also indicates suspension stability or 





stable (Silva et al. 2011). The zeta potential of both PDP and PDP-PF68 NPs were 
negative (-10 to -12 mV), however, they were not below -30 mV suggesting possibly low 
suspension stability and potential for agglomeration.  
 
The PDI is ununited and calculated by dividing the standard deviation of the NP diameter 
by the average NP diameter, this can reflect the size distribution and stability of NP 
suspension. High PDI values (e.g. 0.5-1) can indicate a NP suspension with a broad size 
distribution or possible aggregation/agglomeration, while low values (e.g. <0.5) suggest 
a monodispersed population of NPs in the suspension (Cutts et al. 2015; Clayton et al. 
2016). The low PDI values of both NPs, also suggests that NP suspensions are 
monodispersed, which agrees with the images of these NPs obtained by TEM. Since these 
NPs are intended for medical use, monodispersed and stable suspensions are necessary to 
ensure an accurate drug dose in vivo (Qian et al. 2010). 
 
However, there was a higher PDI value for PDP-PF68 NPs compared with PDP NPs at 
both time points, suggesting that the PDP-PF68 NP suspension had marginally higher 
variability in size, less stability and therefore the PDP-PF68 NPs were more likely to 
aggregate/agglomerate than their PDP NP counterparts. This increased PDI may be due 
to the adsorbed coating being unstable. However, previous research indicated that a PF68 
coating increases iron oxide NP and PLGA NP stability in saline solutions (Morales et al. 
2005; Santander-Ortega et al. 2006).  
 
The stability of the PDP NPs in Complete Medium containing 10% FBS remains constant 
over time, while there was a significant decrease in the PDI of PDP-PF68 NPs between 0 
hours and 24 hours, suggesting that they had become more stable. Increases in dispersion 
stability over time were also seen at 24 hours for ZnO NPs in a cell culture medium, due 
to the presence of a protein corona (Semete et al. 2010). This suggests that components 
of the Complete Medium may form a different protein corona on the PDP-PF68 NPs 
compared with the PDP NPs, allowing increased stability over time for the PDP-PF68 
NPs.  
 
However, there are limitations to the methods used in this project. To establish NP 





the hydrodynamic diameter of NPs in suspension, and their size distribution. Even so, this 
technique uses computational algorithms which assume NPs are spherical and 
monodispersed in water. While TEM gives a visual representation of the size and size 
distribution of NPs, due to the low contrast of TEM, it can be challenging to image 
polymers and polymer coatings on NPs. Therefore measurements from TEM images may 
not be accurate (Zucker et al. 2012).  
 
Ideally, additional measurement techniques would have been used to establish NP size 
directly in a biological medium, such as atomic force microscopy, a high-resolution 
imaging technique that physical measurement NPs using a scanning probe in any 
appropriate medium (Lin et al. 2014; Constantin et al. 2017). However, this technique 
would not provide higher resolution than that used in the current study, requires highly 
specialised equipment and is not as widely available as TEM (Win & Feng 2005; 
Klapetek et al. 2011; Wibroe et al. 2016).  
 
2.5.3  Cytotoxicity of PDP and PDP-PF68 NPs 
 
Data obtained showed that all three cytotoxicity assays gave similar results for both PDP 
and PDP-PF68 NPs. More specifically, the results demonstrated that both NPs were of 
relatively low toxicity in C3A cells, with less than a 20% reduction in cell viability 
observed at all concentrations tested, 24 hours post-exposure. Indeed, similar to previous 
studies which have demonstrated that biodegradable polymer NPs show low cytotoxicity 
in human hepatic (L02) and lung (A549/Calu-3) cells after 24 hours exposure (Cong et 
al. 2015; Maiolino et al. 2015). Low levels of cytotoxicity are ideally required for 
unloaded nanomedicines, as adverse side effects need to be limited in clinical 
applications, and the low cytotoxicity observed for both NPs suggests they could be 
clinically useful.  
 
In the case of these PNPs that elicit low cytotoxicity, the benchmark concentration 
approach, that allowed for the addition of different concentrations to be assessed for 
cytotoxicity between replicates, did not provide additional information. Therefore, the 
benchmark concentration approach may not be a useful tool for safety profiling of low 






Previous studies investigating the toxicity of PNPs have used higher concentrations than 
those used here. For example, THP-1 macrophages were exposed to PF68-coated PLGA 
NPs at concentrations of 1-10 mg/mL, which had a significant impact on viability, 
membrane activity and cytokine production (IL-6) (Grabowski et al. 2015). Using a 
higher concentration of PDP and PDP-PF68 NPs may have had a cytotoxic outcome, and 
it may have been possible to determine EC20 for both NPs. However, as this study 
intended to reflect a more ‘realistic’ concentration range, the concentrations selected for 
in vitro testing were determined from calculations that reflected therapeutic application 
(Section 2.2.4).  
 
Using three different assays for cytotoxicity of low toxicity PNPs may be redundant. It 
would be better in future to focus on the assay, such as AB, that has produced the most 
robust data, as well as previously been used in the cytotoxic testing of multiple engineered 
NPs. 
 
2.5.4 Uptake of PDP and PDP-PF68 NPs  
 
The current study used a combination of microscopy and a fluorescence plate reader to 
investigate uptake. The findings from both approaches were complementary. The plate 
based method was high throughput, which was beneficial in that it allowed the time and 
concentration dependence of NP uptake to be quantified. Therefore, the method 
developed in this study provides a quick, sensitive approach for screening fluorescent NP 
uptake by cells. While confocal microscopy provides useful information on NPs’ 
intracellular fate, it cannot quantify uptake and takes a substantial investment of time. 
Such methods only apply to fluorescent NPs, with the investigation of the uptake of non-
fluorescent NPs often more challenging. 
 
Both methods showed an increase in NP uptake with time. These results agree with 
previous research, with uptake of PNPs (such as polystyrene) ranging from 20-200 nm 
within macrophages, kidney epithelial, hepatocytes and fibroblast cells increased over 
time (Davda & Labhasetwar 2002; Johnston et al. 2010; Nicolete et al. 2011; Firdessa et 





to increase at higher concentrations. These observations may be related to the mild 
cytotoxic effects seen for these NPs at the higher concentrations, as fewer cells would be 
present, resulting in the lower fluorescent signal. The increased uptake with time suggests 
that, once administered, when NPs remain stable they could continue to circulate and 
deliver a therapeutic load for up to 24 hours. 
 
The lower level of uptake observed for PDP-PF68 NPs were most likely due to the 
presence of the surface coating. A decrease in uptake of non-target cells is advantageous 
for nanomedicines, as many NPs are cleared rapidly in the liver and RES following 
administration (Ogawara et al. 2001). The reduced uptake seen for the PDP-PF68 NPs 
may indicate that these nanomedicines would circulate longer within the body, increasing 
the chance that NPs will reach target cells and potentially decrease the frequency of 
administration. 
 
The contribution of active or passive uptake was also investigated by assessing uptake 
following treatment of cells with NPs at 4○C, as at 4○C the predominant form of uptake 
is passive (Firdessa et al. 2014). A lack of uptake of both NPs at 4°C indicated that C3A 
cells actively internalise both PDP and PDP-PF68 NPs. Moreover, it is preferable to have 
nanomedicines that are less likely to enter healthy cells. Therefore, limiting NPs entering 
cells via passive uptake could reduce non-specific uptake by healthy cells. 
 
In the current study compartmentalisation of both PDP and PDP-PF68 NPs was seen at 
10-240 minutes within the cells suggests localisation within organelles such as 
endosomes or lysosomes. In previous studies, the uptake of 20 nm polystyrene NPs in 
hepatocyte and macrophage cell lines had a similar pattern of compartmentalisation to 
that seen in the current study. Although NPs in hepatocyte cells appeared to localise in 
the endosomes and lysosomes, while in macrophage NPs appeared to prefer to localise in 
the mitochondria (Johnston et al. 2010; Firdessa et al. 2014).  
 
Further research could be performed for these NPs in the current study to confirm the 
localisation of NPs within the organelles of C3A cells, using markers such as Lysotracker 
and Mitotracker to provide valuable information regarding the effects of PF68 coating on 





targeted delivery of these NPs. Equally, markers such as FM4-64 could be used to label 
the endosomes fluorescently (Au et al. 2011). TEM is useful for observing localisation of 
many NPs such as silver NPs within cells. When using polymer NPs on the other hand, 
perhaps due to a similar density to the cells, it can be more difficult to differentiate 
between NPs and cell components. 
 
The observation that the NPs accumulated between adjacent C3A cells may suggest NPs 
accumulating within bile canaliculi-like structures. Indeed, a similar observation was 
made when C3A cells were exposed to 20 nm polystyrene NPs in a previous study, with 
the fluorescent bile acid, cholyl lysyl fluorescein (CLF) used to confirm colocalisation of 
the NPs and bile (Johnston et al. 2010). This could indicate the active removal of NPs 
from the cells via bile, as has been observed in vivo (Guy et al. 1989; Kanakia et al. 2014). 
In the future, to investigate the possibility of PDP-PF68 NPs colocalising in bile 
canaliculi-like structures, CLF could be used in vitro (Milkiewicz et al. 2002; Johnston et 
al. 2010). Removal of NPs via the bile canaliculi could be clinically necessary, as this 
could reduce biopersistence in the liver, reducing the possibility of long-term adverse 
effects. 
 
Both PDP and PDP-PF68 NPs are initially observed in the perinuclear region of cells and 
later diffused throughout the nucleus, which could indicate some form of targeting 
towards the nucleus (Akita et al. 2013). The nucleus has previously been targeted by 
liposomal NPs of similar size to PDP and PDP-PF68 NPs to deliver gene therapy (Akita 
et al. 2013). Since these NPs are intended for bioimaging or delivery of drugs, it may not 
be beneficial for these NPs to enter the nucleus and potentially interact with and damage 
the DNA. The localisation of these NPs in the nucleus could be further clarified using 
super-resolution microscopy technique (van der Zwaag et al. 2016). 
 
Due to the enhanced biodegradable nature of the polymer used to produce both the PDP-
PF68 and PDP NPs in the current study, it may be possible that these NPs degrade within 
the cells or extracellularly. Degradation profiles were performed over 90 days for the PDP 
NPs by collaborators at the University of Nottingham, with and without incubation with 
Pseudomonas cepacia lipase (0.2 mg/mL), a hydrolytic enzyme to identify 





solution, there was only a marginal decrease in molar mass, while NPs without this 
enzyme remained stable. Therefore, extensive extracellular degradation within the 
experimental conditions over 24 hours was unlikely. After 90 days, the molar mass was 
decreased by half for NPs treated with the hydrolytic enzyme, suggesting that these NPs 
could potentially be broken down in the body and cleared. This is necessary for 
nanomedicines, as prolonged persistence may have detrimental effects on patients. 
 
2.5.5 Cytokine production related to PDP and PDP-PF68 NPs 
 
In this study, there was no increase in IL-8 production by cells exposed to both PDP-PF68 
and PDP NPs. This is in line with other studies exposing macrophages to PF68-coated 
PLGA NPs, where no IL-8 production was observed (Grabowski et al. 2015). There 
appears to be a decrease in IL-8 production for PDP NPs; however due to low levels of 
IL-8 production, this is unlikely to be biologically relevant. C3A cells appear to produce 
little to no TNF-α when treated with the control or NPs, indicating these cells may be 
unresponsive. Nonetheless, a lack of IL-8 and TNF-α production could indicate that there 
was no significant pro-inflammatory response activated by these NPs.  
 
Interestingly, there was a significant increase in IL-1ra and Gro-α in a concentration-
dependent manner for PDP-PF68 NPs. IL-1ra is produced in the liver and in vitro in 
human hepatocytes in response to inflammation (Gabay et al. 1997). This anti-
inflammatory cytokine competitively inhibits the pro-inflammatory cytokines, IL-1α and 
IL-1β, therefore halting an inflammatory cascade, reducing the inflammatory response 
(Duque & Descoteaux 2014). Studies have investigated NPs loaded with IL-1ra with the 
intention to treat inflammatory diseases such as osteoarthrosis (Agarwal et al. 2016). 
However, there are limited studies assessing IL-1rα production in vitro and in vivo. 
However, a significant increase in IL-1rα production was observed with the THP-1 
(human macrophage) cell line exposure to TiO2 NPs at 100 µg/mL (Kim et al. 2007). 
When osteoporosis patients were treated with 100 mg/day of alginate sodium NPs 
(approx. 200 nm), this also induced an increase in IL-1ra production (Qu et al. 2017).  
 
Gro-α (also known as CXCL1) is a neutrophilic chemoattractant, known to stimulate 





for cells exposed to PDP-PF68 NPs was similar to previous studies using other PNP 
which  showed increased Gro-α mRNA expression and significant DNA damage when 
VK2 (vaginal epithelial) cells were exposed to 100 μg/mL PLGA-PEG NPs (approx. 50 
nm diameter) (Wagner et al. 2017).  
 
The stimulation of IL-1ra and Gro-α production may suggest that the PDP-PF68 NPs 
provoke an innate immune response (Moles et al. 2014). It has previously been shown 
that PF68 can elicit hypersensitive reactions in vivo via complementary activation, which, 
in turn, could lead to increased production of pro-inflammatory cytokines and further 
downstream effects such as genotoxicity (Moghimi et al. 2004). It would be of interest to 
investigate the production of other cytokines such as IL-6, that can be either pro-
inflammatory or anti-inflammatory.  
 
2.5.6 Genotoxicity of PDP and PDP-PF68 NPs 
 
Genotoxicity would be a significant hurdle in nanomedicine development, as it could lead 
to the development of cancers and promote cell death. Although due to the limited volume 
and concentration of NPs the number of concentrations was limited to two and not the 
recommended three (OECD 2015). Although, these results could provide indication of 
potential genotoxicity of NPs, results most be considered preliminary. 
 
Unlike PDP-PF68 NPs, PDP NPs did not appear to induce genotoxicity in C3A cells. The 
genetic damage caused by PDP-PF68 NPs appears to be mediated via oxidative stress, as 
DNA damage was heightened in the presence of Fpg. These results indicated that a PF68 
coating may contribute to NP genotoxicity. Moreover, PF68 alone at relevant 
concentrations did not induce genotoxicity, indicating that this was a NP relevant issue. 
These results highlight the importance of establishing the safety of different nanoforms 
of the same core NP. 
 
It was possible that when these PDP-PF68 NPs interact with C3A cells, ROS are 
produced. ROS is a crucial player in NP toxicity, and if levels exceed antioxidant levels 
within the cell, this may lead to oxidative damage (Nel et al. 2006). Prior studies of PF68 





membrane potential in Caco-2 cells (colon epithelial). The downstream effects of a 
reduction in the mitochondrial membrane could be ROS production (Ehrenberg et al. 
1988).  
 
It would be interesting to determine ROS production of these NPs in the future. ROS 
could be investigated using the fluorogenic dye 2’, 7’-Dichlorodihydrofluorescein 
diacetate (DCFH-DA). The DCFH-DA dye enters cells and is rendered non-permeable to 
the cell membrane by esterases in the cell. In the presence of ROS, the dye will be rapidly 
oxidised to a highly fluorescent dye (Rota et al. 1999; Wilson et al. 2002). DNA damage 
was measured after four hours’ exposure. Therefore, in the future, it would be useful to 
look at genotoxicity after 24 hours of NP exposure to reflect other endpoints used in the 
study (e.g. cytokine production). The measurement of NP genotoxicity using the Comet 
Assay can have limitations, and concerns have previously been raised regarding NP 
interference with measurement of this assay, however, this can be mitigated by suitable 
controls (Stone et al. 2009). Ideally, the results from the Comet Assay would be verified 
using additional genotoxic assays such as the robust micronuclei assay that quantifies the 
micronucleus produced in response to DNA damage.  
 
2.5.7 Impact of PDP and PDP-PF68 NPs on J774 cells 
 
The effects of PNP exposure on macrophages (J774) was briefly examined, to gain greater 
insight into the response of different cell lines to PNP toxicity. The AB and CFDA-AM 
assays did not suggest cytotoxicity for these NPs in J774 cells. Nonetheless, the NR assay 
did suggest an adverse effect on lysosome function by PDP-PF68 NPs at high NP 
concentrations. A previous study indicated that coating hexadecylcyanoacrylate NPs with 
PEG, which is an element of PF68, decreased toxicity in the J774 cell line, most likely 
mediated by PEG’s steric repulsion reducing cell-NP interaction (Peracchia et al. 1999).  
 
However, in the current study, PDP-PF68 NPs appear to be more cytotoxic than PDP 
NPs. PF68-coated poly (ε-caprolactone) NPs have been shown to reduce the viability of 
J774 cells by 60% at 100 µg/mL (Espuelas et al. 2003). Moreover, macrophage cells 
(THP-1) exposed to PF68-coated PLGA NPs induced a significant decrease in 





2015). These results indicate that macrophage cells may be adversely affected by a range 
of PNPs coated in PF68. It is noteworthy that the J774 cell line appears to be a more 
sensitive model, than the C3A cell line. The differences seen in the current study could 
be due to macrophages being specifically phagocytic cells, possibly altering the way these 
NPs are taken up, the amount internalised which is lower than hepatocytes and the 
intracellular localisation, compared with hepatocyte cells, which are predominantly non-
phagocytic. Compartmentalisation of both NPs within the cells suggested localisation 
within organelles such as endosomes or lysosomes, this is similar to previous studies 
exposing J774 cells to 200 nm polystyrene PNPs (Clift et al. 2008; Clift et al. 2011).  
 
Uptake of both NPs using microscopy and a fluorescence plate reader indicated higher 
internalisation of the PDP NPs by macrophages. The localisation was similar for both 
NPs, with cytoplasmic compartmentalisation and no apparent nucleus entry. These 
observations may suggest that the PF68 coating has the potential to decrease NPs uptake 
in J774 cells. This outcome would be preferred, as the addition of the PF68 coating was 
designed not only to increase NP stability but to decrease NP interactions with non-target 
cells, thus reducing clearance via the RES (Ogawara et al. 2001). These results could 
indicate that coating these NPs with PF68, helps increase circulation time, therefore 
allowing the drug cargo to reach the target, as well as increasing the time between 
treatment administrations.  
 
For both the PDP and PDP-PF68 NPs at all time points, there appeared to be less NP 
uptake at concentrations above 75 µg/mL as this decrease was seen for both NPs and on 
PDP-PF68 had a cytotoxic effect, this may point to alternative reasons for less uptake at 
higher concentrations, perhaps exocytosis or intracellular degradation of NPs. Previous 
studies have seen iron (II,III) oxide NPs exocytose from macrophages via membrane 
vesicles (Serda et al. 2010). Additionally, a study using vascular smooth muscle cells 
observed that most endocytosed PLGA NPs were exocytosed to the cell’s surface 
(Labhasetwar 2002). Therefore, the presence of PDP NPs on the surface of the J774 cells 
after 24 hours may suggest exocytosis of these NPs. This could be useful for certain 
nanomedicines as intracellular delivery of NP cargo may be needed, and therefore it can 
be important that nanomedicines escape membrane-bound organelles within the cell to 






Of interest is the significant uptake of the PDP NPs at 4○C at 1440 minutes, at a similar 
level to that seen at 37○C for 1440 minutes. This uptake at 4○C suggests that the PDP NPs 
can enter the J774 cells passively (Mu et al. 2012). This non-phagocytic means of uptake 
could be initiated by the physiochemical characteristics of the NPs, such as Van de Waals 
forces or surface charge, and may be influenced by the NPs’ protein corona (Rimai et al. 
2000). This passive entry of NPs such as seen with positivity charged PAMAM dendrimer 
NPs may rupture the cell's membrane (Leroueil et al. 2008). Further imaging of cells 
incubated at 4○C using Wortmannin, a phagocytosis inhibitor, could give greater insight 
into whether uptake of these NPs is a mix of active or passive mechanisms (Nie et al. 
2011).  
 
The pattern of internalised NPs in J774 cells compared with C3A cells differs in that PDP-
PF68 NPs in C3A cells were diffuse throughout the cytoplasm and nucleus at 1440 
minutes. Additionally, the PDP NPs in C3A cells had a mixture of compartmentalised 
and diffuse NPs at 24 hours. Differences can also be seen between C3A and J774 cells 
internalising NPs using the quantitative method. It appears that there was a higher 
internalisation of these NPs by C3A cells. However, as macrophages are professional 
phagocytic cells, these NPs would be expected to be taken up more readily by J774 cells 
(Shu et al. 2005; Tsai & Discher 2008). These differences in the internalisation pattern 
may indicate that J774 and C3A cells differentially take up and traffic these NPs, 





This study employed methods that allowed for investigation of the cellular toxicity and 
quantification of uptake of novel PDP-PF68 and PDP NPs. Results indicated that these 
NPs had relatively low cytotoxicity and that uptake was more efficient for the PDP NPs 
in C3A cells. The presence of a PF68 coating may alter the intracellular fate of the NPs 
and decrease cellular uptake. Results suggest that PDP NPs are relatively non-toxic. 
However, the addition of the PF68 coating to PDP NPs may enhance the PNPs toxicity, 





genotoxicity via an oxidative mechanism. This highlights the need for multiple endpoints 
and specific regulatory guidelines regarding nanomedicines.  
 
The brief investigation of an additional cell line, J774, gave insights into the suitability 
of this cell line as a predictive model of PNP toxicity. This macrophage-like model was 
a more sensitive indicator of cytotoxicity than the C3A cells. However, PDP NP 
internalisation by J774 cells appears in this study to involve a passive mechanism not 
observed in C3A cells. This difference in uptake route could lead to a fundamentally 
different intracellular localisation and therefore downstream adverse effects of these NPs 
on cellular function. The use of primary hepatocytes in future experiments could also 
provide a greater understanding of any toxicity observed for these NPs. In vivo work could 
also provide invaluable information regarding biodistribution, clearance and systemic 
toxicity. The observations made in this study suggest genotoxicity could be used to inform 
future design of NPs and should encourage others to consider the effects of PNP coating 
on NP toxicity. 
 
As hypothesised, both NPs had low cytotoxicity. Although there was less uptake of PDP-
PF68 NPs, this did not link to reduced cytokine production or genotoxic effects. These 
results may be attributed to the coating altering how these NPs are internalised and 
trafficked once inside the cell. The results of this study suggest that, although these PNPs 
have low cytotoxicity, further investigations and considerations of an alternative NP 
coating would be necessary before this nanomedicine could be considered for use in a 
clinical setting.  
 
The information from this study could be used to further develop the tier 1 and 2 of the 
testing strategies suggested (Figure 1.3). This could allow for the identification of 
indicators of toxicity for PNPs before progressing with more advanced in vitro testing or 
in vivo testing, where appropriate potential to reduce the investment and resources 
required for safety testing of PNPs. This information could be used by the generator of 
these PNPs to aid in designing with safety in mind. 
 
Although cytotoxicity testing is required to establish non-lethal concentrations for further 





does not provide additional information needed to progress with testing. Additionally, 
PNP uptake did not provide as clear indication of toxicity and therefore may not need to 
be priorities or performed at multiple concentrations and time points in a PNP testing 
strategy. Again, cytokines can provide important information regarding cell health 
however when prioritising endpoints for testing the safety of PNPs, investigation of initial 
cytokines that are clear indicators of the safety of PNPs such as IL-8 and TNF-a could be 
performed before progressing to analysis of additional cytokines. Genotoxicity is 
probably the most impactful endpoint as when genotoxicity is observed it limited the 
potential of a PNP nanomedical progressing to the clinic. When testing for genotoxicity 
additional concentrations would provide future information as well as additional time 
points as both short and long exposures are suggested to capture the full scope of 









Chapter 3. In vitro assessment of the influence of copolymer chain length on NP 







3.1.1 Designing safe PLGA-PEG PNPs for nanomedicine 
 
In this study three different PLGA-PEG polymers were used to generate the PNPs: 
PEG2K-PLGA4K (4K NPs), PEG2K-PLGA15K (15K NPs) and PEG5K-PLGA55K 
(55K NPs). The PNPs were loaded with the non-toxic fluorescent conjugated polymer 
poly(2,5-di(3′,7′-dimethyloctyl) phenylene-1,4-ethynylene) (PPE) for bioimaging (Wu et 
al. 2013) (Figure 3.1). 
 
The core of the PNPs in this study was composed of PLGA, one of the most common 
polymers used to generate PNPs due to FDA approval for clinical use (He et al. 2013; 
Dening et al. 2016). Previous studies suggest that PLGA NPs has low toxicity and are 
biocompatible and biodegradable. For example, when KMC-1 cells (bile duct epithelial) 
were exposed to PLGA NPs there were no changes in cell viability or cytokine production 
(TNF-α and IL-6) (Santos et al. 2013). Additionally, in vivo, following oral 
administration, PLGA NPs showed no histopathological changes in the liver and kidneys 
of exposed mice (Boitumelo Semete et al. 2010). However the by-products of PLGA NPs 
hydrolytic degradation, poly-lactic acid and polyglycolic acid, have been shown to cause 
cytotoxicity as well as TNF-α and ROS production by macrophage cells in vitro (Acharya 
& Sahoo 2011; Nie et al. 2012; Singh & Ramarao 2013).  
 
The shell of the PNPs in this study was composed of PEG, an FDA-approved polymer 
for clinical use that has low toxicity (Cruz et al. 2011). PEG is hydrophilic, resulting in 
less opsonisation, decreased phagocytic recognition and increased circulation time 
(section 1.6 for more detail) (Alexis et al. 2008; Sheng et al. 2009; Jain et al. 2011). 
Moreover, the addition of PEG to PLGA NPs can improve the NPs usefulness as a 
















Figure 3.1 Scheme of PEG-PLGA NPs: 4K, 15K and 55K NPs. 
Representation of PNPs used in this study. PNPs were made of polymer PEG2K (light 
blue), PEG5K (dark blue), PLGA4K (yellow), PLGA15K (orange), PLGA55K (red) and 







3.1.2 The effect of altering polymer chain length on PNP safety 
 
Three different chain lengths of PLGA and two different chain lengths of PEG were used 
in this study to generate 4K, 15K and 55K PNPs. Increasing polymer chain length has 
previously been shown to increase degradation time and decrease non-targeted NP 
uptake, both beneficial properties for NPs formulated to carry a fluorescent cargo such as 
PPE for bioimaging (Alexis et al. 2008; Dinarvand et al. 2011; Conde et al. 2014; Sharma 
et al. 2015). However, changes in polymer chain length can influence PNP toxicity. 
 
When rabbit vascular smooth muscle cells were exposed to polyvinyl alcohol-PLGA NPs 
with varying PLGA chain lengths of 15-30K, there was no impact on viability (Westedt 
et al. 2007). Additionally, when Estradiol containing PLGA NPs were orally administered 
to Sprague Dawley rats, organs including the liver and lung appeared unaffected (Mittal 
et al. 2007).  
 
However, longer PEG chain length can enhance NP stability and reduce cellular uptake, 
and could, therefore, reduce NP toxicity before they reach target cells. Furthermore, an 
increase in PEG chain length can increase PNP diameter (Gref et al. 2000; Ma et al. 2012). 
In a study comparing 2K and 5K PEG chain lengths in vivo using mice and rats, results 
indicated that a longer chain length leads to extended circulation (Bertrand et al. 2017). 
Furthermore, no TNF-α or IL-1β production was observed from macrophage cells 
exposed to chitosan-PEG NPs with 2K and 5K PEG chain lengths, although lower levels 
of internalisation were seen for chitosan-PEG NPs with 5K PEG chain lengths compared 
to 2K (Yang et al. 2017). Longer PEG chains as part of PLGA NPs can reduce serum 
protein adsorption and therefore serum-dependent phagocytosis (Yang et al. 2010).  
 
Previous studies investigating the role of polymer chain length to PNP toxicity have 
focused on assessment of cytotoxicity, uptake and cytokine production. Using the 
complex polymer nanomedicines in this project, it was possible to assess the effects of 
polymer chain length on overall PNP toxicity. This could provide a more comprehensive 
assessment of PNP toxicity and a better understanding of the mechanism of PNP toxicity 





3.1.3 Study design and aims 
 
The aim of this study was to assess the toxicity of PLGA-PEG PNPs of varied polymer 
chain lengths (4K, 15K and 55K PNPs) to hepatocytes in vitro. In addition to the 
endpoints investigated in Chapter 2 (cytotoxicity, cytokine production, cellular uptake, 
genotoxicity), this study investigated cellular ROS production, as well as liver-specific 
indicators of toxicity, urea and albumin.  
 
In the cells of the liver, an increase in intracellular ROS could result in an imbalance of 
ROS and antioxidants, leading to indirect downstream effects such as DNA damage and 
metabolic changes in hepatocytes (Filippi et al. 2014; Evans et al. 2017). Previously, 
polymer NPs composed of PLGA and coated with PEI were observed to elicit ROS 
production in hepatocyte cells (HepG2) (Yu et al. 2014). Additionally, other studies using 
spheroid culture hepatic cells, indicate that polymer PAMAM dendrimer NPs could 
stimulate the production of ROS (Chen et al. 2016). ROS production mediated via 
polymer NPs has not been extensively investigate and could be an important marker of 
PNP toxicity, as has been observed for engineered NPs such as Ag and CuO NPs (Liu et 
al. 2016; Ahmad et al. 2016). Therefor it is important it investigate the ability of these 
PNPs to elicit a ROS response. 
 
Reduction of urea and albumin production are markers of liver disease (Racine-Samson 
et al. 1996). This is an important endpoint in vitro as an indicator of hepatocyte health 
that has not been commonly investigated when assessing the toxicity of PNPs. Therefor 
this could be a useful marker for PNP toxicity, that warrant investigation. In vivo studies 
in mice and rats have shown a decrease in blood urea nitrogen (BUN) levels, an in vivo 
equivalent to urea synthesis, when exposed intravenously to various NPs (TiO2, Ag, ZnO) 
< 300 nm (Wang et al. 2007; Faisst et al. 2010; Pan et al. 2012; Xu et al. 2013). In contrast, 
other in vivo studies in rats have shown that polymer based NPs such as PLGA NPs of < 
500 nm failed to impact on BUN levels following oral and intravenous NP exposure 
(Italia et al. 2007; Moreno et al. 2010). 
 
Similar observations of a marked reduction in urea and albumin synthesis together with 





hepatocytes exposed to TiO2 NPs < 900 nm (Natarajan et al. 2015). It was suggested that 
damage to the mitochondria, contributed to these liver-specific observations (Natarajan 
et al. 2015).  
 
It is hypothesised that: 
 
1. 4K, 15K and 55K NPs, at pharmacologically relevant concentrations would 
stimulate minimal cytotoxicity in C3A hepatocyte cells. 
 
2. 4K, 15K and 55K NPs have increasing PLGA chain lengths, with increasing 
polymer chain length there would be a reduction in overall toxicity due to increased 
PNP stability. 
 
3. 4K, 15K and 55K NPs would stimulate ROS production and activate a pro-
inflammatory response in C3A hepatocyte cells. 
 
4. 4K, 15K and 55K NPs would be internalised by C3A hepatocyte cells  
a. with less uptake observed for PNPs of longer polymer chain lengths. 
 
5. 4K, 15K and 55K NPs at pharmacologically relevant concentrations would 
stimulate minimal genotoxicity in C3A hepatocyte cells.  
 
6. 4K, 15K and 55K NPs would be capable of reducing albumin and urea production 
in C3A hepatocyte cells. 
a. with less of an impact observed for PNPs with longer polymer chain 
lengths. 
 
In parallel to the assessment of PNP toxicity the physicochemical properties of the PNPs 
will be investigated via DLS and TEM. These batch produced NPs had short stability, 
low volume and low NP concentration. Therefore, it was not always possible to perform 
endpoints with a wide range of concentrations, in particular endpoints that require higher 






3.2 Materials and methods 
 
3.2.1 Preparation of 4K, 15K and 55K NPs 
 
NPs were prepared at Heriot Watt University according to the method developed by Prof 
Lea Ann Dailey and Dr Thais Abelha of King’s College London. The amphiphilic diblock 
copolymer PLGA–PEG was used to encapsulate the fluorescent, green-emitting 
conjugated polymer PPE. PLGA-PEG block copolymers of various molecular weights 
(PEG2K-PLGA4K (4K), PEG2K-PLGA15K (15K) and PEG5K-PLGA55K (55K)) were 
purchased from Sigma-Aldrich. A stock solution of each type of polymer was prepared 
at a concentration of 5 mg/mL in the solvent, Tetrahydrofuran (THF) (Sigma-Aldrich), in 
a glass vial. In a separate glass vial, the conducting polymer, PPE, was prepared at a 
concentration of 5 mg/mL in the THF.  
 
Next, the PEG-PLGA copolymer solutions were combined with the PPE solution to a 
final volume of 1 mL in THF. The 4K and 15K solutions had final concentrations of 64.57 
μg/mL (62 μL) of PPE and 645.82 μg/mL (620 μL) for PEG-PLGA, with a final polymer 
concentration (PLGA, PEG and PPE) of 0.710mg/mL. The 55K solution contained 45.83 
μg/mL (44 μL) of PPE and 458.33 μg/mL (440 μL) of PEG-PLGA, giving a final polymer 
concentration (PLGA, PEG and PPE) of 0.504 mg/mL.  
 
Each polymer solution (1 mL) was added dropwise to 4.8 mL of deionised water, under 
low, stirring conditions using a magnetic flea. Overnight stirring was kept at the lowest 
speed to allow complete evaporation of the THF. Any volume of water lost overnight was 
replaced, and NP suspensions were filtered using a sterile membrane syringe filter (pore 
size 200 nm) (Millipore), stored at 4○C and used within one month of preparation. For 
use in experiments, NPs were freshly diluted in cell culture medium and briefly vortexed. 
 
3.2.2 Nanoparticle characterisation  
 
NPs were characterised by DLS and TEM, as in Section 2.2.2. Additionally, the size 
stability of the NP suspensions were determined by monitoring changes in hydrodynamic 






3.2.3 Cell culture 
 
Human C3A hepatocellular carcinoma cells were cultured as in Section 2.2.3.  
 
3.2.4 Cytotoxicity assay: Alamar Blue 
 
A 96-well plate fluorescence-based assay assessed C3A cells viability following exposure 
to NPs using the AB assay as described in Section 2.2.5. NP interference with the AB 
assay was performed as in Section 2.2.5 with NPs prepared at concentrations of (4.6, 9.3, 
18.7, 37.5, 75.0, 150 μg/mL). Inference results were only reported when positive. 
 
 
3.2.5 Measurement of cytokine production 
 
A multiplex sandwich ELISA was used to measure secretion of IL-8, IL-1ra, TNF-α, IL-
1β and IL-6 from C3A cells exposed to NPs. Supernatants obtained from the cytotoxicity 
experiments (Section 3.2.4) were thawed and analysed using a human magnetic Luminex 
assay kit (R&D Systems), as in Section 2.2.9 and as per the manufacturer’s instructions. 
All steps were carried out at RT and in subdued lighting conditions. Sublethal NP 
concentrations (31.25, 62.5 and 125 µg/mL) were assessed, as well as Complete Medium 
(negative control). Additionally, NPs’ interference with this assay was established by 
adding the standard curves midpoint (SCM) concentration to 125 µg/mL NPs prepared in 
the same medium as the standard curve. Any interference observed was presented in 
results, if not presented interference was not observed. 
 
3.2.6 Measurement of intracellular ROS production 
 
A 96 well-plate fluorescence-based assay was used to determine C3A cells ROS 
production. Cells were exposed to UFCB a well-established mediator of ROS production 
as a positive control for ROS production with and without pre-treated with Trolox to 
establish the assay is functioning correctly (Brown et al. 2004). C3A cells were seeded 





at 37○C and 5% CO2. Cells either remained in Complete Medium or were pre-treated with 
Trolox (100 µM in Complete Medium) for one hour at 37○C and 5% CO2. Cells were then 
washed twice using PBS and exposed to NPs at sublethal concentrations (31.25, 62.5 and 
125 µg/mL) or UFCB-Printex-90, 10 µg/mL (positive control) or Complete Medium 
(control) in triplicate for 1440 minutes at 37°C and 5% CO2. Going forward all steps were 
performed in subdued lighting at RT. 
 
Following NP treatment, cells were washed twice with HBSS (Sigma-Aldrich) and then 
incubated for five hours with 5 µM DCFH-DA (Sigma Aldrich) or methanol (without 
DCFH-DA) (100 µL) to assess the NPs potential for interference with DCFH-DA. This 
was measured in a SpectraMax M5 Microplate Reader at Ex/Em 495/529 nm. Data are 
expressed as mean fold change (from control) ± SEM. Interference was only reported 
when it was positive. 
 
3.2.7 Quantification of NP uptake: plate method 
 
A 96 well-plate fluorescence-based uptake assay was used to determine uptake of 
fluorescently loaded NPs by C3A cells at sublethal concentrations (1.9-125 µg/mL), as in 
Section 2.2.7. Data are expressed as average µg/mL of the retained NP suspension in the 
cell lysate, calculated from standard curves.  
 
3.2.8 Assessment of NP uptake: confocal microscopy 
 
Confocal microscopy was used to visualise NP uptake by C3A cells, as in Section 2.2.6. 
One timepoint (1440 minutes) was selected, based on the previously reported findings 
(Section 3.2.7) at one sublethal concentration of NPs of 125 µg/mL. Slides were stored at 
4˚C until they were imaged using a Leica SP5 SMD laser-scanning confocal microscope 
(Edinburgh Super-Resolution Imaging Consortium).  
 
3.2.9 Genotoxicity assessment: Comet assay 
  
A 24-well plate-based assay was used to assess specific oxidative DNA damage and DNA 





(Trevigen) and the Fpg fragment length analysis using repair enzymes (FLARE) assay kit 
(Trevigen). Following this, cells were seeded and grown for 24 hours at 37○C and 5% 
CO2 in 24-well plates (1.56 x10
5 cells/cm2). These cells were washed twice in HBSS and 
exposed to NPs (62.5 and 125 µg/mL), Complete Medium (negative control), 60 M 
hydrogen peroxide (H2O2, positive control) (Sigma-Aldrich). This was done in duplicate 
for 1440 minutes at 37○C and 5% CO2. Due to the limited volume and concentration of 
NPs the number of concentrations assessed was limited to two and not the recommended 
three meaning these results most be considered preliminary (OECD 2015). 
 
The cells were then washed twice with HBSS, trypsinised (Section 2.2.3) before being 
resuspended in Complete Medium (1 mL) and centrifuged at 2000 g for one minute. 
Subsequently, the supernatant was discarded, and the cells resuspended in ice-cold PBS 
(0.2 mL). The cells (100 L) were then added to low melting point agarose (400 L). The 
cell agarose suspension (25 L) was next deposited onto a 24-well comet chip in 
duplicate. Slides were incubated on ice for 15 minutes before being transferred to a lysis 
solution for 12 hours at 4○C.  
 
Following incubation, slides were immersed in the FLARE buffer for 30 minutes with 
three changes of buffer. Slides were next incubated with Fpg enzyme (1:75 dilution in the 
Fpg reaction buffer) or Fpg reaction buffer alone at 37C for 30 minutes in a humidity 
chamber. Afterwards, they were transferred to an electrophoresis solution (300 mM 
sodium hydroxide, 200 mM EDTA, 2 L distilled water, pH 13) and incubated for 30 
minutes at RT, with a single solution change. After this, slides were transferred to an 
electrophoresis tank containing an electrophoresis solution in a room with a temperature 
of 4○C. The solution was allowed to equilibrate for 20 minutes. Electrophoresis was 
performed for 40 minutes at 30 V and 300 mA. Next, slides were washed twice with 
deionised water and then once with 70% ethanol, each wash was five minutes. Slides 
were then dried for 15 minutes at 37C before being stored at 4○C. 
 
Samples were stained with GelRed (Biotum) to visualise DNA. Samples were imaged 
using a fluorescence microscope (Zeiss AX10 with an Allied Vision Technologies 
Stingray camera) connected to image-analysing software (Comet Assay IV, Perceptive 





expressed as mean % Tail DNA ± SEM.  
 
3.2.10 Measurement of urea production 
 
The quantichrom urea assay kit (BioAssay Systems) was used to quantify C3A cells’ urea 
production. Cells were seeded and grown for 24 hours at 37○C and 5% CO2 in 96-well 
plates (1.56 x 105 cells/cm2). Cells were exposed to NPs at a sublethal concentrations 
(31.25, 62.5 and 125 µg/mL) or Complete Medium (control) in triplicate for 24 hours at 
37○C and 5% CO2. 
 
Following exposure, cell supernatants were collected and added to appropriate wells in a 
fresh black 96-well plate, including a set of standards to produce a standard curve (3.5 - 
500 µg/dL) (50 µL). A working reagent (100 µL) was prepared from two components 
(Solution A: 10% sulphuric acid, 0.40% o-phthalaldehyde and 0.04% Brij 35 and Solution 
B: 0.08% Primaquine diphosphate, 22% sulphuric acid, 0.8% boric acid and 0.04% Brij 
35) and added to all wells. The plates were incubated for 50 minutes at RT in subdued 
lighting conditions. Absorbance was measured in a SpectraMax M5 Microplate Reader 
at 430 nm. Data are expressed as average µg/dL of urea, calculated from the standard 
curve. 
 
To determine the potential for NPs interference with this assays the NPs at 125 µg/mL 
were spiked with the SCM for the urea standards. Results were reported only when 
inference was observed. 
 
3.2.11 Measurement of albumin production 
 
Bromocresol green (Sigma Aldrich) was used to establish albumin production in C3A 
cells. Following seeding of cells and 24 hours’ growth at 37○C and 5% CO2 in 96-well 
plates (1.56 x 105 cells/cm2), cells were exposed to NPs at sublethal concentrations (31.25, 
62.5 and 125 µg/mL) or Complete Medium (control) in triplicate for 24 hours at 37○C 
and 5% CO2. 
 





of a fresh black 96-well plate, and a standard curve, 6.25-400 mg/dL of albumin from 
chicken-egg white (Sigma Aldrich) (50 µL). The Bromocresol green (0.066 mM in 100 
mM Succinate Buffer (Sigma Aldrich), pH 4.2) solution (50 µL) was then added to all 
wells. The plates were incubated for five minutes and shaken at RT in subdued lighting. 
Absorbance was measured in a SpectraMax M5 Microplate Reader at 630 nm. Data are 
expressed as average mg/dL of albumin, calculated from the standard curve. 
 
To determine the potential for NPs interference with this assays the NPs at 125 µg/mL 
were spiked with the SCM for the albumin standards. Results were reported only when 
inference was observed. 
 
3.2.12 Statistical analysis 
 
Experimental data were analysed using GraphPad Prism software. One-way ANOVA 
using Tukey post-test or two-way ANOVA, followed by the Bonferroni post-test were 
used to test significance which was set at p< 0.05. All experiments were repeated three 








3.3.1 4K, 15K and 55K NPs: Physicochemical characterisation 
 
Immediately after preparation, and 24 hours after incubation at 37○C and 5% CO2, DLS 
was used to measure the hydrodynamic diameter, zeta potential and PDI of 4K, 15K and 
55K NPs prepared in PRF Complete Medium (Figure 3.2). At both time points, both the 
4K and 15K NPs had similar hydrodynamic diameters of ~140 nm and PDI values of ~0.2 
(Figures 3.2 A/B). The hydrodynamic diameter of 55K NPs was at ~150 nm at both time 
points, which was significantly larger (p< 0.05) than those of both the 4K and 15K NPs 
(Figure 3.2A). After 24 hours’ incubation, there was a significant decrease (p< 0.05) in 
the PDI of 55K (Figure 3.2B). 
 
All NPs exhibited a slightly negative surface charge, ranging from -5 to -12 mV (Figure 
3.2C). The zeta potential of 4K NPs was significantly less negative (p< 0.001) than those 
of both 15K and 55K NPs. On the other hand, 15K NPs showed a significant decrease in 
zeta potential following 24 hours’ incubation. The size and morphology of the NPs were 
assessed using TEM. To closely resemble experimental conditions, all NPs were prepared 
in PRF Complete Medium for TEM imaging (Figure 3.3). All three NPs appear to have a 
mixed population of NPs, with the dominant NPs appearing to be 100-200 nm in diameter. 








Figure 3.2 Characterisation of 4K, 15K and 55K NPs properties using DLS. 
NPs (4K, 15K and 55K) were suspended in PRF Complete Medium (125 µg/mL). 
Hydrodynamic diameter (A), PDI (B) and zeta potential (C) were assessed at 0 (T0) 
and 24 hours (T24) post-incubation at 37○C, 5% CO2 using DLS. Data are expressed 
as mean ± SEM (n=3). Significance indicated by *= p< 0.05 or ***= p< 0.001 when 0 
and 24 hours compared. Significance indicated by $$$= p< 0.001 when 55K compared 



































































Figure 3.3 TEM characterisation of 4K, 15K and 55K NPs. 
Images are of the 4K (A), 15K (B) and 55K NPs (C) when suspended in PRF Complete 
Medium at a concentration of 125 µg/mL and imaged using TEM. Representative 






3.3.2 4K, 15K and 55K NPs: Cytotoxicity  
 
To investigate the effect of 4K, 15K and 55K NPs on cell viability, C3A cells were 
exposed to NPs at concentrations ranging from 4.7-150 µg/ mL, and the AB assay was 
used to measure the cells’ metabolic activity (Figure 3.4). With all NPs, there was a 
concentration-dependent decrease in cell viability. A significant decrease in viability was 
observed for the 4K NPs at concentrations of 37.5 and 150 µg/mL. For the 15K NPs, a 
significant decrease in cell viability was observed at 150 µg/mL. However, for both the 
4K and 15K NPs, viability did not decrease to levels below 80% and therefore was 
unlikely to be biologically relevant. 
 
For the 55K NPs, cell viability decreased significantly (p< 0.001) at all concentrations 
except the lowest of 4.7 µg/mL (significance only indicated when value below 80% 
viability). A decrease in viability below 80% was only observed at the highest 
concentrations of 75 and 150 µg/mL. The reduction in the viability of cells exposed to 
the 55K NPs was significantly higher (p< 0.01) than that observed for the 4K or 15K NPs 
at 150 µg/mL. An EC20 value, indicating the concentration at which NP exposure causes 
20% cell death, could not be calculated within the range of concentrations used for these 
NPs. EC20 calculations require a complete dose-response curve containing a top plateau 
(defined as 100) and a bottom plateau (defined as 0), when data do not have defined 100 
and 0, then 20 is also undefined (Neubig et al. 2003). Although reading off the graph it 











Figure 3.4 Cytotoxicity of 4K, 15K and 55K NPs to C3A cells. 
Cells were exposed to 4K (black), 15K (red) and 55K NPs (blue) at 4.7-150 µg/mL for 
24 hours. Percentage viability was measured via AB assay. Data are expressed as mean 
% viability (i.e. % of untreated control) ± SEM (n=3). Significance indicated by ***= 
p< 0.001 compared with untreated control. Significance indicated by $$= p< 0.01 when 






3.3.3 4K, 15K and 55K NPs: Cytokine production 
 
To determine any potential interference of NPs with cytokine measurement, all NPs at 
125 µg/mL were incubated with a known concentration of cytokines equivalent to the 
SCM. The 55K NPs appeared to show a significant decrease in cytokine measurement of 
TNF- α, IL-6 and IL-1ra (Figure 3.5) (p<0.01 to p<0.001). However, both 4K and 15K 
NPs appeared to decrease significantly (p<0.05) the detection of IL-1ra. Although this 
interference was significant, it was ~5% or lower, suggesting cytokine detection would 
not be prevented.  
 
Production of IL-8, IL-1ra, TNF-α, IL-1β and IL-6 cytokines from C3A cells was 
assessed following exposure to all NPs. For all NPs, there was no significant production 
of cytokines by C3A cells over background levels for TNF-α, IL-1β or IL-6. However, a 
significant (p<0.01 to p<0.001) decrease in IL-8 production was seen with all NPs (Figure 
3.6A), although this was not significantly difference between the different NPs. Since the 
NPs did not interfere with the detection of IL-8 (Figure 3.5), the decrease observed can 
be assumed to accurately reflect the impact of these NPs on IL-8 production. Additionally, 
there appeared to be an increase in IL-1ra production for all NPs, but this was only 












Figure 3.5 Optimisation of cytokine detection for 4K, 15K and 55K NPs. 
The SCM concentration of each cytokine was incubated with 4K, 15K and 55K NPs 
prepared at 125 μg/mL in Complete Medium to observe interference of cytokine 
detection caused by NPs. Data are expressed as mean pg/mL ± SEM (n=3). 








Figure 3.6IL-8 and IL-1ra production induced by the 4K, 15K and 55K NPs in 
C3A. 
Cells were exposed to 4K, 15K and 55K NPs (31.25, 62.5 and 125 μg/mL) for 24 hours. 
Data are expressed as IL-8 (A) or IL-1ra (B) pg/mL ± SEM (n=3). Significance 








3.3.4 4K, 15K and 55K NPs: Intracellular ROS production 
 
To measure the ability of the 4K, 15K and 55K NPs to induce intracellular ROS 
production, the DCFH-DA assay was used. A significant increase (p<0.001) (~five-fold) 
in ROS production was observed for all NPs at all concentrations 24 hours post-exposure 
of C3A cells (Figure 3.7). There appears to be no dependence on NP concentration, 
suggesting all NPs at all concentrations induce the same level of ROS production. 
Although the 55K NPs at 125 µg/mL appeared to stimulate a significantly higher (p<0.05) 
level of ROS production when compared with both the 4K and 15K NPs at 125 µg/mL, 
albeit a small increase of ~ 20% (Figure 3.7C). UFCB (positive control) induced a 






Figure 3.7 ROS produced by C3A cells exposed to 4K, 15K and 55K NPs: DCFH-
DA assay. 
Cells were exposed 4K (A) 15K (B) or 55K (C) at 31.25, 62.5 and 125 µg/mL and to 
UFCB (positive control) at 10 µg/mL for 24 hours. Data are expressed as mean fold 
change (from the untreated control) ± SEM (n=3). Significance indicated by ***=p< 







3.3.5 4K, 15K and 55K NPs: Uptake  
 
A fluorescent plate-based method was used to quantify the internalisation of the 4K, 15K 
and 55K NPs by C3A cells over time (10, 60 and 1440 minutes) at a range of 
concentrations (1.9-125 µg/mL). There appeared to be little or no internalisation of any 
of the NPs at any of the time points or concentrations investigated. The only detectable 
level of uptake observed was for 15K NPs at 125 µg/mL, 24 hours post-exposure (Figure 
3.8).  
 
NP internalisation at 24 hours post-exposure was also evaluated using confocal imaging, 
at a concentration of 125 µg/mL. There appeared to be the minimal uptake of all NPs 
(green) by C3A cells. The highest level of uptake was observed for 15K NPs, with a very 













Figure 3.8 Uptake of 15K NPs in C3A cells, over time: Plate method. 
Cells were exposed to the 15K NPs for 10 (white), 60 (black) and 1440 (grey) minutes 
at 1.9-125 µg/mL. Data are expressed as mean µg/mL retained (from appropriate 











Figure 3.9 Uptake of the 4K, 15K and 55K NPs by C3A cells. 
Cells were exposed to 125 µg/mL NPs (green), 4K (A), 15K (B), 55K (C) or Complete 
Medium (D) for 24 hours. DNA (blue). Representative images (n=3) scale bar 







3.3.6 4K, 15K and 55K NPs: Genotoxic effect  
 
A semi-high throughput Comet assay was used to investigate the NPs’ genotoxicity. C3A 
cells were exposed to all NPs for 24 hours at concentrations of 62.5 and 125 μg/mL, and 
the Fpg enzyme was used to determine the contribution of oxidative stress to any observed 
genetic damage.  
 
There was no significant damage to DNA seen for all three NPs at both concentrations in 
the absence of Fpg (Figure 3.10). In the presence of Fpg, only the 15K NPs caused a small 
but significant increase (p<0.05) in DNA damage at 125 μg/mL. Additionally, when 
compared with the 4K and 55K NPs at the same concentration with Fpg, 15K NPs 
appeared to cause significantly more (p<0.05) DNA damage than the 4K and 55K NPs 
did. The positive control of H2O2 (60 μM) caused a significant increase (p<0.001) in DNA 
damage in the absence and presence of Fpg. In the presence of Fpg, the level of DNA 
damage was significantly higher (p<0.001) for H2O2, indicating that the assay had 







Figure 3.10 Genotoxicity of 4K, 15K and 55K NPs in C3A cells: Comet assay. 
Cells were exposed to 4K (A), 15K (B) and 55K (C) NPs at concentrations of 62.5 and 
125 μg/mL, 60 μM H2O2 and Complete Medium for 24 hours ± Fpg. Data are expressed 
as mean % of DNA in tail ± SEM (n=3). Significance indicated by ***= p< 0.001, *= 







3.3.7 4K, 15K and 55K NPs: urea and albumin production 
 
As a measure of hepatocyte function, urea and albumin production were investigated in 
cells treated with the 4K, 15K and 55K NPs following 24 hours exposure at three 
sublethal concentrations (31.25, 62.5 and 125 µg/mL). To determine the potential for NPs 
to interfere with these assays the NPs (125 µg/mL) were spiked with the SCM for both 
the urea and albumin standards. There did appear to be a significant reduction (p< 0.001) 
in urea measurement when the SCM was spiked with 4K and 15K NPs, both containing 
PEG2K as part of the polymer chain, as this reduced the measurement of urea by approx. 
~ 40-50 %, therefore any reduction less than this cannot be considered to be a NP effect 
(Figure 3.11A). While there was no observed interference for 55K NPs which contains 
PEG5K as part of the polymer chain. There was no interference observed with the 
albumin production assay for any NPs (Figure 3.11 B). 
 
A significant decrease (p< 0.001) in urea production was seen for cells exposed to all the 
NPs. The 55K NPs appeared to reduce significantly (p<0.001) the production of urea in 
a concentration-dependent manner (Figure 3.12A). Additionally, 4K NPs reduced urea 
production to non-detectable (ND) levels at the highest concentration of 125 µg/mL. 
Reduction in urea for the 15K NPs at all concentrations, and the 4K NPs at 31.25 and 
62.5 µg/mL was likely to derive from interference, not NP toxicity. In contrast, there 
appeared to be no effect on albumin production by any of the NPs, at any of the 
concentrations tested (Figure 3.12B).  
 
A previous in vivo (rat) study demonstrated that LPS downregulates urea cycle enzymes 
in the liver, making LPS a useful positive control for both urea and albumin production 
in hepatocytes (Tabuchi et al. 2000). When C3A cells were exposed to LPS, significant 









Figure 3.11 Interference of the 4K, 15K and 55K NPs with urea and albumin 
detection. 
The SCM of urea or albumin standard curves was added to 4K, 15K and 55K NPs 
prepared at 125 μg/mL in Complete Medium for 24 hours at 37°C and 5% CO2 to 
observe the interference of urea (A) and albumin (B) detection caused by NPs. Data 
are expressed as mean fold change ± SEM (n=3). Significance indicated by ***=p< 









Figure 3.12 Urea and albumin production following exposure of C3A cells to 4K, 
15K and 55K NPs. 
Cells were exposed to the 4K, 15K and 55K NPs at 31.25, 62.5 and 125 µg/mL for 24 
hours. Urea (A) and albumin (B). Data are expressed as mean urea µg/mL (A) or mean 
albumin mg/dL (B) ± SEM (n=3). Significance indicated by ***= p<0.001 when 







3.4 Discussion  
 
3.4.1 Overview of results 
 
To understand the impact of varying polymer chain lengths on PLGA NP toxicity in C3A 
cells, NPs were first characterised using DLS and TEM to determine size, morphology 
and surface charge. Characterisation results indicated that all NPs were <150 nm in 
diameter and that the 4K and 15K NPs had no significant difference in size, while the 
55K NPs appeared significantly larger. Following incubation at 37°C for 24h, there was 
no change in the size of any of the NPs, suggesting they remained stable throughout a 24 
hour assay. All NPs had a negative surface charge. The zeta potential of the 15K NPs 
decreased after incubation at 37°C for 24h, which may have influenced the way these NPs 
interacted with cells.  
 
Cytotoxicity assessment using the AB assay indicated that the 4K and 15K NPs did not 
affect C3A cell viability. The 55K NPs significantly decreased cell viability to below 80% 
at the highest concentration tested (150 µg/mL), indicating that NPs with longer PLGA 
chain lengths may negatively affect C3A cells viability. After this, the internalisation of 
NPs by cells was investigated. The internalisation of 4K and 55K NPs by C3A cells was 
negligible at the timepoints and concentrations investigated. However, very low levels of 
uptake of 55K NPs were observed at the highest concentration (125 µg/mL) after 
incubation for 24h. 
 
Genotoxicity was assessed using the Comet assay. However, only the highest 
concentration of the 15K NPs caused a low level of genotoxicity in the presence of Fpg, 
suggesting that DNA damage was mediated by an oxidant mechanism. For all NPs, there 
was no production of TNF-α, IL-1β or IL-6 by cells, although there was a significant 
decrease in IL-8 production for cells exposed to all NPs, and a significant increase in IL-
1ra was seen for cells exposed to 4K NPs at the highest concentration (125 µg/mL). The 
DCFH-DA assay was used to measure intracellular ROS production, and all the NPs 
induced an increase in ROS production by cells. However, there was little difference 






Specific markers of hepatic damage (i.e. urea and albumin production) were investigated, 
and it was observed that for all NPs there was little effect on albumin production. There 
was, however, a significant decrease in urea production for all NPs. Nevertheless, the 4K 
and 15K NPs may interfere with the assay used to assess urea production.  
 
Taken together, these results indicate that increasing PLGA chain length enhances 
polymer NP toxicity to C3A cells. This information could be used in the future to design 
polymeric NPs, design testing strategies to assess polymeric NP toxicity in vitro and feed 
into the development of legislation to protect human health from any risks polymeric NPs 
pose.  
 
3.4.2 Characterisation of 4K, 15K and 55K NPs  
 
The hydrodynamic diameter of all NPs was <150nm, as assessed using DLS. There was 
no change in hydrodynamic diameter over time for any of the NPs, suggesting that these 
NPs are relevantly stable throughout the experimental conditions (24 hours). The 55K 
NPs were significantly larger than the 4K and 15K NPs at both time points, most probably 
due to an increase in both PEG and PLGA chain length. These findings are in line with 
prior studies, which have shown that an increase in PEG chain length (the 4K and 15K 
NPs had a 2K PEG chain, the 55K had a 5K PEG chain) can increase PNP diameter (Gref 
et al. 2000; Ma et al. 2012).  
 
TEM was also used to investigate NP size and morphology. The NP size observed using 
TEM appeared to reflect the measurements obtained using DLS, with the predominant 
population of NPs being ~100–200 nm in diameter. All three NPs appeared to have some 
degree of aggregation/agglomeration, and, for all samples, a mixed population of NP sizes 
was apparent. This could suggest degradation of the NPs before imaging or may also 
reflect the heterogeneous nature of NPs generated via the solvent displacement method. 
A study conducted by Fedatto Abelha et al. (2017), demonstrated that a microfluidic 
solvent displacement (MFSD) method used to synthesise polymeric NPs generated 
smaller, more uniform NPs than the more traditional solvent displacement methods. Thus, 
to translate these block copolymer NPs to the clinic, alternative manufacturing 





et al. 2015). 
  
Although TEM is often used to characterise NPs, polymeric NPs are known to be difficult 
to image with TEM. More specifically, the low density of PNPs produces low-contrast 
images, and the TEM preparation methods used can dry out NPs, causing distortion and 
artefacts (Renz et al. 2016). Therefore, to overcome these obstacles, other imaging 
modalities can be used, such as atomic force microscopy, which could allow visualisation 
and measurement of NP size in an appropriate biological medium (Constantin et al. 2017). 
 
The charge of these NPs was slightly negative, which in line with previous studies 
showing that PEGylation of PLGA NPs  generates NPs with slightly negative zeta 
potential ( Li et al. 2001; Pamujula et al. 2012). It is established that PLGA has a negative 
charge (Yan et al. 2015). Previous studies have indicated that with increasing percentage 
of PEG in a polymer, there is a less negative zeta potential (Pamujula et al. 2012). 
Therefore, the finding that the 4K NPs have a less negative zeta potential compared with 
that of the 15K and 55K NPs, may be related to the higher percentage of PEG in the 
polymer used to prepare the 4K NPs (PEG2K-PLGA4K (4K NPs=33.3% PEG), PEG2K-
PLGA15K (15K NPs=11.8% PEG); PEG5K-PLGA55K (55K NPs=8.3% PEG). 
Following incubation at 37○C for 24 hours, the 15K NPs had a significantly (p< 0.01) 
more negative zeta potential, perhaps due to the accumulation of a protein corona on their 
surface, or degradation of a proportion of the NPs. For example, proteins on the NP 
surface were previously shown to have an overall negative charge at pH7 (Tenzer et al. 
2013). The low PDI of all these NPs points towards the high stability of these suspensions, 
a desirable characteristic for nanomedicines since this would allow for accurate dose 
administration in vivo.  
 
Ideally, further characterisation of the physicochemical properties of these NPs would be 
performed to help identify which NP properties may confer toxicity. For example, the 
surface chemistry has been shown to influence NP toxicity (Voigt et al. 2014) and could 
be measured using a field emission scanning electron microscope (Bandyopadhyay et al. 
2016). Analysis of the composition of the protein corona may also shed light on how or 
why these NPs interact with the cells differently, and could be investigated using 





diffusion coefficient using Fluorine-19 diffusion nuclear magnetic resonance 
spectroscopy (Lazarovits et al. 2014; Carril et al. 2017).  
 
3.4.3 Cytotoxicity of the 4K, 15K and 55K NPs 
 
The AB assay was used to determine mitochondrial function as a measure of cell viability, 
due to its sensitivity and its established position in determining NP cytotoxicity in vitro 
(Zhang et al. 2011; Farcal et al. 2015; Brayden et al. 2015). Additional methods, such as 
the CFDA-AM and NR uptake assays, can also be used to determine cell viability, 
although using three different assays to assess the cytotoxicity of low toxicity PNPs may 
be unnecessary. From previous experiments (section 2.3.2) the Alamar Blue assay was 
seen to produce robust, reliable data. 
 
. Neither the 4K nor the 15K NPs adversely affected cell viability, with viability above 
80% at all concentrations tested, suggesting that these NPs are relatively non-toxic to 
C3A cells. While higher concentrations of NPs could have been tested to identify 
indicators of toxicity (e.g. EC20), a maximal concentration of 150 µg/mL was chosen 
based on the administered dose of a commercially available nanomedicine, Genexol, as a 
reference point for calculating a top concentration for assay use and limited by NP 
concentration (Section 2.2.4). As seen for the polymer-based NPs tested in Chapter 2, and 
in line with previous studies from the wider scientific community, the results of this study 
indicate relatively low cytotoxicity conveyed by polymeric NPs (Yu et al. 2014; Chen et 
al. 2016).  
 
However, the 55K NPs did appear to significantly decrease C3A cell viability when 
compared with untreated cells. More specifically, cell viability was reduced to 67% at the 
highest concentration tested (150 µg/ml). These results could suggest that increasing 
PLGA chain length enhances PNP toxicity. Another potential cause of increased 55K NP 
toxicity could be PLGA degradation products that can lead to the formation of acids and 
a change in pH, potentially negatively affecting cell viability. Interestingly, when PLGA 
is broken down, the by-products have previously induced cytotoxicity in vitro (Singh & 
Ramarao 2013). PLGA microspheres (50–100 µm) have previously induced a cytotoxic 





2007). Therefore, the higher PLGA content in the 55K NPs may be responsible for the 
higher toxicity, as considerably more by-product could be produced compared with the 
4K and 15K NPs.  
 
The results could also suggest that increasing PEG chain length enhances PNP 
cytotoxicity. The 55K NPs (PEG5K-PLGA55K), while having the longest PLGA 
component to the polymer chain, also had the longest PEG component compared with the 
4K and 15K NPs (PEG2K-PLGA4K, PEG2K-PLGA15K). These findings could be used 
when designing PEG-PLGA polymeric nanoparticles for nanomedicine to optimise their 
safety profile. 
 
3.4.4 Cytokine production related to 4K, 15K and 55K NPs 
 
PNPs can stimulate inflammatory responses in vivo and in vitro (e.g. Beyerle et al. 2009; 
Silva et al. 2016). To investigate the cytokine response to the 5K, 15K and 55K NPs after 
exposure for 24 hours, the production of TNF-α, IL-6, IL-8, IL-1β and IL-ra by C3A cells 
was measured.  
 
All NPs appeared to decrease IL-8 production by C3A cells. Nonetheless, while 
statistically significant, the decrease in cytokine production was very low (<35 pg/mL), 
indicating that it may not be biologically relevant. There is limited research into IL-8 
production in relation to PNP exposure, however existing research suggests that cytokine 
production is influenced by PNP size, surface charge and cell line. When respiratory 
epithelial cells (A549) were exposed to cationic polystyrene NPs (57 nm), a slight 
reduction in IL-8 production was observed (Thach & Finkelstein 2013). However, anionic 
polystyrene NPs (20 nm) induced a 17.2 fold up-regulation of the expression of the IL-8 
gene in the human endothelial cell line (EA.hy926) treated, while 200 nm anionic 
polystyrene NPs did not affect expression of this gene (Fröhlich et al. 2014).  
 
All NPs appeared to increase the production of anti-inflammatory cytokine IL-1ra. 
However only the 4K NPs at 125 µg/mL induced a significant increase. This suggests that 






Although IL-1ra loaded within PNPs has been used to treat diseases such as liver failure 
(Xiao et al. 2013), there has been limited investigation of PNP-induced IL-1ra production 
in vitro and in vivo. In a human study, patients with the degenerative lumbar disease were 
orally administered Pluronic PNPs or alginate oligosaccharide NPs (<200 nm) for one 
month. After this time, according to patient blood samples, IL-1ra production appeared 
to be unaffected by Pluronic PNPs. However, a significant increase in IL-1ra production 
was seen for humans exposed to alginate oligosaccharide NPs (Qu et al. 2017). 
Additionally, an in vitro study demonstrated that silica oxide NPs (<100 nm) decreased 
IL-1ra production in human peripheral blood mononuclear cells (PBMC), while titanium 
dioxide NPs (<100 nm) were seen to increase IL-1ra production in PBMCs (Mendoza et 
al. 2014; Høl et al. 2018).  
 
NPs can interfere with the detection of cytokines, due to protein adsorption on to the NP 
surface, which decreases the protein’s detectability. For example, IL-8 has been observed 
to adsorb on to the surface of UFCB NPs, making the protein undetectable (Brown et al. 
2010). Therefore, it is prudent to assess whether polymeric NPs interfere with the assays 
used to quantify cytokine production. When NP interference was investigated, all NPs 
caused a significant decrease in IL-1ra detection. The 55K NPs decreased TNF-α and IL-
6 detection, meaning that any increase in cytokine production mediated by NPs may be 
under-represented.  
 
3.4.5 ROS production related to 4K, 15K and 55K NPs  
 
For NPs such as TiO2 and ZnO, toxicity to hepatocytes in vitro has been linked to their 
ability to stimulate oxidative stress and thus has been commonly investigated in vitro (e.g. 
Kermanizadeh et al. 2012). However, cellular ROS production stimulated by PNPs has 
not been widely investigated. In this study, the potential for PNPs to generate ROS was 
investigated with the commonly used DCFH-DA assay. All three NPs stimulated a 
significant ROS response by hepatocytes, with a ~ five-fold increase in ROS production 
compared with the control.  
 
Interestingly, a previous study indicated adequate uptake and retention of PLGA-PEI 





similar composition to the 4K, 15K and 55K NPs are capable of inducing ROS production 
without high levels of cytotoxicity.  
 
Other studies using hepatic cells, as a spheroid culture, indicated that PAMAM dendrimer 
NPs could stimulate the production of ROS. Interestingly, this response was not seen to 
change with increasing NP concentration (Chen et al. 2016). As ROS production was the 
same at all concentrations for 4K, 15K and 55K NPs, this suggests that low concentrations 
of PNPs are capable of stimulating ROS production. These results highlight the need for 
safety profiling of PNPs using more than cytotoxicity testing alone to indicate toxicity. 
Induction of ROS production could lead to undesirable downstream effects, which could 
be a significant hurdle for nanomedicine development if the benefits do not outweigh the 
gains. 
 
There did not appear to be a difference between the levels of ROS produced by the 4K 
and 15K NPs, although there was a significant increase in ROS production for cells 
treated with 55K NPs, albeit a small increase when compared with the 4K and 15K NPs. 
This could suggest that ROS generation depended on the polymer chain length of the 55K 
NPs. The 55K NPs have a significantly larger hydrodynamic diameter compared with 
both the 4K and 15K NPs. However as there was little difference between the ROS 
produced by these NPs suggesting that this ROS assay may not be sensitive enough for 
these PNPs. Alternative methods for assessing the involvement of oxidative stress in the 
toxicity of  these PNPs could be used to understand further their impact on the C3A cells, 
such as measuring depletion of antioxidants (e.g. GSH), evaluating antioxidant activity 
(e.g. catalase, superoxide dismutase (SOD)) or identifying of markers of oxidative 
damage (e.g. marker of lipid peroxidation, Malondialdehyde (MDA)) (Gaiser et al. 2013; 
Johnston et al. 2018). 
 
3.4.6 Uptake of the 4K, 15K and 55K NPs 
 
The internalisation of these NPs was quantified using a semi-high throughput plate-based 
method that allows for assessment of the uptake of a panel of NPs, at multiple 





the timepoints and concentrations tested, except for the 15K NPs at 125 µg/mL after 
exposure for 24 hours.  
 
Previous studies have suggested that with increasing PEG chain length, there is a 
proportional decrease in NP opsonisation and NP-cell interactions (Alexis et al. 2008). 
This could allow for longer circulation time in vivo. Indeed, in the past, it has been noted 
that when administered via intravenous injection, PLGA-PEG NPs of 140 nm with a 5K 
PEG component were taken up by the liver half as much as PLGA-PEG NPs of the same 
size with a 2.5K PEG component (Bertrand et al. 2017). The 55K NPs have a 5K PEG 
component to their polymer chain compared with the 4K and 15K NPs, which have a 2K 
PEG component. Therefore, this could explain the particularly low level of uptake seen 
for the 55K NPs (Bertrand et al. 2017). Other studies have shown that NPs with shorter 
PLGA-containing polymer chains take less time to degrade than longer polymer chains. 
Therefore, it is possible that the 4K NPs degraded rapidly and therefore little uptake is 
observed (Sharma et al. 2015).  
 
To further investigate NP uptake, confocal images were taken. Uptake was only evaluated 
at 24 hours post exposure, since this was the only timepoint at which internalisation of 
any NPs was observed. There appears to be little to no uptake of all of the NPs by C3A 
cells. However, some compartmentalisation of the 15K NPs was observed in the 
cytoplasm surrounding the nucleus. Quenching of conjugated polymers once they are 
suspended in cell culture medium has been previously observed, and can occur due to 
protein binding directly to the conjugated polymer changing the polymer structure 
(Herland & Inganäs 2007).  
 
For example, in studies using PPE-loaded polymer NPs, it has been demonstrated that 
fluorescence was substantially quenched in the presence of 10% serum (Khanbeigi et al. 
2015). This could suggest that the 10% FBS present in the C3A cell medium may quench 
PPE to below detectable levels. While it would be expected that the PEG of these NPs 
would lower protein-NP interactions, similar decreases in fluorescence have been seen 






While PPE is located within the ‘core’ of the PLGA-PEG NPs, it may be possible for 
serum proteins to interact, depending on the density of the PEG coating and the 
conformation of PPE within the polymer chains which could result in areas of PPE 
exposure (Fredenberg et al. 2011; Xu et al. 2015; Bertrand et al. 2017). Therefore, it 
would be relevant to investigate the effects of serum on the NP fluorescence in the future, 
since if this quenching persisted when NPs were administered in vivo, the NPs would 
have limited use in bioimaging. To further understand the uptake of these NPs with 
relation to coating, an alternative conjugated polymer such as the bright near infrared CN-
PPV (poly(2,5-di(hexyloxy) cyanoterephthalylidene) could be used since this is less 
susceptible to quenching (Kemal et al. 2017).  
 
3.4.7  Genotoxicity of 4K, 15K and 55K NPs 
 
A semi-high throughput Comet assay was used to assess NP genotoxicity.. Due to the 
limited volume and concentration of these NPs the number of concentrations analysed 
was limited to two and not the recommended minimum of three, therefore although these 
data is a useful indicator of NP genotoxicity results should be considered preliminary 
(OECD 2015). There appeared to be no significant DNA damage for C3A cells exposed 
to the 4K and 55K NPs. However, a low level of DNA damage was observed in cells 
exposed to the 15K NPs.  
 
These results could point towards the 15K NPs having the potential to induce DNA 
damage in hepatic cells. Interestingly, the 15K NPs had high levels of ROS and were the 
only NPs observed to be taken up by C3A cells. This could indicate that these NPs may 
be internalised by the cells to a greater extent than the 4K and 55K NPs and therefore had 
more opportunity to interact either indirectly or directly with the DNA, resulting in higher 
levels of DNA damage. This could be due to the difference in polymer chain length 
between these PNPs, altering the 15K NPs corona and how it interacts with the cells 
(Alexis et al. 2008). Additionally, when compared to 4K NPs ,15K NPs have an increase 
in overall polymer chain length, this increase has previously been noted to prolong 
degradation time, therefore it may be possible that 15K NPs have more opportunities to 
interact with the cells (Alexis et al. 2008; Dinarvand et al. 2011; Conde et al. 2014; 





an increase in PEG chain length as well as overall polymer chain length. This increase 
has already been seen to increase the diameter of 55K NPs and it may also have increased 
the NP stability and reduce cellular uptake, therefore, reduce the potential for 55K NPs 
to induced genotoxicity (Gref et al. 2000; Ma et al. 2012). 
 
Using the Comet assay, similar levels of DNA damage were seen when mononucleated 
TK6 (human B-lymphoblastoid) cells and human PBMCs were exposed to 75 µg/cm2 of 
PLGA-PEO, a polymer extremely similar to in composition to PLGA-PEG (Kazimirova 
et al. 2012; Zhang et al. 2014; Tulinska et al. 2015).  
It is recommended that more than one assay be used to assess genotoxicity (Doak & 
Dusinska 2017). In the future, it would, therefore, be useful to investigate the genotoxic 
potential of these NPs using the micronucleus assay or perhaps a sister chromatid 
exchange assay. High genotoxicity in any nanomedicine would be prohibitive for use in 
the clinic since NPs with genotoxic potential may lead to the formation of cancers. 
 
3.4.8 Urea and albumin production related to 4K, 15K and 55K NPs 
 
Quantification of urea and albumin together can be used as a specific indicator of liver 
function (Watts et al. 1995). Following exposure of C3A cells to 4K, 15K and 55K NPs, 
it became evident that there was a decrease in the level of urea, but not albumin 
production. In the past, PLGA-PEG NPs have been seen to interfere in fluorescent assays 
via quenching of the detection dye’s emission (Aranda et al. 2013). The 4K and 15K NPs 
were observed to interfere with the urea assay, highlighting the need to assess NP assay 
interference in parallel with the fluorescent-based assays.  
 
However, at the highest concentration, the 4K NPs decreased urea production to below 
detectable levels (unrelated to NP interference), and 55K NPs were seen to significantly 
reduce urea production in a concentration-dependent manner, indicating that these NPs 
can affect hepatic function. The concentrations of 4K NPs used were previously shown 
not to affect viability, and results here indicate that these NPs are capable of significantly 
impairing hepatic functions. These results highlight that the use of viability assays alone 





that the 55K NPs have a stronger impact on hepatic function than the 4K NPs, which 
could be linked to the longer polymer chain present in these NPs.  
 
3.5 Conclusion  
 
This study used a range of approaches to investigate the toxicity of polymeric NPs to 
hepatocytes, including cytotoxicity, cytokine production, ROS production, genotoxicity, 
cellular uptake and urea and albumin production (as indicators of hepatocyte function). 
A hepatocyte cell line was investigated in this study; however, a more extensive range of 
cells should be considered in future studies. In particular, macrophages within the liver, 
Kupffer cells, are known to accumulate NPs and can be a sensitive model for assessing 
NP toxicity in vitro (Owens & Peppas 2006; Singh & Ramarao 2013; Brown et al. 2018). 
Therefore, to assess likely immune response in the liver, it would be important in the 
future to investigate the effects of these NPs on Kupffer cells. Furthermore, it is 
recommended that the response of primary cells is assessed in future studies to identify if 
cell lines provide a good prediction of PNP toxicity. 
 
Previous studies have shown polymer NPs to have generally low toxicity both in vitro 
and in vivo. However, due to a focus on PNP efficiency and not PNP safety, other studies 
have not investigated the array of endpoints used in this investigation, which suggests 
that future studies should perform a more comprehensive in vitro assessment of PNP 
toxicity. A perceived lack of information on the translatability of in vitro to in vivo results 
for PNP safety profiling, together with clinical, regulatory guidelines requiring in vivo 
testing has resulted in PNP testing being performed primarily using in vivo models. The 
future use of in vitro assays to determine the safety profile of PNPs is essential, since 
commercially this will yield financial and time benefits. Furthermore, in vitro testing has 
the potential to reduce the number of animals needed for testing to align nanotoxicology 
testing with the 3Rs principles (Burden et al. 2017).  
 
The varying length of the polymer chains used to generate these NPs may contribute to 
the toxic effects observed in this study. The 4K NPs cause lower levels of toxicity, while 
the 55K NPs significantly reduced cell viability. However, 55K NPs did significantly 





NPs. An understanding of which properties confer toxicity can feed into the design of 
future generations of NPs, and also support legislation development. Because these NPs 
are intended for medical applications, it is important to also assess their efficacy in order 
to conduct a risk-benefit analysis.  
 
In this study, these NPs were loaded with fluorescent polymer PPE for bioimaging. 
Additional therapeutics could also be loaded for use in clinical applications. The nature 
of the cargo may influence NPs toxicity, and further assessment may be required. The 
usefulness of these NPs in a clinical setting may be promising, with relatively low levels 
of cytotoxicity and low levels of uptake by hepatocytes, meaning that if they were 
modified to target specific cells, there might be little accumulation in the liver, prolonging 
circulation time and increasing chances of NP-target cell interactions.  
However, some of these results highlighted that there is still a need for a greater 
understanding of the toxicity of these PNPs with decreases in urea production suggesting 
there may be an adverse effect on hepatocyte cell health, although this would need to be 
investigated further in vivo. It is also evident that safety testing of PNPs should not just 
rely on cytotoxicity testing but should be performed using a broader panel of indicators 
of toxicity. This generates a greater understanding of the mechanism of action for PNP 
toxicity to inform future testing strategies to assess PNP toxicity and could be used in the 
future design of PNPs for clinical use. Toxicity testing in this study did point to longer 
polymer chain lengths being more toxic, the findings from the additional endpoints 
complemented these results, increasing confidence in these findings.  
 
The observed results from this study could aid in the development of an in vitro testing 
strategy as highlighted in Figure 1.3. Identifying endpoints that will provide the most 
impactful information could both reduce the amount and time needed for safety testing of 
these polymer nanomedicines, meaning that they are available as safe and effective 
medical tools sooner. 
 
With regards the developing a testing strategy the reduced number of cytotoxic assays 





confocal imaging, while using the semi high through put fluorescent plate method 
allowed for similar understanding of the impact of PNP uptake on safety. The most 
informative cytokine that provided a clear indication of PNP safety was IL-8 suggesting 
that initial cytokine screening with IL-8 could be performed before progressing to 
investigation of additional cytokines. Again, genotoxicity provided the most insight on 
potential safety concerns regarding the safety of these PNPs, although due to limited 
supply of PNPs it was not possible to perform additional concentrations or timepoints, 
these would still provide valuable safety information in a testing strategy. Unfortunate 
ROS measurement using DCFH-DA was not able to provide sufficient information 
regarding the oxidative impact of these PNPs, therefore additional endpoints may be 
required such as GSH. Although, albumin did not appear to provide information regarding 
the impact of these PNPs on liver cell health, measurement of urea did, however for this 
endpoint to be utilised with in a testing strategy a greater understanding of the impact of 









Chapter 4. In vitro assessment of the influence of a redox-reactive coating on 






4.1 Introduction  
 
4.1.1 Designing safe novel redox reactive PNPs for nanomedicine 
 
The low solubility, instability and non-targeted nature of many therapies such as cancer-
related drugs like Paclitaxel, has been a hurdle to their clinical application (Wiernik et al. 
1986; Guo et al. 2011; Li et al. 2014). However, the opportunity to design PNPs with 
multiple functionalities can help overcome these challenges. One approach is to generate 
PNPs with elements that can allow controllable drug release in response to one or several 
intracellular or extracellular stimuli such as temperature, pH, light or redox potential (Han 
et al. 2015; Constantin et al. 2017; Yeh et al. 2018).  
 
Previous research has shown that GSH levels within the cytosol and intracellular 
compartments such as the mitochondria and nucleus of cells can be higher in cancer cells 
than in normal cells (Griffith & Meister 1985; Lee et al. 1989; Gilbert 1990; Yao et al. 
1995). This can be exploited in the clinic as NPs can be designed to release their cargo 
when there is a change in redox potential once inside the cell (Russo et al. 1986; Navath 
et al. 2009). Redox reactive NPs can respond to a change in redox potential and could be 
a promising new delivery agent for cancer therapies as they could provide effective 
targeting to cancer cells.  
 
To date, redox reactive NPs have been assessed for their ability to deliver cancer drugs 
and genes using predominantly polymer and liposomal-based NPs (Kirpotin et al. 1996; 
Zalipsky et al. 1999; Petros et al. 2008; Takae et al. 2008). Redox reactive elements in 
the NPs, such as disulphide linkers, can be cleaved by GSH and allows for the targeted 
and controlled release of the cargo within cells (Holmgren 1979; Wang et al. 2011). The 
inclusion of disulphide linkers in NP delivery devices has been utilised in the 
development of FDA approved drugs such as Gemtuzumab ozogamicin, used in the 
treatment of myeloid lymphoma (Niculescu-Duvaz 2000; Hamann et al. 2002).  
 
In this study, PLGA-PEG NPs were generated with (RR-NPs) and without (nRR-NP) a 
novel redox-responsive disulphide linker at an ethanoate ester between the PLGA core 





intracellular or extracellular thiols, such as GSH, is likely to stimulate the release of the 
PEG shell from the PLGA core, potentially resulting in a reduction in size or an increase 
in PNP agglomeration due to a decrease in NP stable and steric repulsion that were 
derived from the PEG coating (Lee et al. 1989; Yao et al. 1995; Gref et al. 2000; Tobı́o 
et al. 2000; Sun & Davis 2010). Additionally, cleavage of the disulphide linker at the 
ethanoate ester in PLGA generates new nucleophilic end groups that can increase the rate 
of PLGA degradation via hydrolysis, increasing the rate of RR-NP degradation, thereby 
promoting cargo release (Avgoustakis et al. 2002; Fomby & Cherlin 2011; Souza et al. 
2015).  
 
These relatively new PNPs with coatings/shells (e.g. PEG) that can be removed 
selectivley have great promise as targeted delivery agent. Using these complex polymer 
nanomedicines, it was possible to compare the toxicity of PNPs with a cleavable coated 
and PNPs without this element, allowing for the assessment the influence of cleavable 
coated polymer based nanomedicines on overall PNP toxicity. 
 
The PNPs used in this study were loaded with the green fluorescent hydrophobic dye DiO 
(3,3'-dioctadecyloxacarbocyanine perchlorate) to mimic drug loading and allow for 
visualisation of NP uptake by cells. DiO together with DiL (1,1′- dioctadecyl-3,3,3′,3′-
tetramethyl indocarbocyanine perchlorate) are widely used lipophilic tracers and share a 
similar structure (Muñoz-Barroso et al. 1998). DiL has been shown to have a low impact 
on viability, suggesting DiO would have similar low toxicity (Haldar & Uyetake 1992). 
 
4.1.2 The effect of redox reactive elements on PNP safety 
 
Redox-responsive PNPs have been observed to enhance cargo release in cancer cells in 
previous studies. For example, using respiratory epithelial cells (A549), disulphide linker 
containing poly(ε-caprolactone)-SS-poly(ethyl ethylene phosphate) NPs loaded with the 
chemotherapeutic doxorubicin, have been shown to be cleaved at the disulphide linker 
following internalisation, leading to NP disassembly and cargo release intracellularly 
(Tang et al. 2009). Additionally, polylysine PNPs containing a disulphide linker, used for 
gene delivery has demonstrated increased intracellular release and internalisation of DNA 





In Human hepatocyte cells (QGY-7703), disulphide linker cleavage followed by NP 
dissociation was only seen intracellularly within endosomes/lysosomes for multi-layered 
redox active nanocomplexes used to deliver doxorubicin and siRNA, with no NP 











Figure 4.1 Scheme of RR-NPs and nRR-NPs. 
Representation of the RR and nRR NPs used in this study. PNPs are made of the polymer 






Redox-responsive NPs can be targeted and increase drug delivery to cancer cells ( Lee et 
al. 1989; Yao et al. 1995). For example, previous studies have used redox-responsive poly 
(oligo-L-arginine) PNPs for gene delivery to reduce atherosclerotic inflammation, in 
which endothelium α-2 adrenoceptors promoted targeted delivery following intravenous 
administration to mice (Ain et al. 2017). Other studies have used disulphide linker specific 
degradation (dithiothreitol) in biodegradable redox-responsive methoxy PEG-poly (lactic 
acid) PNPs to increase curcumin dye release by 3 times compared to non-redox-
responsive NPs (Cao et al. 2015). This could indicate that these redox-responsive NPs 
have the potential to increase drug delivery. Interestingly, higher cellular uptake was 
observed for redox-responsive methoxy PEG-poly (lactic acid) PNPs in vitro following 
exposure of cervical cells (HeLa) for 24 hours (Cao et al. 2015).  
 
4.1.3 Study aim and hypothesis 
 
This study aimed to investigate the effects of the introduction of a redox-responsive 
disulphide linker on PNP toxicity via assessment of cytotoxicity, uptake, cytokine 
production, ROS production, genotoxicity, urea and albumin production as well as 
increases in intracellular calcium concentration.  
 
It was hypothesised that: 
 
1. RR-NPs and nRR-NPs, at pharmacologically relevant concentrations would 
stimulate minimal cytotoxicity in C3A hepatocyte cells.  
2. RR-NPs and nRR-NPs would be internalised by C3A hepatocyte cells  
a. With less uptake observed for nRR-NPs. 
3. RR-NPs and nRR-NPs would stimulate ROS production and activate a pro-
inflammatory response in C3A hepatocyte cells. 
4. RR-NPs and nRR-NPs at pharmacologically relevant concentrations would 
stimulate minimal genotoxicity in C3A hepatocyte cells.  
5. RR-NPs and nRR-NPs would be capable of reducing albumin and urea production 
in C3A hepatocyte cells. 





6. RR-NPs and nRR-NPs would be capable of increase in intracellular calcium 
concentration in C3A hepatocyte cells. 
a. With less of an impact observed for nRR-NPs. 
 
For all responses, it is hypothesised that RR-NPs would be less toxic than nRR-NPs due 
to the presence of the disulphide linker that would allow RR-NPs to degrade more readily 
once internalised within the cell, decreasing the potential NP-cell interactions and 
therefore potentially decreasing NP-specific toxicity to the cells. These NPS produced via 
multiple batches had short stability, low volume and low NP concentration, this resulted 
in limited concentrations used for some particularly endpoints that require higher volumes 





4.2 Materials and methods 
 
4.2.1 Nanoparticle synthesis 
 
A non-redox active PLGA-PEG block copolymer (Figure 4.1 A) and a redox reactive 
PLGA-ss-PEG block copolymer were synthesised (Figure 4.1 B) by collaborators (Prof 
Cameron Alexander and Dr Claudia Conte) at the University of Nottingham.  
 
NPs were loaded with DiO, a green fluorescent dye, using a double emulsion solvent 
evaporation method. Briefly, copolymer PLGA-PEG (10 mg) and DiO (0.1 mg) were 
dissolved in methylene chloride (1 mL), then probe sonicated (Sonicator 3000, Misonix) 
for 1 minute in a glass vial. Water (10 mL) containing 0.5% polyvinyl alcohol was then 
added and the suspension was probe sonicated for 3 minutes. To aid in solvent 
evaporation, the suspension was stirred without a lid for four hours at RT. The 
suspensions were then filtered through a membrane syringe filter (pore size: 450 nm) 
(Millipore) and centrifuged (17,000×g, 30 minutes, 4°C) to separate the free dye and 
surfactant from the suspension. To remove polyvinyl alcohol from the NP suspension, 
NPs were washed twice with sterile water. Finally, NPs were resuspended in sterile water 
(1 mL) and stored at 4°C and used within one month of preparation. Loading and 
entrapment efficiency was similar for both redox reactive and non-redox reactive NPs 
(Conte et al. 2018). For use in experiments, NPs were freshly diluted in cell culture 













Figure 4.2 PLGA-PEG and PLGA-ss-PEG PNP polymer synthesis. 
Chemical structure and polymer synthesis scheme of the non- redox active block 
copolymer, PLGA-PEG (A) and the redox active block copolymer, PLGA-ss-PEG (B) 







4.2.2 Nanoparticle characterisation  
 
Nanoparticles were characterised by DLS as described in section 2.2.2. TEM was 
performed by Dr Conte. 
 
4.2.3 Cell culture 
 
Human C3A hepatocellular carcinoma cell maintenance and seeding as described in 
section 2.2.3.  
 
4.2.4 Cytotoxicity Assays: AB and NR 
 
A 96-well plate fluorescent-based assay which simultaneously assessed the viability of 
C3A cells following exposure to NPs using AB and NR uptake assays was applied. The 
method was performed as described in section 2.2.5. NP interference with the AB assay 
was performed as in Section 2.2.5 with NPs prepared at concentrations of (5, 10, 25, 50, 
100, 250 μg/mL). Inference results were only reported when positive. 
 
4.2.5 Uptake Assay: Plate. 
 
A 96 well-plate fluorescence-based uptake assay was used to quantify the uptake of 
fluorescently loaded NPs by C3A cells as described in section 2.2.7. Fluorescence was 
measured at Ex/Em 488/526 nm. NPs were prepared in cell lysate to produce a standard 
curve, ranging from 5-250 µg/mL 
 
4.2.6 Uptake Assay: Confocal Microscopy. 
 
Confocal microscopy was used to visualise NP uptake by C3A cells. A single time point 
(1440 minutes) was selected, based on the findings from the plate-based method (section 
4.2.5). Cells were seeded onto 12 mm uncoated glass coverslips in 24-well plates at a 
concentration of 6.58 x104 cells/cm2 and incubated at 37○C and 5% CO2. Following 24 
hours growth cells were exposed to a sub-lethal concentration of nanoparticles (125 





minutes at 37○C and 5% CO2.  
 
Cells were prepared for imaging as described in section 2.2.6. with DAPI staining 
omitted. Slides were stored at 4˚C until imaged using A Leica SP5 SMD gated-STED 
confocal laser scanning microscope and Leica Application Suite program. 
 
4.2.7 Genotoxicity assessment: Comet assay 
  
A Trevigen 24-well Comet Chip assay kit was used to assess oxidative DNA damage as 
described in section 3.2.9. NP concentrations of 125 and 250 µg/mL were used, as 
determined by the cytotoxicity assays. 
 
4.2.8 Genotoxicity assessment: Micronucleus assay 
 
The micronuclei assay is one of the most common genotoxicity assays, micronuclei 
formed by chromosomal fragmentation or chromosomal loss during nuclear division are 
used as markers for chromosomal damage (Heddle 1973). The cytokinesis-block 
micronucleus assay uses actin inhibitor (cytochalasin-B) during mitosis to produce a 
population of once-divided nuclei (binucleated cells), this increases accuracy as it 
counteracts changes in the rate of cell division that may occur due to genotoxic compound 
exposure (Umegaki & Fenech 2000; Fenech 2000). This assay has been utilised in 
previous studies when assessing the genotoxicity of PNPs (Kazimirova et al. 2012). 
 
A 24-well based Micronucleus assay was used to assess DNA damage. C3A cells were 
seeded at a concentration of 1.56 x105 cells/cm2 into 24-well plates and incubated at 37○C 
and 5% CO2. Following 24 hours growth C3A cells were washed twice with PBS (Sigma-
Aldrich) then exposed to nanoparticles (125 µg/mL) or Complete Medium (control) in 
duplicate for 24h at 37○C and 5% CO2. Due to the limited volume and concentration of 
these NPs, analyse of one concentration was priorities, not the recommended three 
concentrations (OECD 2015). Although these data can be a useful indicator of NP 
genotoxicity, results should be considered preliminary. 
 





(6 µg/mL, in Complete Medium) (Sigma-Aldrich) for 36 hours (Kirsch-Volders & 
Fenech 2001). Subsequently, the supernatant was discarded, the cells were washed twice 
with PBS and trypsinised (section 4.2.2). Following this, cells were centrifuged at 2000 
g for 1 minute and washed another 2 times with PBS and resuspended in ice-cold PBS 
(0.5 mL). Cells were then added (100 µL) to a Cytospin (Shandon) and spun at 1500 g 
for 5 minutes. Slides were air-dried and fixed for 10 minutes in ice-cold 90% methanol.  
 
Cells were stained with 20% Giemsa stain (VWR) for 6 minutes then washed twice with 
PBS. Following air drying for 4-5 hours, slides were dipped in Xylene (Sigma-Aldrich) 
for 10 seconds, allowed to dry and SlowFade Diamond Antifade mounting medium 
containing DAPI (ThermoFisher) was used to mount the coverslips onto glass slides. 
Binucleated cells were confirmed in the bright field, and the DAPI filter used to image 
micronuclei (Zeiss AX10 with Allied Vision Technologies Stingray camera). A total of 
1000 binucleated cells were analysed, for each treatment. Data are expressed % 
micronucleus mean ± SEM. 
 
4.2.9 Measurement of urea production 
 
The QuantiChrom Urea assay kit (BioAssay Systems) was used as described in section 
3.2.10 to establish urea production by C3A cells at sub-lethal NP concentrations of 62.5, 
125 and 250 µg/mL. 
 
To determine the potential for NPs interference with this assays the NPs at 250 µg/mL 
were spiked with the SCM for the urea standards. Results were reported only when 
inference was observed. 
 
4.2.10 Measurement of albumin production 
 
Bromocresol Green (Sigma Aldrich) was used as described in section 3.2.11 to establish 
albumin production in C3A cells at sub-lethal NP concentrations 62.5, 125 and 250 
µg/mL as well as Complete Medium (negative control). 
 





were spiked with the SCM for the albumin standards. Results were reported only when 
inference was observed. 
 
4.2.11 Measurement of intracellular ROS production 
 
ROS production by C3A cells was determined as described in section 3.2.6 at sub-lethal 
NP concentrations of 62.5, 125 and 250 µg/mL as well as Complete Medium (negative 
control).  
 
4.2.12 Measurement of cytokine production 
 
Secretion of IL-8, TNF-α, IL-6, IL-1ra and IL-1β from C3A cells exposed to NPs was 
measured using a multiplex sandwich ELISA as in section 3.2.5, at sub-lethal NP 
concentrations (62.5, 125 and 250 µg/mL) as well as Complete Medium (negative 
control). Additionally, interference of NPs with this assay was established by adding the 
SCM concentration to 250 µg/mL NPs prepared in the same medium as the standard curve 
and quantifying the concentration of cytokine via an ELISA. 
 
4.2.13 Measurement of intracellular calcium 
 
A 96 well-plate fluorescence-based assay was used to determine changes in intracellular 
calcium concentration following exposure of C3A cells to NPs. Fura-2-AM is a widely 
used radiometric dye to measure intracellular calcium. Once this dye penetrates the cell, 
esterases cleave the dye so it can no longer leave the cell. When Fura-2-AM is not bound 
to calcium, the Ex/Em is 380/510 nm. When Fura-2-AM is bound to calcium, the Ex/Em 
is 340/510 nm (Grynkiewicz et al. 1985).  
 
C3A cells were seeded at a concentration of 1.56 x105 cells/cm2 into 96-well well black 
plate with an optic bottom (Nunc) and incubated at 37○C and 5% CO2. Following 24 hours 
growth, cells were washed twice with PBS.  
 
The Fura-2 working solution was prepared; 5 µL of Fura-2-AM (1 mM in dimethyl 





reduce dye leakage from the cells (Sigma Aldrich); 1 µL 20% Pluronic F127 (in DMSO) 
(Sigma Aldrich) to help disperse Fura-2-AM, and 5 mL Serum free MEM medium 
(Gibco, Invitrogen) containing 10 mM HEPES (Sigma Aldrich). The dye-free working 
solution was prepared as above without Fura-2-AM to allow for observation of NP 
interference. When interference was observed results were presented, if no interference 
present results will not be presented. 
 
Cells were loaded with either the Fura-2 working solution (100 µL) or dye free working 
solution for 1 hour at 37○C and 5% CO2. The cells were then washed once with HEPES 
containing FBS free Complete Medium. Basal fluorescence was measured with a 
SpectraMax M5 Microplate Reader at Ex/Em 340/510 nm and 380/510 nm, before adding 
100 µL of NPs at a sub-lethal concentration (125 µg/mL prepared in Complete Medium), 
UFCB-Printex-90, 5 µg/mL prepared in Complete Medium or Complete Medium 
(Control) in triplicate. Fluorescence intensity was measured every 120 seconds for 36 
minutes. Data are expressed as mean Ratio 340/380 ± SEM. 
 
4.2.14 Statistical analysis 
 
Experimental data were analysed using GraphPad Prism software. One-way ANOVA 
using Tukey post-test or two-way ANOVA followed by the Bonferroni post-test were 
used to test for statistical significance. Significance was set at p < 0.05. All experiments 







4.3.1 RR-NPs and nRR-NPs: Physiochemical characterisation 
 
Immediately following preparation in PFR Complete Medium, and 24 hours post 
incubation at 37○C, 5% CO2 both nRR-NPs and RR-NPs were of comparable size, with a 
hydrodynamic diameter of approx. ~60 nm (Figure 4.3A). The PDI values were relatively 
high (0.6-0.7) for both NP types at both time points (Figure 4.3B). The zeta potential of 
these NPs were slightly negative, ranging from -5 to -8 mV at both time points (Figure 
4.3C). The zeta potential of RR-NPs after 24 hours is significantly more negative 
(p<0.05), indicates a change in surface charge over time. 
 
TEM images of the nRR-NPs and RR-NPs (prepared in PBS) are presented in Figure 4.4 
and were provided by Dr Conte. TEM images of RR-NPs appear to indicate 2 populations 
of NPs; one of ~ 50 nm in size with a low density indicated by lighter colour, and another 
of NPs that were ~ 100 nm in diameter, with higher density indicated by a darker colour. 
The nRR-NPs appear to be consistent in density, although there is some variation in size 








Figure 4.3 Characterisation of RR-NPs and nRR-NPs properties using DLS. 
NPs (RR-NPs and nRR-NPs) were suspended in PFR Complete Medium (125 µg/mL). 
Hydrodynamic diameter (A), PDI (B) and zeta potential (C) assessed at 0 hours (T0) 
and 24 hours (T24) post incubation at 37○C, 5% CO2. Data are expressed as mean ± 













Figure 4.4 TEM characterisation of RR-NPs and nRR-NPs. 
Images of RR-NPs (A) and nRR-NPs (B), suspended in PBS at 500 µg/mL. 









4.3.2 RR-NPs and nRR-NPs: Cytotoxicity  
 
To investigate the impact of RR-NPs and nRR-NPs on C3A cell viability, two fluorescent 
based assays were performed; the AB and NR assays (Figure 4.4). The CFDA-AM assay 
was found to be incompatible with these NPs. AB assay showed no significant reduction 
in viability for cells exposed to both RR-NPs and nRR-NPs when compared with the 
control, at all concentrations tested (Figure 4.4A). The NR assay showed no significant 
effects for either nRR-NPs or RR-NPs on cell viability (Figure 4.4B). An EC20, the 
concentration where NP exposure leads to 20% cell death, could not be calculated for 







Figure 4.5 Cytotoxicity of RR-NPs and nRR-NPs to C3A cells. 
Cells were exposed to RR-NPs (red) or nRR-NPs (black) at 5-250 µg/mL for 24 hours. 
Viability was measured via the AB (A) and NR (B) assays. Data are expressed as mean 







4.3.3 RR-NPs and nRR-NPs: Uptake  
 
To quantify the internalisation of the nRR-NPs and RR-NPs by C3A cells, a plate-based 
method was used to quantify uptake over time (10, 60 and 1440 minutes), at a range of 
NP concentrations (5-250 µg/mL). There was a significant concentration and time-
dependent increase (p<0.001) in NP internalisation for both RR and nRR-NPs (Figure 
4.6). The highest level of uptake (~3.5 µg/mL retained) was observed for both NPs at a 
concentration of 250 µg/mL, following exposure for 1440 minutes. The uptake of RR-
NPs was significantly higher (p< 0.001) than that of nRR-NPs. 
 
Based on results from the plate-based method for evaluating uptake and observations 
made for other PNPs (sections 2.4.2 and 3.3.5), NP uptake was imaged using confocal 
microscopy at one-time point (1440 minutes) and a concentration of 125 µg/mL. Both 
NPs were internalised by C3A cells (Figure 4.7). However, uptake appears to be relatively 
low for both NPs, RR-NPs did appear to have marginally higher internalisation (Figure 
4.7A). The NPs within the cells appear to be compartmentalised, potentially within 
organelles such as endosomes, lysosomes or mitochondria. There does not appear to be 
any NPs located on the surface or between the cells. Additionally, there appears to be no 
colocalization of these NPs with the tubulin cytoskeleton. 
 
NP within the interior of the cell were confirmed in the xy-yz micrographs generated from 
z-stacks (Figure 4.8). Although there is no nuclear stain used, the nucleus was located 
using transillumination (denoted as N in Figure 4.7 and 4.8), and it can be observed that 









Figure 4.6 Uptake of RR-NPs and nRR-NPs by C3A cells, over time:  Plate 
method. 
Cells were exposed to RR-NPs (red) or nRR-NPs (black) for 10 (A), 60 (B) or 1440 
(C) minutes, at 5-250 µg/mL. Data are expressed as mean µg/mL retained in cells (from 
appropriate standard curves) (n=3). Significance indicated by ***= p< 0.001 compared 
with control. Significance indicated by $ = p< 0.05 for RR-NPs compared with nRR-
NPs at the same concentration and timepoint. 








Figure 4.7 Uptake of RR-NPs and nRR-NPs by C3A cells. 
Cells were treated with 125 µg/mL of RR-NPs (A), nRR-NPs (B) (green) or Complete 
Medium (C) for 1440 minutes. Representative images (n=3). Tubulin (red) and N 









Figure 4.8 Uptake of RR and nRR-NPs by C3A cells: Z stacks. 
Cells were treated with 125 µg/mL of RR-NPs (A), nRR-NPs (B) (green) or Complete 
Medium (C) for 1440 minutes, and xy and yz micrographs generated from z stacks. 
Representative images (n=3). Tubulin (red) and N indicates the location of the nucleus, 






4.3.4 RR-NPs and nRR-NPs: Genotoxicity  
 
The Comet assay was used to assess whether RR-NPs and nRR-NPs (125 μg/mL and 250 
μg/mL for 24 hours) caused DNA damage in C3A cells. The potential contribution of 
oxidative stress was assessed by conducting the assay in the presence and absence of Fpg. 
The RR-NPs did not induce DNA damage, at either concentration tested, in the presence 
and absence of Fpg (Figure 4.8A). The nRR- NPs induced a significant increase (p< 
0.001) in DNA damage in the presence of Fpg, with 25 and 27% DNA observed in the 
tail at concentrations of 125 and 250 µg/mL respectively, this was significantly higher 
(p< 0.001) than RR-NPs (Figure 4.8B). No DNA damage was observed following 
exposure of cells to nRR-NPs in the absence of Fpg. The positive control H2O2 stimulated 
a significant increase (p< 0.001) in DNA damage (~45-55% in the tail) in the presence 
and absence of Fpg. The Fpg treated samples had significantly higher (p< 0.001) DNA 
damage than H2O2 samples not treated with Fpg. 
 
In this study, the micronucleus assay was also used to assess the genotoxicity of RR-NPs 
and nRR-NPs (125μg/mL for 24 hours) to C3A cells. Binucleated cells were confirmed 
using a light microscope to observe the Giemsa staining and formation of micronuclei, 
nuclear budding and nucleoplasm bridges observed. As seen previously in the Comet 
Assay, the RR-NPs do not appear to induce significant DNA damage (Figure 4.10A). 
However, the nRR-NPs induced a very low but significant increase (p< 0.05) in the % of 
micronuclei observed in binucleated cells (Figure 4.10B and C). There was no significant 
difference in nuclear budding or nucleoplasm bridge formation seen in cells treated with 









Figure 4.9 Genotoxicity of RR and nRR-NPs in C3A cells: Comet assay. 
C3A cells were exposed to RR-NPs (A) or nRR-NPs (B) at 125 and 250 μg/mL for 
1440 minutes, 60 μM H2O2 and Complete Medium ± Fpg. Data are expressed as mean 
%Tail DNA ± SEM (n=3). Significance indicated by *** = p< 0.001 compared with 
control. Significance indicated by $$$ = p< 0.001 for nRR-NPs compared to RR-NPs 









Figure 4.10 Genotoxicity of RR and nRR-NPs in C3A cells: Micronucleus assay. 
Cells were exposed to RR-NPs or nRR-NPs at 125 μg/mL, and Complete Medium 
(control), for 1440 minutes (A). Data are expressed as mean % MN ± SEM (n=3). 
Significance indicated by *= p< 0.05 when compared with untreated control. 
Representative images (n=3) of binucleated cells (B) (C= cytoplasm, N= nucleus), 
micronuclei (highlighted by arrow) (C), blebbing (D) and a nucleoplasm bridge (E). 





4.3.5 RR-NPs and nRR-NPs: Cytokine and ROS production 
 
For both NPs, there was no significant production of IL-8, TNF-α, IL-1β and IL-6 by 
C3A cells. However, there was a significant increase (p<0.01) in the production of the 
anti-inflammatory cytokine IL-1ra (Figure 4.11B) at all concentrations for nRR-NPs (p 
<0.01) and at concentrations of 125 and 250 µg/mL for RR-NPs (p<0.05). Interference of 
RR-NPs and nRR-NPs with detection of cytokines was observed with an underestimation 
of IL-1ra by 15 and 8% respectively (Figure 4.11A).  
 
C3A cells were exposed to RR-NPs and nRR-NPs at concentrations of 62.5, 125 and 250 
µg/mL for 24 hours and intracellular ROS production assessed using the DCFH-DA 
assay. There was a significant increase (p <0.001) in ROS production seen for both RR-
NPs and nRR-NPs at all concentrations, with a ~5-fold increase in fluorescence compared 
to the control (Figure 4.12A and B). The positive control UFCB (10 µg/mL) caused a 







Figure 4.11 Optimisation of cytokine detection and IL-1ra production induced by 
RR-NPs and nRR-NPs in C3A cells. 
The SCM concentration of each cytokine was incubated with RR-NPs or nRR-NPs 
(250 µg/mL), prepared in Complete Medium to observe interference of cytokine 
detection related to NPs (A). Cells were exposed to RR-NPs and nRR-NPs (62.5, 125 
and 250 μg/mL) for 24 hours, IL-1ra(B). Data are expressed as mean (pg/mL) ± SEM 
(n=3). Significance indicated by ***= p< 0.001 when compared to SCM (A). 









Figure 4.12 ROS production by RR-NPs and nRR-NPs in C3A cells: DCFH-DA 
assay. 
Cells were exposed to RR-NPs (A) or nRR-NPs (B) at 62.5, 125 and 250 µg/mL or 
UFCB (10 µg/mL) for 24 hours. Data are expressed as fold increase in fluorescence 
(from the untreated control) ± SEM (n=3). Significance indicated by ***= p< 0.001 







4.3.6 RR-NPs and nRR-NPs: Urea and albumin production 
 
Two essential hepatocyte functions; urea and albumin production were investigated 
following the exposure of C3A cells to NPs. Cells were treated with RR-NPs and nRR-
NPs for 24 hours at three sub-lethal concentrations (62.5, 125 and 250 µg/mL).  
 
Urea production was significantly reduced (p< 0.005-0.001) after exposure of cells to 
nRR-NPs, at all concentrations (Figure 4.13A). RR-NPs only decreased urea production 
at a concentration of 250 µg/mL. Similarly, albumin production was significantly reduced 
by cells exposed to nRR-NPs at concentrations of 125 and 250 µg/mL (Figure 4.13B). 









Figure 4.13. Urea and albumin production following exposure of C3A cells to RR-
NPs and nRR-NPs. 
Cells were exposed to RR-NPs and nRR-NPs at 62.5, 125 and 250 µg/mL for 24 hours 
and urea (A) and albumin (B). Data for urea expressed as mean µg/dL ± SEM(n=3). 
Data for albumin expressed as mean mg/dL ± SEM (n=3). Significance indicated by 
***= p< 0.001, **= p< 0.005, *= p< 0.05 treatments compared with the untreated 
control. Significance indicated by $$$ = p< 0.001 when comparing nRR-NPs to RR-
NPs at the same concentration. 





4.3.7 RR-NPs and nRR-NPs: Intracellular calcium concentration 
 
Fura-2 is a ratiometric dye that shifts excitation wavelength from 340 nm to 380 nm when 
bound with calcium, allowing accurate quantification of increases in [Ca2+]i (Grynkiewicz 
et al. 1985). Fura-2 was used to monitor increases in [Ca2+]i following exposure of C3A 
cells to RR-NPs and nRR-NPs at a concentration of 125 µg/mL for 30 minutes. UFCB (5 
µg/mL) was included as a positive control.  
 
The RR-NPs treatment resulted in significantly higher (p <0.001) [Ca2+]i compared to 
nRR-NPs and untreated control at 2-36 minutes (Figure 4.14). The nRR-NPs only 
significantly increased (p<0.05) [Ca2+]i at 4 and 8 minutes. The UFCB treatment resulted 









Figure 4.14 Intracellular calcium following exposure of C3A cells to RR-NPs and 
nRR-NPs. 
Cells were exposed to RR-NPs, nRR-NPs (125 µg/mL), UFCB (5 µg/mL) or Complete 
Medium (control) for 36 minutes. Fura-2 was used to quantify increase in intracellular 
calcium concentration [Ca2+]i. Data are expressed as mean Ratio 340/380 ± SEM (n=3). 
Significance indicated by ***= p< 0.001 and **= p< 0.005 compared with the untreated 







4.4 Discussion  
 
4.4.1 Overview of results 
 
Before assessing the impact of the RR-NPs and the nRR-NPs on C3A cells, the 
physiochemical properties of the NPs such as size, morphology and surface charge were 
determined. Results indicated that RR-NPs and nRR-NPs were spherical, ~60 nm in 
diameter and had a slightly negative surface charge of ~ (-6) mV.  
 
Following this, cytotoxicity was assessed, and it was observed that after 24 hours of 
exposure to RR-NPs and the nRR-NPs, there was no reduction in C3A cell viability 
observed. Next, NP uptake by C3A cells was assessed, and a concentration and time-
dependent increase in NP internalisation as seen for both NPs. RR-NPs were internalised 
by cells to a greater extent than nRR-NPs. 
 
To further investigate the safety of these NPs, genotoxicity was assessed, and results 
indicated that nRR-NPs induced greater DNA damage than RR-NPs, which was 
predominantly mediated by an oxidant mechanism. Furthermore, both NPs stimulated an 
increase in intracellular ROS production, although there was little difference between 
NPs. There was no increase in cytokine production for C3A cells exposed to both NPs, 
with the exception of IL-1ra, observed to be significantly increase compared to control 
when cells exposed to either NP.  
 
Both NPs stimulated a decrease in urea and albumin production (markers of hepatocyte 
function), with the greatest effect observed for nRR-NPs. Finally, [Ca2+]i was seen to 
increase for both NPs, with RR-NPs inducing a higher response than nRR-NPs.  
 
Taken together these findings demonstrated that RR-NPs were less toxic than nRR-NPs. 
By performing a range of tests, a more detailed understanding of the in vitro toxicity of 







4.4.2 Characterisation of nRR-NPs and RR-NPs  
 
The hydrodynamic diameter of RR-NPs and nRR-NPs were assessed immediately after 
preparation in cell culture medium and 24 hours post incubation at 37○C. The 
hydrodynamic diameter remained unchanged at both time points at ~60 nm, which 
suggests that both NPs are relatively stable up to 24 hours in cell culture conditions. TEM 
images confirmed that the NPs were spherical. The nRR-NPs were monodispersed, 
whereas RR-NPs appeared to have two different sized populations with some 
agglomerates present. Therefore it is possible that RR-NPs may have lost some of the 
PEG coating from the PLGA core resulting in a reduction in size or an increase in NP 
agglomeration, due to a lack of the steric repulsive forces of the PEG coating (Gref et al. 
2000).  
 
In the future to investigate PEG dissociation from these NPs, size exclusion 
chromatography could be used to differentiate between NPs with and without PEG via 
molecular mass (Spek et al. 2015). Imaging of PNPs using TEM can be difficult due to 
the harsh preparation methods, and the low density of the PNPs producing lower contrast 
images than those obtained for other NPs such as silver (Renz et al. 2016). Due to a less 
invasive preparation method, cryogenic scanning electron microscopy may be a suitable 
imaging alternative, with the added benefit of imaging hydrated NPs (Win & Feng 2005). 
 
The relatively high PDI values for both NPs also suggests that the NPs are not 
monodispersed. Uniform and monodisperse NP suspensions are essential for 
nanomedicines to ensure accurate drug dosing (Venkataraman et al. 2011). Therefore, the 
synthesis of RR-NPs may require additional optimisation before they can be used in a 
clinical setting.  
 
The zeta potentials of RR and nRR- NPs were slightly negative. After 24 hours incubation 
at 37oC, RR-NPs ween observed to become more negatively charged. However, this 
change was small and was therefore unlikely to have a biological effect. Previous studies 
have shown that PEGylated PLGA NPs have a less negative zeta potential than non 
PEGylated NPs, perhaps the more negative zeta potential observed for RR-NPs may be 






As collaborators were interested in targeting tumour cells, a degradation study was 
performed by the University of Nottingham in a biological medium that reflected the 
tumour microenvironment. Tumour cells can have elevated intracellular and extracellular 
GSH concentration compared to healthy cells (Lee et al. 1989; Edward et al. 1990; Yao 
et al. 1995; Sun & Davis 2010). Therefore, NPs were suspended in media containing GSH 
10 mM, for 24 hours, to reflect the tumour microenvironment. Using TEM, it was evident 
that there was aggregation/disassembly of RR-NPS as NP shape and size had changed 
compared to nRR-NPs. This physical change of RR-NPs was most likely due to the 
cleavage of the disulphide linker between PLGA and PEG, which in turn reduced the 
stability of the RR-NPs.  
 
This selective NP degradation would be clinically beneficial as it would ensure that NPs 
are targeted to tumour cells, and it could reduce the adverse effects of extended NP 
persistence within the body. In the future it could be useful to further characterise the size, 
shape and zeta potential of the NPs after incubation in media at a range of GSH 
concentrations, to provide more insight into how these NPs interact with different cells. 
 
4.4.3 Cytotoxicity of nRR-NPs and RR-NPs  
 
The viability of cells exposed to RR-NPs and nRR-NPs was assessed using the AB assay 
and the NR assay. The NR assay was performed in addition to the robust AB assay as 
when preliminary imaging was performed it appeared that NPs may be contained in 
organelles such as lysosomes and NR assay was had the potential for additional insight. 
Both assays gave similar results for both NPs, with less than 10% reduction in cell 
viability observed at all concentrations tested, 24 hours post exposure.  
 
These results would suggest that RR-NPs and nRR-NPs have little effect on C3A cell 
viability. These results are similar to other studies, showing relatively low cytotoxicity of 
polymer-based NPs such as NPs generated from thermo-responsive and biocompatible 






Cytotoxicity of RR-NPs and nRR-NPs was assessed at one-time point (24 hours) with a 
single NP exposure. Therefore, in the future to reflect the repeated administration of 
nanomedicines in vivo, it would be useful to assess toxicity following repeated exposures 
over a wider range of time points in vitro. 
 
4.4.4 Uptake of nRR-NPs and RR-NPs  
 
To investigate the internalisation of RR-NPs and nRR-NPs by C3A cells, a semi-high 
throughput plate-based method was used to quantify uptake, and confocal microscopy 
was used to visualise uptake. Both methods demonstrated that the uptake for both NPs 
was low and that uptake of RR-NPs was higher than that of nRR-NPs.  
 
C3A cells are derived from carcinoma cells, that has the potential for higher intracellular 
and extracellular GSH compared to other non-hepatocyte cell lines (Lee et al. 1989; Yao 
et al. 1995; Sun & Davis 2010). Additionally, C3A cells are hepatocytes, which in vivo 
are responsible for synthesising the majority of newly circulating GSH (Griffith & 
Meister 1985; García-Ruiz et al. 1992). Therefore GSH levels outside C3A cells may be 
high enough to cleave the disulphide linkers in RR-NPs, thus removing the PEG from the 
PGLA NP core (Edward et al. 1990; Sun & Davis 2010). This may allow NPs to 
agglomerate or increase NP-cell interactions and uptake, due to increased NP 
hydrophobicity that has been shown to increase NP opsonisation (Gref et al. 2000; Ruge 
et al. 2012; Nocito et al. 2015; Pelaz et al. 2015). It may therefore be of interest in the 
future to perform a Rose Bengal adsorption assay that characterises the surface 
hydrophobicity of the NPs by observing changes in absorption in NP/ Rose Bengal 
solution (Muller et al. 1997; Doktorovova et al. 2012). 
 
In the future, it would be useful to evaluate the total free GSH in the media of C3A cells 
over time in the presence and absence of the NPs. This could establish the contribution 
of extracellular GSH to increased RR-NP uptake as well as allow characterisation of NP 







The pattern and level of NP uptake were in line with those published by our collaborator, 
where greater uptake was seen for RR-NPs than for nRR-NPs in alveolar epithelial cells 
(A549), although levels appear to be much lower in C3A cells (Conte et al. 2018).  
 
Other studies have seen similarly low levels of uptake such as fluorescein-loaded PLGA 
NPs into human breast epithelial cells (MCF-10A neoT) alone or in coculture with Caco-
2 cells (colon epithelial) 24 hours post exposure. (Kocbek et al. 2007). Moreover, 
polyester (PEG-polycaprolactone-poly(dimethylamino ethyl methacrylate) NPs with a 
hydrophobic core, much like the hydrophobic DiO dye loaded RR-NPs and nRR-NPs, 
observed similar uptake to RR-NPs and nRR-NPs, in hepatocyte cells (HepG2) (Han et 
al. 2015). 
 
To further investigate the uptake of these NPs by C3A cells, confocal microscopy was 
used. A single time point, 24 hours, was selected to visualise NP uptake. This time point 
was selected as the plate-based method indicated the highest uptake of RR-NPs and nRR-
NPs at 24 hours. The uptake of both NPs appears low, although RR-NPs appear to be 
taken up more readily than nRR-NPs. Although confocal microscopy has a resolution of 
approx. 250 nm. Therefore, it may not have been possible to visualise some of the NPs. 
Both NPs were compartmentalised, potentially in organelles such as the endosomes or 
lysosomes.  
 
To gain greater insight into how the presence of the disulphide linker in RR-NPs effects 
the intracellular fate of these NPs, colocalisation with organelles such as the lysosome 
could be investigated using live confocal microscopy. The lysosome has been a prime 
candidate organelle for cleavage of disulphide linkers following internalisation due to the 
presence of gamma-interferon-inducible lysosomal thiol reductase (Phan et al. 2000; 
Arunachalam et al. 2000). Therefore, lysosomal labelling with the fluorescent 
LysoTracker dye could be used to investigate NP-lysosomal colocalization. As 
endosomes are another potential location of disulphide linker cleavage, NP localisation 
to the endosome could be established using a fluorescent label such as a fluorescent 
transferrin-conjugate or an endosome marker eg EEA-1 (Dautry-Varsat et al. 1983; 






Of benefit is that the findings from the plate-based method and confocal microscopy 
agreed. The plate-based method allows a semi high throughput screening of NPs uptake 
and can enable quantification of NP internalisation. However, it cannot provide 
information on intracellular localisation. This suggests that it was beneficial to use a 
combination of approaches when investigating NP-cell interactions. 
 
4.4.5 Genotoxicity of nRR-NPs and RR-NPs  
 
The Comet assay is commonly used to assess NP genotoxicity in vitro. Nonetheless, it 
can have a high level of variance (as reviewed by Rojas et al. 1999; Lee et al. 2004; Evans 
et al. 2017). To improve confidence in findings, use of more than one method to assess 
the genetic damage caused by NPs is desirable. In this study, the comet assay and MN 
assays were used to assess genotoxicity stimulated by RR-NPs and nRR-NPs. Different 
assays measure different endpoints; the comet assay measures transient DNA strand 
breaks and the MN assesses chromosomal damage. The combination of the two assays 
could allow for a more reliable indication of the genotoxic potential of NPs (Heddle 1973; 
Cook & Brazell 1976; Magdolenova et al. 2012). Due to the limited volume and 
concentration of these NPs, analyse of one concentration was priorities, not the 
recommended three concentrations (OECD 2015). Although these data can be a useful 
indicator of NP genotoxicity, results should be considered preliminary. 
 
The RR-NPs did not stimulate DNA damage in C3A cells. However, nRR-NPs stimulated 
DNA damage, in both assays. The DNA damage observed appears to be mediated by an 
oxidative mechanism due to the higher level of DNA damage evident when using the 
lesion-specific repair Fpg enzyme in the Comet assay (Collins et al. 1996).  
 
Prior studies using the sister chromatid exchange assay indicated that PLGA-PEG NPs 
with a similar composition to nRR-NPs, induced genotoxicity in vitro using Chinese 
hamster ovary cells (He et al. 2009). Additionally, in vitro studies using the Comet assay 
showed that PLGA-PEO NPs (PEO differs from PEG only in molecular weight) was 
genotoxic to primary rat hepatocytes as well as Kupffer cells (Cowie et al. 2015). 
Moreover, mononucleated TK6 (human B-lymphoblastoid) cells exposed to PLGA-PEO 





DNA (Kazimirova et al. 2012). In contrast, there have been studies that show a lack of 
genotoxicity by PLGA NPs. For example, Setyawati et al. 2013 demonstrated that NP-
mediated genotoxicity in vitro was dependent on cell type and NP surface coating such 
as PEG (Setyawati et al. 2013).  
 
Therefore, it appears that nRR-NPs have the potential to cause mutations or genetic 
damage in the C3A cell line in not repaired. Moreover, the addition of a disulphide linker 
appears to reduce the potential of these NPs to cause genetic damage making them more 
attractive as a candidate nanomedicine. However, this finding would have to be further 
investigated in other cell types, and in vivo.  
 
4.4.6 Cytokine production by RR-NPs and nRR-NPs  
 
Assessment of cytokine production is commonly used to investigate the inflammatory 
response stimulated by NPs in vitro (Stone et al. 2009). The cytokines IL-8, IL-6, TNF-
α, IL-1β and of IL-1ra were selected based on data from existing studies which have 
investigated cytokine production by C3A cells following exposure to NPs such as TiO2, 
Ag, ZnO and carbon nanotubes (e.g. Kermanizadeh et al. 2012; Gaiser et al. 2013). 
Furthermore, PNPs have been seen to elicit a cytokine response in hepatocyte cell lines, 
with an increase in the production of IL-6, TNF-α observed previously (Bisht et al. 2011).  
 
In alveolar epithelial cells (A549), IL-6 production was elevated when exposed to PNPs 
such as PEI NPs and PLGA/ polyvinyl alcohol NPs (Robbens et al. 2010; Grabowski et 
al. 2013). Additionally, C3A cells exposed to TiO2 NPs increased mRNA expression of 
TNF-α, IL-1RI, IL-1β and IL-1ra receptors (Gaiser et al. 2013). Also, in vivo, TNF-α and 
IL-6 expression were elevated after oral exposure to PNPs such as polyurethane NPs and 
N-isopropylacrylamide-vinylpyrrolidone-acrylic acid NPs (Bisht et al. 2007; Silva et al. 
2016). Interestingly, macrophage cell lines have also been seen to increase production of 
IL-1β when exposed to Ag or SiO2 NPs (Carlson et al. 2008; Park & Park 2009). Although 
not often investigated the production of IL-1ra was increased by RAW cells exposed to 
CeO2 hydroxyapatite NPs (Li et al. 2017). These studies highlight the importance of 






The only cytokine with increased production following exposure to both nRR-NPs and 
RR-NPs was the anti-inflammatory cytokine IL-1ra. Previous studies exposing 
monocytes and polymorphonuclear cells to PLGA-PEG NPs also failed to induce the 
production of pro-inflammatory (IL-1β, IL-6, TNF-α and IL-8) cytokines (Segat et al. 
2011). Furthermore, although an increase in IL-6 was seen for hepatic cells exposed to 
polyethene imine NPs, these NPs failed to increase production of IL-8, the most common 
cytokine investigated for hepatocytes exposed to NPs (Robbens et al. 2010).  
 
However, only one-time point was investigated for cytokine production, and there may 
have been the production of pro-inflammatory cytokines at earlier time points. Previous 
studies observed cytokine production such as IL-6, after 4 hours of exposure to 
hepatocytes (Brown et al. 2014). However, other studies have seen increases in cytokine 
production such as IL-8 using human liver microtissue following exposure to ZnO NPs 
for 24-312 hours (Kermanizadeh et al. 2014). Therefore in future studies, it would be 
informative to investigate cytokine production at a range of time points. 
 
The results of this study suggest that the PNPs did not stimulate a pro-inflammatory 
response, although this would need to be confirmed in vivo. Notwithstanding, the 
observed increase in the anti-inflammatory cytokine IL-1ra could be an early indicator of 
low levels of cellular damage.  
 
4.4.7 nRR-NPs and RR-NPs Intracellular ROS production  
 
In this study, the potential for PNPs to generate intracellular ROS was investigated using 
the DCFH-DA assay. Both RR-NPs and nRR-NPs produced a similar ROS response at 
all concentrations, with a ~5-fold increase in ROS production compared to untreated cells. 
Previous studies have shown that PNPs can induce ROS production without affecting cell 
viability (Yu et al. 2014). This aligns with the findings of this study, where nRR-NPs 
stimulated DNA damage via an oxidant mechanism. 
 
As elevation in ROS production has the potential to affect cell health negatively, it would 
be essential to understand the impact of this elevated ROS in more detail as it would not 





shown that an increase in ROS generation by NPs was strongly correlated with a decrease 
in GSH, suggesting that NPs may stimulate oxidative stress, interestingly, in turn, this 
may decrease the rate of RR-NP cleavage (Hussain et al. 2005). Therefore, it would be 
important in the future to investigate the levels or activities of antioxidants (e.g. GSH, 
catalase, SOD) in cells exposed to these NPs, as these antioxidants are essential in 
protection against oxidative stress through scavenging of ROS (Dewanjee et al. 2011).  
 
Also, Kermanizadeh et al. demonstrated that NP-mediated cytokine production and 
genotoxicity in C3A cells were mediated by oxidants as pre-treatment with the anti-
oxidant Trolox could protect against NP toxicity (Kermanizadeh et al. 2012). This 
approach could be employed in future studies to dissect out the role of ROS in PNP 
toxicity. To further investigate the role of oxidative stress in RR-NP and nRR-NP toxicity, 
dihydroethidium (DHE), a superoxide indicator that changes colour upon oxidisation, 
could be used (Filippi et al. 2014; Kung et al. 2015). Another method, electron spin 
resonance (ESR) uses a spectroscope to assess production of short-lived oxidants 
indirectly, and is typically used to assess acellular ROS production by NPs. This is 
achieved when oxidants bind with molecules such as alpha-phenyl N-tertiary-butyl 
nitrone to generate longer lived adducts with specific spectra that can be measured using 
ESR (Kadiiska et al. 1996; Sato et al. 2002; Žuvić-Butorac et al. 2005).  
 
When cysteine thiols (e.g. in GSH) are exposed to ROS, sulfenic acid is formed, which 
in turn promote the formation of oxidant-mediated disulphide linkers (Claiborne et al. 
1993; Rehder & Borges 2010). These oxidant-mediated disulphide linkers are distinct 
from structural disulphide linkers which are formed by a direct thiol-disulphide exchange 
reaction. To cleave oxidant-mediated disulphide linkers specific antioxidants are required 
such as thioredoxin or glutaredoxin (Holmgren 1979).While the structural disulphide 
bonds present in RR-NPs are designed to cleave in high redox environments (e.g. GSH) 
(Wang et al. 2011). Therefore, although the RR-NPs are redox reactive, it would not be 
expected that the increase in ROS production mediated by these NPs would increase 
cleavage of disulphide linker between PLGA and PEG.  
 
However, a previous study demonstrated that some disulphide linkers had the potential 





Paclitaxel and citronellol linked with varying lengths of disulphide linker (1-3 carbons). 
These disulphide linkers were observed to act as an oxidation-responsive element (Xiao 
et al. 2015; Luo et al. 2016; Sun et al. 2018). The RR-NPs in this study had a linker of 2 
carbons, in the study performed by Sun et al. above it was observed that disulphide linkers 
containing 2 carbon bonds when exposed to either 10 mM dithiothreitol (similar to GSH) 
or 10 mM H2O2 both treatments resulted in similar levels of disulphide linker cleavage 
rate. Although these differ significantly in regards to location and composition of 
elements being linked, it is possible that ROS could cleave these disulphide bonds. 
However, this would need to be confirmed by exposing RR-NPs to H2O2 and analysising 
for sulfoxide, and sulphone production as these products are only produced when 
disulphide linkers are cleaved by ROS (Xiao et al. 2015; Luo et al. 2016; Sun et al. 2018). 
 
The results of this study suggest that both RR-NPs and nRR-NPs may stimulate ROS 
production. However as there results were not dose dependent it is possible that this assay 
is not sensitive or reliable enough for these PNPs. Furthermore, assessment of the 
contribution of oxidative stress would  require investigation of markers of oxidative stress 
such as the marker of lipid peroxidation, MDA (Ohkawa et al. 1979; Williams et al. 1998; 
Wheeler et al. 2001; Elchuri et al. 2005). Previous studies have indicated that NPs have 
the potential to induce increases in MDA production in vitro in hepatocyte cells (HepG2) 
exposed to silver NPs and in vivo in the livers of mice intravenously administered with 
cadmium telluride QDs (Oliveira et al. 2013; Zhang et al. 2015). 
 
It was not possible to identify any current studies investigating the ROS production of 
PNP containing a disulphide linker. Also, it would be of interest in the future to look at 
mitochondrial antioxidant manganese superoxide dismutase (MnSOD) enzyme activity, 
as this enzyme can scavenge superoxide radical to protect the cells from damage caused 
by ROS. MnSOD could provide greater insight into the impact of RR-NPs and nRR-NPs 
on hepatocyte function, as well as provide insight relating to the elevated ROS levels 
observed (Gregory & Fridovich 1973). 
 






Following exposure of C3A cells to RR-NPs and nRR-NPs, a decrease in the levels of 
both urea and albumin were observed, indicating their potential to cause damage to 
hepatocytes. RR-NPs had a less pronounced effect.  
In the current study RR-NPs and nRR-NPs did not appear to negatively impact on 
mitochondrial function according to the AB assay. However, alternative methods can be 
used to investigate mitochondrial function, such as the positively charged fluorescent dye 
tetramethylrhodamine, ethyl ester that is used as an indicator of mitochondrial membrane 
potential and readily accumulates in active mitochondria due to the mitochondria relative 
negative charge (Lammel et al. 2013). 
 
Both these NPs appeared to affect hepatic function negatively. Although, results suggest 
that the disulphide linker in the RR-NP may have the potential to reduce adverse effects, 
therefore improving the safety profile of this NP as a nanomedicine.  
 
4.4.9 nRR-NPs and RR-NPs effects on intracellular calcium concentration  
 
Elevation of [Ca2+]i in hepatocytes can occur as a response to cellular injury and has 
potential as a marker for nanomedicine induced hepatotoxicity (Trump et al. 1984; Tolosa 
et al. 2012; Jemnitz et al. 2017). In this study, Fura-2 was used to quantify increases in 
[Ca2+]i. Both NPs could increase [Ca
2+]i , and RR-NPs stimulated a higher response than 
nRR-NPs.  
 
These results are in line with other studies that had shown an increase in [Ca2+]i when 
hepatocytes were exposed to PNPs such as PAMAM dendrimer NPs, while there was no 
impact on cell viability (Jemnitz et al. 2017). Interestingly, PEGylated PAMAM 
dendrimer NPs also elicited less of an increase in [Ca2+]i in primary rat Kupffer cells 
(Jemnitz et al. 2017). Also, previous studies have shown that polystyrene NPs of < 100 
nm were capable of inducing an increase in [Ca2+]i in macrophage and neuroblasts (Brown 
et al. 2001; Meindl et al. 2015). Furthermore, PLGA NPs <100 nm increased intracellular 
calcium flux in both macrophage cells (RAW264.7) and human lung cells (BEAS-2B) 





in [Ca2+]i in a range of cell lines and that NP physicochemical properties such as PEG 
coatings impact upon the magnitude of the response observed. 
 
An increase in [Ca2+]i can stimulate an array of downstream effects, such as apoptosis, 
cytokine production and membrane repair (Bement & Capco 1991; Steinhardt 1994; 
Terasaki et al. 1997; Shareia et al. 2009; Brown et al. 2010). To further investigate the 
effects of intracellular calcium and to confirm the observed increased [Ca2+]i observed for 
RR-NPs and nRR-NPs it would be of interest to inhibit calcium signalling via calcium 
antagonists such as verapamil, which have previously been seen to decrease PM10 
induced release of TNF-α protein related to increased [Ca2+]i in human primary 
monocytes (Brown et al. 2013). However, although verapamil has been seen to have a 
protective effect on liver cells at low concentrations, it has also been observed to enhance 
the toxicity of specific compounds such as diclofenac in isolated hepatocytes (Schmitz et 
al. 1995; Szelag et al. 2003). Therefore endpoints investigated following calcium 
signalling inhibition may be difficult to distinguish from NP effect and toxic side effects 
of the calcium antagonists.  
 
Cell membrane repair requires an influx of extracellular calcium, without this some forms 
of membrane repair cannot occur such as contraction and exocytosis (Bement & Capco 
1991; Steinhardt 1994; Terasaki et al. 1997). It is possible that upon initial exposure RR-
NPs cause injury to the membrane of C3A cells, therefore these cells could require an 
influx of extracellular calcium for repair. As there appears to be no extensive cell death 
observed perhaps this membrane damage was transient. This could be further studied by 
investigating the NP uptake over time using live imaging together with an appropriate 
cell stain such as Fura-2.  
 
The results of the current study suggest that PNPs have the potential to increase [Ca2+]i, 
an endpoint that is not commonly investigated when assessing the safety of PNPs in vitro. 
Previous studies have indicated that ROS has a role in modulating [Ca2+]i (Stone et al. 
2000; Huang et al. 2010). To further investigate the contributions of ROS production to 
modulating [Ca2+]i cells could be treated with an antioxidant such as Trolox which has 
previously been seen to effectively prevent NP induced calcium increase when 





study both RR-NPs and nRR-NPs appear to induce similar levels of ROS, suggesting that 
more than NP induced ROS alone plays a part in increasing [Ca2+]i.. These results 
highlight the need to increase the understanding of the mechanism of toxicity of PNPs 




This study used a range of methods to investigate the cellular toxicity of PLGA-PEG NPs 
with (RR-NPs) and without (nRR-NP) a novel redox-responsive disulphide linker 
including; uptake; genotoxicity; cytokine production; ROS production; urea and albumin 
production as well as increases in intracellular calcium concentration. 
 
As hypothesised, both NPs had low cytotoxicity. There appeared to be a higher level of 
uptake of RR-NPs compared to nRR-NPs which was expected as the disulphide linker 
was designed to be degraded within a high GSH environment, which has previously been 
noted for cancer cell lines and in particular hepatocytes. Furthermore, the differential 
degradation rates of nRR-NPs and RR-NPs, as well as the disulphide linker in the RR-
NPs may alter NP internalisation and trafficking within the cells, and therefore explain 
the differences in responses observed. Although, it would be expected that the NPs 
internalised to a greater extent would produce a greater toxic response. There was a 
marginally lower internalisation of nRR-NPs compared to RR-NPs, however the nRR-
NPs should remain as intact NPs for longer within the cells than the GSH cleavable RR-
NPs. Therefore, once inside the cell the nRR-NPs may have had more opportunity to 
interact with elements within the cell such as DNA leading to more genotoxic and 
stimulated a more prominent reduction in urea and albumin production than RR-NPs.  
 
Both RR-NPs and nRR-NPs may increase ROS production and caused a moderate 
increase in IL-1ra production. Of interest was the increased [Ca2+]i for both NPs but 
predominantly RR-NPs. Although in previous studies ROS has been linked to increased 
[Ca2+]i, there appears to be little difference in ROS production between RR-NPs and nRR-
NPs, while there was a significant difference in intracellular [Ca2+]i suggesting that in this 
situation other factors also influence [Ca2+]i. The relatively higher impact of nRR-NPs on 





shell of these PLGA NPs. The reduced degradation rate of nRR-NPs could delay 
degradation once internalised by cells compared to RR-NPs. This could lead to 
differences in how these NPs interact with the cells both extracellularly and intracellularly 
resulting in differential impacts of urea and albumin production. 
 
As RR-NPs are the particles of interest in a medical application, these results are 
promising as it appears to indicate that the addition of the disulphide linker potentially 
increases the safety of these PLGA-PEG NPs. However, this would need further 
investigation in other cell lines and using in vivo studies. This information could be used 
in the design of future nanomedicines to increase safety while also increasing the targeting 
of the medically relevant NPs cargo.  
 
The observations made during this study could contribute to refining a in vitro testing 
strategy for PNPs such as in tier 1 in Figure 1.3. Identifying the most informative 
endpoints has the potential to reduce in vitro testing required as well as in vivo, which 
has the potential to reduce the time and cost of bringing safe and useful nanomedicines 
to the patients. 
 
Again, with a testing strategy in mind to determine PNP safety, limited cytotoxicity 
testing and PNP uptake assessment provided adequate information to make safety related 
decisions. Using two methodologies to assess genotoxicity provided a greater weight to 
the value of the genotoxic results and would be useful in a testing strategy for PNPs. 
Although concentrations and timepoints were limited due to the quantity of NPs available. 
For these PNPs cytokine production did not provide information regarding PNP safety. 
Additionally, ROS assessment via the DCFH-DA assay appeared to be an unsuitable 
indicator of the oxidative state of the cells. However, for these PNP both albumin and 
urea appear to be useful indicators of liver cell health. Although, greater understanding 
of how NPs impact on urea and albumin production would be require for this to be used 
















5.1 Overview of project aims and objectives   
 
Currently, due to the diversity of PNPs under development and lack of an in-depth 
understanding of their safety profile, the toxicity testing of a range of PNPs of varied 
physicochemical properties using evidence-based endpoints and physiologically relevant 
concentrations is needed for their successful clinical application. Obtaining a better 
understanding of the physicochemical properties of PNPs that confer toxicity and the 
cellular and molecular events which underlie any observed toxicity will inform future 
testing strategies used to assess PNP toxicity and ensure the safer design of future 
generations of PNPs.  
 
The most commonly used and investigated PNPs for nanomedical use are spherical, 
micellar PNPs. These PNPs are usually composed of a hydrophobic “core” and a 
hydrophilic “shell”. The PNP shell is the primary part of the PNP that comes into contact 
with cells, making it essential to investigate the impact of alterations of the micellar PNP 
shell on PNP safety. Accordingly, in this study, the toxicity of a panel of PNPs of varied 
shell composition was conducted to achieve a greater understanding of the influence of 
PNP physicochemical properties on their toxicity.  
 
More specifically, a panel of PNPs of varying complexity were selected for investigation. 
PDP-PF68 PNPs had an adsorbed hydrophilic shell (PF68) which aimed to increase PNP 
stability and circulation time, for drug delivery via inhalation. The 4K, 15K and 55K 
PNPs had a chemically linked hydrophilic shell (PEG) and hydrophobic segment (PLGA) 
of varying lengths which aimed to increase PNP stability and circulation time, while 
improving the safety of these PNPs for bioimaging following intravenous administration. 
Also, RR-NPs had a chemically linked hydrophilic shell (PEG) that was responsive to a 
redox environment, making these PNPs specifically targeted to cancer cells and are 
intended for delivery via intravenous injection. Safety by design was used within each of 
the PNPs tested. More specifically, the hydrophilic polymer component shell of each of 
the PNPs was expected to increase PNP efficacy and safety, by increasing NP stability 
and circulation time for PDP-PF68 PNPs and 4K, 15K and 55K PNPs as well as 






Furthermore, when developing a testing strategy for assessing PNP safety, an 
understanding of the mechanisms underlying their toxicity is vital to identify which 
markers to prioritise when screening NP toxicity (Henderson et al. 2014; Boyles et al. 
2015). Several in vitro studies have investigated the safety of PNPs but have used limited 
endpoints to assess toxicity. Also, only a limited range of cell models such as gut and 
breast cancer cells have been used. Therefore, there is an absence of information 
regarding the response of other cell types to PNPs. Accordingly, this study focused on 
assessing the response of the liver to address this knowledge gap and used a battery of 
tests to perform a thorough assessment of the hepatotoxicity for clinically relevant PNPs.  
 
The overall aim of this project is to inform the development of evidence-based in vitro 
approaches to screen the toxicity of PNPs of varied physio-chemical properties. It is 
intended that the information obtained will inform the development of a tiered testing 
approach by allowing indicators of toxicity to be identified that can be used when 
screening PNP safety before progressing with in vivo testing, if deemed appropriate. This 
has the potential to reduce the resources required for testing these PNPs such as time, 
financial investment and animals, therefore becoming more in line with the principles of 
the 3Rs (replacement, refinement, and reduction of animal testing) (Burden et al. 2017). 
Also, it is envisioned that obtained data will inform the safe design of future generations 
of PNPs. 
 
5.2 Hypothesis  
 
It was hypothesised that PNPs would stimulate low cytotoxicity in C3A hepatocytes. 
Additionally, due to evidence from a large body of evidence for engineered NPs (metal, 
metal oxides), it was excepted that if any toxicity was observed it would be predominantly 
mediated by ROS and pro-inflammatory driven responses. It was expected that the 
physico-chemical properties of the PNPs would influence their toxicity such as PNP size, 








5.3 Overview of outcomes  
 
A heat-map was generated to summarise results across all the tested PNPs (Table 5.1).  
 
From the heat-map, there did not appear to be a consistent relationship between toxicity 
and the physicochemical characteristics of PNP such as hydrodynamic diameter, PDI or 
zeta potential. However, the NPs are all generated according to different preparation 
methods with varying polymers, and further research would be required to further probe 
the importance of physio-chemical characteristics to PNP toxicity. What is interesting is 
that the cytotoxicity assays (AB, CFDA and NR), which in previous studies have been 
the predominant method to assess PNP toxicity, appear to indicate little to no toxicity, 
while other endpoints such as genotoxicity suggest that further investigation of PNP 
safety may be required.  
 
Ranking of PNP toxicity considered the findings from all assays. Interestingly, some 
assays were found to be consistently more sensitive to PNP toxicity than others. For 
example, assessment of PNP uptake by cells via quantitative and qualitative means did 
not appear to relate to the overall toxicity of PNPs. This may suggest that the level of 
PNP uptake observed for the PNPs under investigation to C3A cells had little impact on 
overall toxicity. To further investigate the uptake and intracellular fate of these PNPs in 
hepatocytes, it would be interesting to determine if these PNPs co-localise with cell 
organelles such as lysosomes or mitochondria using fluorescent probes such as 
Lysotracker or Mitotracker. As discussed in previous chapters it would also be useful to 
assess the mechanism of PNP uptake to allow for further relationships to be understood 
between PNP uptake and PNP safety. As hepatocytes are not professional phagocytes, 
and as the PNPs in this study are not targeted to hepatocytes, levels of uptake may not be 
high enough to elicit a toxic response. The response of other cell types such as 
macrophages that are likely to experience higher levels of PNP uptake should therefore 







Table 5.1 Heat-map of outcomes C3A cells (A/B), Ranking of PNP toxicity (C). 
Endpoint results are coded according to the change from untreated control; no change-
green, small change-yellow, moderate change-orange, larger change-red, incompatible 
assay-grey and assays not performed-white. Assays were weighted according to combined 
toxicity information obtained for all PNPs together with the assays sensitivity of 
predicting PNP safety. The weighted outcome was calculated as the sum of the weight of 
the assays 2= unacceptable safety impact, 1= acceptable safety impact and 0= 
undetermined impact on safety by PNPs (A/B). Table ranking from PNPs with lowest 
toxicity to highest toxicity according the weighted outcome (C). 
 
A End point* PDP PDP-PF68 4K 15K 55K nRR-NPs RR-NPs
DLS (nm) <150 <150 <150 <150 <150 <70 <70
PDI <0.3 <0.3 <0.3 <0.3 <0.3 <0.7 <0.7
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* =End point at 24 hours max change observed compared to untreated control Undetermined 0
# =36 minutes Acceptable 1
Unacceptable 2
Compared to untreated control 
Assay weight (Wt.) by 





Genotoxicity appears to be a sensitive marker of potential adverse effects of PNPs in C3A 
cells. However, as the number of NP concentrations that could be tested were limited 
results should be considered preliminary (OECD 2015). When both the comet assay and 
the MN assay were used to assess PNP genotoxicity similar results were observed 
indicating that both these assays are suitable to assess PNP toxicity in hepatocytes.  
 
DNA damage for all PNPs appeared to be mediated via an oxidative mechanism, as a 
higher level of DNA damage was evident for Fpg treated samples, a specific measure of 
oxidised DNA base lesions (Collins et al. 1996). ROS production was increased following 
exposure of the hepatocytes to these materials, however, as ROS was also increased in 
cells that experienced no measurable DNA damage, the involvement of ROS production 
in PNP toxicity would need future investigation using additional markers for oxidative 
stress.  
 
Interestingly alterations to the PNP shell differentially affected genotoxicity, indicating 
that when it comes to safety by design, the impact of the outer shell that comes into contact 
with the cells is essential to consider. Although, investigating the genotoxic potential of 
PNPs can be time-consuming as well as costly, if these PNPs are to be used as 
nanomedicines, it is an essential endpoint to investigate before progressing to in vivo 
studies.  
 
When cellular ROS production was investigated it was elevated for all PNPs assessed 
regardless of PNP properties. This may indicate that the DCFH-DA assay is not suitable 
for assessment of ROS produced by PNP. Therefore, these results would require furthered 
investigation of other indicators of the oxidative state in the cell such as measurement of 
MDA, a by-product of lipid peroxidation (i.e. the oxidative degradation of the cells lipid 
membrane by free radicals) or the levels/activities of antioxidants such as SOD or 
glutathione peroxidase (GPx). If along with ROS and MDA elevation, the levels of the 
antioxidants (SOD or GPx) were observed to be decreased this could indicate oxidative 
stress. This oxidative stress, in turn, has the potential to damage DNA and alter 
metabolism in hepatocytes such as reduced urea production (Filippi et al. 2014; Evans et 






The majority of cytokines analysed do not appear to be impacted by exposure of C3A 
cells to PNPs, except for IL-1ra and IL-8. Increased production of the anti-inflammatory 
protein, IL-1ra appears to be elevated regardless of PNP properties. These results 
therefore indicate that IL-1ra may be a good candidate to use during initial toxicity testing, 
along with IL-8. 
 
What was interesting and in need of further investigation in vivo is the impact of PNPs 
on liver-specific markers such as urea production. This is a marker not commonly used 
within in vitro tests, especially with PNPs. However all PNPs investigated stimulated a 
decrease in urea production that was PNP concentration dependent. Therefore, additional 
studies using in vivo models could assess circulating levels of BUN to provide further 
insight into whether PNPs elicit liver damage. Here in vivo models would be useful as 
these PNPs may be cleared from the liver by Kupffer macrophage cells as well via 
hepatobiliary clearance, therefore potentially decreasing the adverse impact on 
hepatocytes (Tsai & Liu 2004). 
 
[Ca2+]i  was a maker of interest as previous studies showed that elevated calcium was 
linked to NP toxicity. The semi-high throughput [Ca2+]i  assay developed during this study 
proved promising as changes in [Ca2+]i  were observed for RR-NPs using fewer resources 
and time needed for traditional imaged based measurement of [Ca2+]i. It would be 
interesting to investigate the impact of N-acetylcysteine (NAC) on [Ca2+]i, as previous 
studies have shown that increases in [Ca2+]i could be negated by the addition of the 
antioxidant NAC (Stone et al. 2000; Huang et al. 2010). This could give additional insight 
into the role of PNP induced ROS in the increase in [Ca2+]i by PNPs (Dubes et al. 2017).  
 
The assays were weighted to aid in ranking with the combined toxicity information 
obtained for all PNPs and the sensitivity of the different assays employed to predicting 
PNP safety (Table 5.1 A/B). The results from this heatmap were used to rank the PNPs 
from lowest to highest overall toxicity as follows PDP NPs <4K NPs <PDP-PF68<55K 
NPs <RR-NPs <15K NPs <nRR-NPs (Table 5.1 C). It can be seen that for nRR-NPs the 
alteration of the PNP shell appears to have reduced PNP toxicity. In addition, the toxicity 
of PLGA-PEG PNPs may be influenced by PLGA chain length when PEG is of the same 





greater toxicity. The nRR-NPs were typically more toxic than RR-NPs. Taken together, 
the results therefore suggest that the composition and surface properties of PNPs 
influence their toxicity. 
 
5.4 Screening strategies  
 
During pre-clinical development of PNPs it is important that safety by design is 
considered to produce effective as well as safe nanomedicines. Therefore, existing 
knowledge of NP toxicity can inform the design of PNPs to reduce the likelihood of 
adverse health effects manifesting in the clinic. This requires a comprehensive analysis 
of the physico-chemical properties of PNPs in the first tier of testing and thorough review 
of the literature (Figure 5.1). Next, it is suggested that in vitro screening (tier 2) be 
performed, using simple monocultures of cells (that represent a relevant target site) 
focusing on assessment of cytotoxicity, uptake, cytokine production, oxidative stress and 
genotoxicity (Figure 5.1). Testing can then progress to more advanced in vitro models 
and a more diverse array of endpoints, only with suitable candidate PNPs that have 
demonstrated low toxicity in earlier tiers of testing. Following an acceptable in vitro 
outcome candidate PNPs could then progress to in vivo analysis (Figure 5.1). Using a 
tiered testing strategy will ensure that testing of PNP safety is conducted in an evidence 
based and focused manner. This approach could reduce resources required for testing 








Figure 5.1 Expanded tiered testing strategy for assessment of nanomedicine safety. 
Expansion on the tiered testing approach suggested in Figure 1.3. Endpoint and method 
as for the PNPs tested in this study. Allowing for progression only with suitable NPs to 
in vivo analysis. Information generated from each step in the tiered testing strategy can 
prompt additional testing, design reconsideration or progression to the next tier of testing. 
This approach could reduce resources required for testing PNPs toxicity and information 





The results from the PNPs examined in these projects in hepatocyte cells could be 
implemented to focus in vitro screening for future generations of PNPs, by informing 
what endpoints are prioritised within tier 2 testing when considering PNP safety with in 
the liver (Figure 5.2). 
 
When developing PNP nanomedicines it is key to consider genotoxicity, as when 
unacceptable levels of genotoxicity are observed, at therapeutically relevant 
concentrations, PNPs may not be useful as nanomedicines due to related adverse effects 
such as cancer. Figure 5.2 suggests an approach to PNP screening that starts by 
performing cytotoxicity testing (AB assay) to identify non-lethal concentrations of PNPs, 
followed by genotoxicity testing examined by both the Comet assay and the MN assay (4 
and 24 hrs, at 3 or more concentrations). If results indicate unacceptable levels of 
genotoxicity, dependent on the application of these nanomedicines, the design of the 
PNPs may need to be reconsidered. If the results suggest low to no genotoxicity at 
clinically relevant concentrations, these PNPs could progress to the next endpoint.  
 
Although ROS measurement via the DCFH-DA assay, was not suitable for these PNPs, 
it may be a useful endpoint for other PNPs, therefore genotoxicity testing could be 
followed by analysis of indicators of oxidative stress, via ROS and GSH measurement 
(e.g. MDA). Although the PNPs tested in this study appear to have limited impact on 
cytokine production, it is established that NPs can stimulate inflammatory responses in 
vitro and in vitro, and thus it is suggested to follow analysis of oxidative stress by focusing 
on the production of cytokines such as IL-8 in hepatocytes, although using other cell lines 
other cytokines such as TNF-α could be useful markers of an inflammatory response. 
When changes in IL-8 levels are observed in hepatocytes, additional cytokine analysis 
should be considered. When there is an absence of effect on cytokines it can be suggested 
to progress to the next phase of testing.  
 
Although NP uptake is important to investigate for PNPs as it can influence their efficacy 
and safety of PNPs, there are currently not clear thresholds with regards to what level of 
PNP uptake or PNP retention within cells are associated with toxicity. Therefore, uptake 
studies should be performed during the screening of PNPs in pre-clinical development to 





urea, albumin and [Ca2+]i, although these have all proven useful markers of liver cell 
health further understanding would be required for these endpoints to prove useful in a 
pre-clinical screening process as currently there are no clear thresholds to indicate these 






Figure 5.2 In vitro tiered testing strategy for assessment of nanomedicine safety. 
Expansion on the in vitro tier 2 testing approach suggested in Figure 5.1. Endpoint and 
method selection were informed by data collected for the PNPs tested in this study. This 
approach could be used to aid PNP safety by design and reduce resources required for in 






5.5 Future  
 
This study focused on the investigation of impacts on hepatocytes and used the C3A cell 
line. Ideally primary human or animal cells would also be investigated. However these 
primary cells come with a high cost, high rate of variability and ethical implications 
associated with their use. In addition, previous studies have shown that the C3A cell line 
provides a good prediction of primary human or rat hepatocytes. However comparative 
studies would be useful to identify whether the cell line gives a good prediction of the 
response of primary cells. Assessment of the response of other toxicologically important 
cell lines to PNPs would also be beneficial. For example, assessment of the response of 
macrophages could provide additional information regarding the safety of these PNPs. 
As seen when the macrophage-like J774 cells were exposed to PDP and PDP-PF68 NPs. 
In addition, it would be of interest to investigate the response of neutrophils. More 
specifically, when hepatocytes are exposed to NPs, pro-inflammatory cytokines such as 
TNF-α, IL-8 or IL-1 and lipid peroxidation products can be released, promoting 
neutrophil accumulation and activation in the liver potentially causing excessive ROS 
production leading to inflammation and liver damage (Clark 1999; Leifeld et al. 2002; 
Antoniades et al. 2008; Kermanizadeh et al. 2013). It could also be of benefit to 
investigate the safety impact on target cells such as lung epithelial cells or intestinal 
epithelial cells, as well as additional target sites such as renal proximal tubule epithelial 
cells. 
 
Cells used in this study were grown in monocultures. The use of 3-D cell models is 
increasing when investigating NP toxicity (Chen et al. 2016; Conte et al. 2018). InSphero 
is a 3-D cell culture system, consisting of hepatocytes together with Kupffer macrophage 
cells in a microtissue form. The presence of Kupffer (macrophage) cells is relevant as 
these cells are part of the RES that clear PNPs in vivo, and their presence may influence 
the toxicological impact observed (Bruderer et al. 2015). Therefore, these 3-D cell models 
could produce results that more closely reflect in vivo results. Additional advantages of 
these models are that they are long-lived, allowing for responses following longer term, 
repeated exposures to be investigated. Other advantages are that these models can be 





(Hendriks et al. 2016). However, these microtissues do have limitations such as difficulty 
of high-resolution imaging as well as their high cost.  
 
Although a human-derived hepatocyte cell line was used in this study, PNPs would 
benefit from in vivo safety profiling following initial in vitro screening. It is 
acknowledged that in vivo work is invaluable for information regarding PNP 
biodistribution, clearance and systemic toxicity, although there are concerns regarding 
the suitability of rodent models due to species differences and issues surrounding the 
reproducibility of findings (Bale et al. 2014; Johnston et al. 2018). However currently, in 
vivo models are essential tools to confirm in vitro findings before progressing to clinical 
trials in man. With time and increased research efforts, an increase in the translatability 
of in vitro to in vivo results may reduce in vivo testing even further. 
 
5.6 Final conclusion  
 
Commonly measured physiochemical properties such as NP diameter, PDI and zeta 
potential were difficult to distinguish as contributing factors to the toxicity of the PNPs 
investigated in this study. However, the PNP coating was identified to be the most 
influential property on PNP toxicity in this study. Therefore, coating modification appears 
to be a promising way to enhance PNP safety. This study used a battery of endpoints to 
assess PNP toxicity, and the findings will guide future testing strategies which investigate 
PNP safety. More specifically, the ability to distinguish between these PNPs via assays 
investigating genotoxicity, cytokine and urea production as well as via changes in 
intracellular calcium concentration suggest that the C3A in vitro model is useful in 
assessing PNP toxicity. Therefore, results from this project may allow for the prioritising 
of endpoints when assessing PNP toxicity. Although commonly used to investigate PNP 
toxicity it would appear that assessment of cytotoxicity, cellular uptake and cytokine 
production should not be used in isolation to assess PNP toxicity and that instead a more 
diverse range of endpoints are considered in the future.  
 
When using a tiered approach to safety testing the toxicity of PNPs can be screened using 
a battery of endpoints before progressing to in vivo studies of PNPs. The utilisation of in 





use and interest of PNPs for medical use in vitro assays use will need to grow to save 
resources as well as align toxicity testing to the principles of the 3R’s.  
 
This study provides information on the hazards associated with a realistic level of PNP 
exposure. This data could be used in the future for risk assessment of PNPs where both 
the hazard and the level of exposure are taken into account. However, progressing the use 
of PNPs as nanomedicines is currently difficult as without method standardisation it can 
be challenging to compare toxicological data across studies. Additionally, a lack of 
specific regulations and guidelines for the safety testing of nanomedicines can make it 
challenging to have PNPs accepted by medical approval bodies such as the EMA and 
FDA. However, this is set to improve in the future as current European Union 
nanomedicine focused projects aim to developed risk management frameworks as well as 
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